

Index

Note: Page numbers followed by *b* indicate boxes, *f* indicate figures, and *t* indicate tables.

A

- abacavir
HIV infection, 628*t*
pharmacogenetics, 66
- abarelix, 763
- abatacept, 842
- ABCB1 gene, 56–57
- abciximab
arterial thromboembolism, 386
ST elevation myocardial infarction, 324
- ABC transporters, 56–57
- abdominal pain in liver disease, 242
- ABL gene, 788, 793
- absence attacks, 491
- absorption (of drugs), 35
drug interactions, 52
in the elderly, 150
in neonates, 124
in pregnancy, 742
- ABVD (adriamycin, bleomycin, vinblastine, dacarbazine), Hodgkin's lymphoma, 804, 805, 807*t*
- acanthosis, 900–901
- acarbose
adverse effects, 704
diabetes mellitus, 699, 704
- accelerated hypertension, 296–297, 299*t*
- accountability, 16–17
- acebutolol
arrhythmias, 370
coronary heart disease, 318*t*
- ACE inhibitors *see* angiotensin converting enzyme (ACE) inhibitors
- acenocoumarol, 381
- acetazolamide
epilepsy, 497
glaucoma, 865, 873
- acetylcholine
affective disorders, 466
anxiety, 456
- acetylcholinesterase inhibitors
and dementia, 153
and diarrhoea, 215*t*
- acetylcysteine
hepatotoxicity antidote, 231
paracetamol overdose, 232
- aciclovir
meningitis, 592
opportunistic infections in HIV, 639*t*
postherpetic neuralgia, 529
- acid-base balance, 83, 260
- acidosis
in acute kidney injury, 264
in chronic kidney disease, 287
metabolic, 83
- acid suppression, peptic ulcer disease, 169–170, 173
- acipimox, 407
- acitretin
drug interactions, 899*t*
eczema, 904*t*
psoriasis, 904, 904*t*
- acneiform eruptions, drug-induced, 884, 885*b*, 890
- acquired immune deficiency syndrome (AIDS), 621
see also HIV infection
- acrolein, 825
- activated charcoal, paracetamol overdose, 232
- activated partial thromboplastin time (APTT), 92–93, 379
- activated protein C, 715
- acupuncture, 527
dysmenorrhoea, 718
pregnancy-associated nausea and vomiting, 541
- acute coronary syndrome (ACS), 320–329
causes, 320–321
classification, 322*f*
definition, 320–321
diagnostic criteria, 321
mortality rates, 321
- acute generalised exanthematous pustulosis (AGEP), 888, 888*b*
- acute kidney injury (AKI), 255–271
case studies, 269*b*
causes, 255–259, 256*f*
classification, 255–259, 255*t*
clinical evaluation, 260, 261*f*
clinical manifestations, 259–260
course, 260–262
definition, 255, 256*f*
diagnosis, 260, 261*f*
incidence, 255
intra-renal, 257–259, 257*t*
definition, 255*t*
vs. pre-renal, 259, 259*t*
management, 262–263
drug therapy and renal auto-regulation, 263
early preventative and supportive strategies, 262–263
mortality rates, 261
non-dialysis treatment, 263–265
acidosis, 264
hyperkalaemia, 264
hyperphosphataemia, 264
hypocalcaemia, 264
infection, 264
nutrition, 265
uraemia and intravascular volume overload, 263–264
uraemic gastro-intestinal erosions, 264–265
parenteral nutrition in, 110–111
post-renal, 259
course and prognosis, 261
definition, 255*t*
pre-renal, 256–257, 256*f*
course and prognosis, 260–262
definition, 255*t*
vs. intra-renal, 259, 259*t*
prognosis, 260–262
renal replacement therapy *see* renal replacement therapy
RIFLE criteria, 255, 256*f*
staging, 256*f*
with volume depletion, 259, 259*t*
with volume overload, 259*t*, 260
vs. chronic kidney disease, 272
- acute liver failure (ALF), 250
in acute liver disease, 238
characteristics of types of, 223*t*
drug-induced, 222, 222*f*
- acute lymphoblastic leukaemia (ALL), 133, 786
case studies, 800
classification, 788, 788*t*
clinical manifestations, 788
epidemiology, 786
pathophysiology, 787
treatment, 790–791, 790*t*, 812
- acute myeloblastic leukaemia (AML), 786
case studies, 799, 800
classification, 788, 788*t*
clinical manifestations, 788
epidemiology, 786
pathophysiology, 787
treatment, 791–792, 791*f*
- acute peritoneal dialysis, 266–267, 267*f*, 267*t*
- acute promyelocytic leukaemia (APL), 788, 792, 801
- acute renal failure (ARF) *see* acute kidney injury (AKI)
- acute tubular necrosis (ATN), 257–258, 257*t*, 260–261
- adalimumab
guidance on the use of, 841
inflammatory bowel disease, 199, 200, 200*t*, 201–202, 203*t*
psoriasis, 905
rheumatoid arthritis, 840
- Addison's disease, 80
- adefovir, hepatitis B, 251
- adenosine
adverse effects, 367*t*
arrhythmias, 371–372
- adenosine triphosphate (ATP), 371–372
- adenoviruses, 214, 573
- adherence/non-adherence, 5, 24
- antiretrovirals, 627
children, 141–142
costs of, 121–122
elderly, 158
glaucoma treatment, 877–878
intentional, 24

- likelihood of, 5–6
tuberculosis treatment, 617
unintentional, 24
- adipokines, 687
- adiponectin, 687
- adolescents
adverse drug reactions, 65
definition, 132
- adrenaline
chronic heart failure, 343
neonates, 124
- adrenergic receptors *see* α -adrenoceptors;
 α_1 -adrenoceptors; α_2 -adrenoceptors;
 β -adrenoceptors
- adrenocorticotropic hormone (ACTH), 761–762
- adriamycin *see* doxorubicin
- adsorption, 52
- adult polycystic kidney disease (APKD), 275
- adult T-cell leukaemia/lymphoma (ATLL), 807
- adverse drug events (ADEs), 63
- adverse drug reactions (ADRs), 62–75
affecting the liver *see* drug-induced liver disease (DILD)
assessing the safety of drugs, 63
benefits of pharmaceutical care, 4
in breastfed infants, 745*t*
case studies, 73, 74
in children, 144
classification, 63–64
DoTS system, 64, 65*t*
Rawlins-Thompson classification, 63–64, 64*t*
cost of, 4
definitions, 63
in the elderly, 158
epidemiology, 68
factors affecting susceptibility to, 64–67
age, 65
co-morbidities and concomitant medicine use, 65
erythrocyte glucose-6-phosphatase dehydrogenase (G6PD) deficiency, 66
ethnicity, 66
gender, 65
pharmacogenetics, 66
porphyrias, 67
formulation issues, 67–68
immunological reactions, 67, 67*t*
pharmacovigilance and epidemiological detection methods, 68–71
case-control studies, 70–71
cohort studies, 70
published case reports, 70
spontaneous reporting, 68–69, 69*t*
Yellow Card Scheme, 69–70
rates of, 4
risk management of, 120–121
roles of health professionals, 71–74
explaining risks to patients, 72–74
identifying and assessing ADRs, 71
monitoring therapy, 72
presenting ADRs, 71–72
skin *see* skin disorders, drug-induced
time-dependent, 64
topical drugs, 136
- advertising of medicines, 27
- affective disorders, 465–478
aetiology, 466
biochemical factors, 466
endocrine factors, 466
environmental factors, 466
genetic causes, 466
physical illness and side effects of medication, 466, 467*b*
case studies, 476*b*
classification, 465
clinical manifestations, 467
common therapeutic problems in management of, 475*t*
epidemiology, 465–466
investigations, 467–468
patient care, 474–478
rating scales, 468
severity, 467
treatment, 469–474, 475*t*
- affective reactions of benzodiazepines, 459
- age
adverse drug reactions, 65
and chronic kidney disease, 272
and dyslipidaemia, 396
and fibrinolysis, 324
and hormone replacement therapy, 727–728
and prostate cancer, 759
risk for drug-induced liver disease, 223
and surgical site infection, 599
and total cholesterol, 390
and venous thromboembolism, 377
and wound healing, 913
see also geriatrics
- agomelatine, depression, 472
- agonists, 57
- agoraphobia, 456
- agranulocytosis, 89*t*, 676
- AIDA, 30, 30*t*
- AIDS *see* acquired immune deficiency syndrome (AIDS)
- AIDS dementia complex, 645–646
- airflow limitation, chronic obstructive pulmonary disease, 433, 434*b*
- airflow obstruction, chronic obstructive pulmonary disease, 435, 435*t*
- airflow optimisation, bronchitis/chronic obstructive pulmonary disease, 549
- airway remodelling, 433
- akathisia, 481
- alanine transaminase (ALT), 85
in liver disease, 244
liver function tests, 86
- albumin, 53
in the elderly, 150
extracellular fluid osmolality, 77
in liver disease, 244
liver function tests, 84–85
pregnancy, 742, 743
and serum calcium, 81
- albumin creatinine ratio (ACR), 277–278
- alcohol
children and, 134
diabetes mellitus, 694–695
distribution in the elderly, 150
and drug metabolism, 54
and dyslipidaemia, 395
effect on lipoprotein levels, 394*t*
and folate deficiency anaemia, 777
gout, 851
hepatotoxicity, 224
and liver disease, 240–241
in oral preparations, 139
and psoriasis, 899–900
sideroblastic anaemia, 774–775
transfer into breast milk, 749
- aldosterone, 273
effects of, 341–342
premenstrual syndrome, 713
- aldosterone antagonists
chronic heart failure, 336, 339*t*, 341–342
hypertension, 304*b*
- alendronate
adverse effects, 154
alternatives to HRT, 731
osteoporosis, 154
- alfacalcidol, 287
hypoparathyroidism/hypocalcaemia, 680, 681*t*
osteoporosis, 154
- Alfalfa, 59
- alfuzosin, benign prostatic hyperplasia, 757
- alimemazine, 285
- aliphatics, schizophrenia, 483*t*
- aliskiren, hypertension, 301
- alitreinoin, Kaposi's sarcoma, 645
- alkaemia, 82
- alkaline phosphatase
in liver disease, 244
liver function tests, 84, 85–86
- alkalosis, 81, 83
- allantoin, 856
- allergic contact dermatitis, 894–895, 895*t*
- allergic rhinitis *see* hay fever
- allergy, drug, 749
see also adverse drug reactions (ADRs)
- allopurinol
drug interactions, 61, 198
gout, 853, 855–856
interstitial nephritis, 258–259
tumour lysis syndrome, 813–814
- all-trans retinoic acid (ATRA), acute promyelocytic leukaemia, 792
- alopecia
chemotherapy-induced, 813*t*
drug-induced, 882, 882*b*
- α_1 -acid glycoprotein, 53, 150
- α -adrenoceptor blockers
benign prostatic hyperplasia, 757, 758
and diarrhoea, 215*t*
hypertension, 301, 303*t*
in diabetes, 305
indications/contraindications, 307*t*
- α -adrenoceptors, age-related changes, 151
- α_1 -adrenoceptors, age-related changes, 151
- α_2 -adrenoceptors, age-related changes, 151
- α -agonists, 57
- α -antagonists, 57
- α_1 -antitrypsin deficiency, 241
liver disease, 244
- α_1 -blockers
hypertension in chronic kidney disease, 284–285
urinary incontinence, 156–157
- α -glucosidase inhibitors, diabetes mellitus, 704
- 5 α -reductase, urinary incontinence, 157
- 5 α -reductase inhibitors
benign prostatic hyperplasia, 757–758
prostate cancer, 764
- α -synuclein, 508
- α thalassaemias, 782
- Alport syndrome, 277
- alprazolam
anxiety disorders, 459
profile, 458*t*
- alteplase
ST elevation myocardial infarction, 323*t*, 324
stroke, 153
venous thromboembolism, 385
- alternative medicines *see* complementary and alternative medicines
- aluminium hydroxide, hyperphosphataemia, 287
- alveolitis, 433
- Alzheimer's disease, 152–153, 736
- amantadine
influenza, 546
Parkinson's disease, 513
- American College of Rheumatology (ACR)
response, 833–834

- American Rheumatism Association (ARA)
criteria, 833–834, 833*b*
- American Society of Anaesthesiology (ASA)
classification of physical status, 598*t*
- amfebutamone *see* bupropion
- amfetamines, 58
- amikacin
hypomagnesaemia, 82
mycobacteria, 644
tuberculosis, 616*t*
- amiloride
ascites, 247*t*
hyperkalaemia, 80
- amino acids
essential, 98
parenteral nutrition, 98–99
stability, 107
- amino acid solutions, electrolyte-free, 265
- aminoglycosides
acute pyelonephritis, 568
acute tubular necrosis, 257*t*
cystic fibrosis, 556*t*
drug distribution in children, 137
elimination in children, 138
hypocalcaemia, 82
meningitis, 587–588
in neonates
infections, 127
monitoring in, 129
pneumonia, 554*t*
- 5-aminolaevulinic acid synthase, 774
- 5-aminolaevulinic acid (ALA), 67
- aminophylline, 39, 47
asthma, 418*t*, 422
chronic obstructive pulmonary disease, 439
intravenous, 422, 422*t*
- Aminoplasma[®], 98, 99*t*
- 4-aminopyridine, 152
- aminosalicylates
formulations, 197–198, 197*t*
inflammatory bowel disease, 193, 196–198,
196*f*, 197*t*, 203*t*
- aminotransferases, liver disease, 244
- Aminoven[®], 98, 99*t*
- amiodarone
adverse effects, 367*t*, 370–371
arrhythmias, 359, 363, 365, 370–371
dosage, 370
hypothyroidism, 671, 679
pharmacokinetics, 368*t*, 370
thyrotoxicosis, 679
- amisulpride, schizophrenia, 483*t*
- amitriptyline
anxiety disorders, 461
depression, 470
pain, 526
sedative properties, 470
- amlodipine
chronic heart failure, 343–344
clinical trials, 302
studies, 299–300
- ammonia, 83
hepatic encephalopathy, 248
liver function tests, 86
- amoebiasis, 580
- amoxicillin
bacteriuria of pregnancy, 570
bronchitis/chronic obstructive pulmonary
disease, 549–550
cholera, 579–580
gastro-intestinal infections, 579
Helicobacter pylori eradication, 171, 172
hepatotoxicity, 234
meningitis, 587–588, 591
- otitis media, 548
pneumonia, 551
urinary tract infections, 568*t*
- amphotericin
acute tubular necrosis, 257*t*
candidiasis, 657
fungal ear infections, 659
infection in neutropenia, 797
opportunistic infections in HIV, 639*t*
oropharyngeal candidiasis, 638–643
- amphotericin B
cryptococcus neoformans, 643
fungal infections in compromised host, 660–662
and hypomagnesaemia, 82
lipid formulations *see* amphotericin B lipid
formulations
meningitis, 591–592
mode of action, 661
pharmacokinetics, 664*t*
spectrum of activity, 661–662
- amphotericin B deoxycholate (ABD), 662
- amphotericin B lipid formulations, 662
amphotericin B lipid colloidal, 662, 664*t*
amphotericin B lipid complex, 662, 664*t*
choosing, 662
liposomal amphotericin B, 662, 664*t*
- ampicillin
cholera, 579–580
gastro-intestinal infections, 579
meningitis, 587–588, 589*t*, 591
- amsacrine, acute myeloblastic leukaemia, 791–792
- amylase, liver function tests, 86
- amyloid, 152–153
- amyloid- β , 736
- amyloid precursor protein (APP), 152–153
- anabolic steroids, 884
- anaemia, 769–785
aetiology, 769–771
case studies, 783*b*
of chronic disease, 773–774, 773*t*
in chronic kidney disease, 278, 286–287
classification, 770*b*
clinical manifestations, 770, 770*b*
definition, 769
epidemiology, 769
haemolytic *see* haemolytic anaemias
in inflammatory bowel disease, 191, 204
investigations, 770–771
iron deficiency *see* iron deficiency anaemia
macrocytic, 93
megaloblastic *see* megaloblastic anaemias
microcytic, 769*t*, 784
sideroblastic *see* sideroblastic anaemia
treatment, 814
- anaesthetic agents
acute tubular necrosis, 257*t*
local, 524–525
pain, 525*t*
- anakinra
gout, 854
rheumatoid arthritis, 842
- analgesia
epidural, 524
solid tumours, 827
stimulation-produced, 527
- analgesic drugs, 520–525
agonist-antagonists, 523
non-opioid, 520–521, 525
partial agonists, 523
strong opioids, 520, 522–523
weak opioids, 520, 521–522
- analgesic ladder, 520, 520*f*
- anal intraepithelial neoplasia (AIN), 645
- Ananas comosus*, 59
- androgen deprivation therapy, prostate cancer,
761–763
- androgens
effect on lipoprotein levels, 394*t*
hair changes, 882
- androstenedione, 726
- Angelica, 59
- angina
atherosclerosis, 313–314
Prinzmetal's, 317–318, 319
stable, 315–317
characteristics, 315
symptom relief and prevention, 317–320
beta-blockers, 317–318, 318*t*
calcium channel blockers, 318–319
ivabradine, 320
nicorandil, 319
nitrates, 319, 320*t*
ranolazine, 320
treatment, 315, 316*f*
ACE inhibitors, 317
antithrombotic drugs, 315–317
statins, 317
unstable, 313–314, 320, 327
- angioedema, drug-induced, 883–884, 884*b*, 890
- angiogenesis, 912
- angioplasty, arterial leg ulcers, 920
- angiotensin converting enzyme (ACE), 273
- angiotensin converting enzyme (ACE) inhibitors
acute kidney injury, 262, 262*f*
adverse reactions, 66, 74, 339–340, 347–348
arrhythmias, 365
chronic heart failure, 336, 338–341, 340*t*, 344,
350
clinical trials, 302
contraindications, 341
coronary heart disease, 317
diabetic nephropathy, 693
diarrhoea, 215*t*
disease interactions, 348*t*
drug interactions, 348*t*
effect on lipoprotein levels, 394*t*
hyperkalaemia, 80
hypertension, 156, 301, 302–304, 303*t*, 304*b*
in chronic kidney disease, 283–284
in diabetes, 305, 705
indications/contraindications, 307*t*
in pregnancy, 306
in renal disease, 305
intolerance, 339–340
pre-renal acute kidney injury, 256–257
as pro-drugs, 348
self-monitoring, 345*t*
ST elevation myocardial infarction, 326
teratogenicity, 740, 741*t*
- angiotensin I, 273
- angiotensin II, 262, 273
escape phenomenon, 284
- angiotensinogen, 273
- angiotensin receptor blockers (ARBs)
acute kidney injury, 262, 262*f*
adverse reactions, 347–348
chronic heart failure, 336, 340*t*, 341, 344
diabetic nephropathy, 693
diarrhoea, 215*t*
drug interactions, 348*t*
hypertension, 156, 301, 302–304, 303*t*
in chronic kidney disease, 283–284
in diabetes, 705
indications/contraindications, 307*t*
in pregnancy, 306
pre-renal acute kidney injury, 256–257
- Anglo Scandinavian Cardiac Outcomes Trial
(ASCOT) study, 299–300, 302, 306

- anidulafungin, 664*t*
- anion exchange resins, pruritus in liver disease, 245
- anisocytosis, 89*t*
- ankle brachial pressure index (ABPI), 918
- Ann Arbor classification system, Cotswolds modification of, 804, 804*b*
- anorexia, 242
- antacids
- absorption, 52
 - diarrhoea, 215*t*
 - gastro-oesophageal reflux disease, 173–174
 - peptic ulcer disease, 178
- antagonists, 57
- anthracyclines
- acute lymphoblastic leukaemia, 790
 - acute promyelocytic leukaemia, 792
 - Kaposi's sarcoma, 645
 - nausea and vomiting, 540
- anti-androgens, prostate cancer, 762–763
- antiarrhythmic drugs, 366–373
- class I, 366–368, 367*t*
 - class IA, 368–369
 - class IB, 369
 - class IC, 369
 - class II, 367*t*, 369–370
 - class III, 367*t*, 370–371
 - class IV, 367*t*, 371
 - electrophysiological effects of, 366*t*
 - pharmacokinetics, 368*t*
- antibiotics
- bronchitis, 549–550
 - chronic obstructive pulmonary disease, 438–439, 549–550
 - cystic fibrosis, 555–556
 - diarrhoea, 214, 215*t*, 217–218
 - elimination, 56
 - gastro-intestinal infections, 573–574, 578–581
 - hepatic encephalopathy, 248
 - infection in neutropenia, 797
 - inflammatory bowel disease, 186, 193, 202, 203*t*
 - interstitial nephritis, 258–259
 - intrathecal and intraventricular administration, 593, 593*t*
- neonates
- infections, 127
 - monitoring in, 129
 - necrotizing enterocolitis, 128
 - respiratory distress syndrome, 130
- otitis media, 548
- pain, 525*t*
- pneumonia, 553–554
- prophylaxis
- leukaemia, 796, 797*t*
 - surgical site infection *see* surgical site infection, prevention/antibiotic prophylaxis
 - urinary tract infections, 570
- prostatitis, 765, 766
- quinolone *see* quinolone antibiotics
- renal transplantation, 292
- resistance, 567
- urinary tract infections, 566
- sore throat, 547
- urinary tract infections, 568*t*
- anti-CD33 antibody, 792
- anti-CD3 monoclonal antibodies, 686
- anticholinergic agents
- absorption, 52
 - adverse effects, 151
 - antiemesis, 538
 - asthma, 415
 - constipation, 210
 - Parkinson's disease, 514
 - schizophrenia, 485
- anticholinesterases, 152
- anticoagulants, 246
- metabolism, 55, 55*t*
 - monitoring, 91–95
 - activated partial thromboplastin time (APTT), 92–93
 - D-dimers, 93
 - folate, 93–95
 - international normalised ratio (INR), 92
 - iron, 93
 - iron binding, 93
 - one stage prothrombin time, 91
 - transferrin, 93
 - vitamin B₁₂, 93–95
 - xanthochromia, 93
- non-ST elevation myocardial infarction, 327–329
- ST elevation myocardial infarction, 324, 326
- stroke, 153, 154
- venous thromboembolism, 381–384
- anticonvulsants *see* antiepileptic agents
- anti-cyclic citrullinated peptide antibodies, 834
- anti-cytokine monoclonal antibodies, 795
- antidepressants
- adverse effects, 469
 - anxiety disorders, 460–461
 - choice of, 472
 - dependence, 469
 - depression, 469
 - diarrhoea, 215*t*
 - drug-induced parkinsonism, 509–510
 - hepatitis C, 251–252
 - insomnia, 450
 - pain, 525–526, 525*t*
 - premenstrual syndrome, 716
 - ST elevation myocardial infarction, 326
 - withdrawal, 469
 - see also* tricyclic antidepressants
- antidiabetic agents, 215*t*
- antidiarrhoeals, 202
- antidiuretic hormone (ADH), 76, 273
- and blood pressure, 296
- extracellular fluid osmolality, 78
 - oesophageal varices, 250
 - secretion, 78
- antidopaminergics, 538
- antidotes, 231
- antiemetics, 215*t*, 536–539
- antiepileptic agents
- action, 497, 497*f*
 - adverse reactions, 66
 - altering drug regimens, 494
 - development, 497
 - diarrhoea, 215*t*
 - dose changes, 494–495
 - drug interactions, 499*t*
 - follow-up, 496
 - initiation of therapy, 494
 - long-term, 493
 - maintenance dosage, 494, 498*t*
 - mania, 474
 - metabolism, 54
 - monitoring, 496–497
 - neonates, monitoring in, 129
 - neuropathic pain, 530
 - newer, 495*t*, 503–506
 - pain, 525*t*, 526
 - pharmacokinetics, 498*t*
 - profiles, 497–503
 - starting dosage, 498*t*
 - withdrawal, 494, 496
- antifibrinolytic drugs, menorrhagia, 720
- antifungals, 655
- administration difficulties, 666*t*
 - adverse effects, 656*t*
- diarrhoea, 215*t*
- infection in neutropenia, 797
 - pharmacokinetics, 664*t*
 - resistance, 666*t*
 - spectrum of activity, 661*t*
 - toxicity, 666*t*
- antiglutamic acid decarboxylase (GAD) antibodies, 685–686
- antihistamines
- absorption, 52
 - antiemesis, 536–538, 541
 - eczema, 897
 - insomnia, 448*t*, 450
 - pain, 526
 - pruritus
 - in chronic kidney disease, 285
 - in liver disease, 245
- Anti-hypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT), 300, 302
- antihypertensives, 155
- adverse effects, 308
 - classes, 299–304
 - clinical trial evidence, 302
 - drug selection, 302
 - and dyslipidaemia, 395
 - hepatotoxicity, 228
 - hypertension in chronic kidney disease, 283
 - recommendations for drugs sequencing, 302–304
- anti-IgE monoclonal antibodies, asthma, 419
- anti-inflammatories, asthma, 418–419
- anti-ischaemic drugs, non-ST elevation myocardial infarction, 329
- antilymphocyte globulin (ALG), 291
- antimalarials
- diarrhoea, 215*t*
 - psoriasis, 899
- antimicrobial catheters, 569
- antimicrobials
- diarrhoea, 217–218
 - hepatotoxicity, 228
 - inappropriate prescribing of, 15
 - meningitis, 587–593
 - pharmacokinetics, 587–593
 - urinary tract infections, 566
 - see also* antibiotics; antifungals; antivirals
- antimotility agents, 217
- antimuscarinic drugs
- asthma, 11*t*
 - urinary incontinence, 157
- anti-neutrophil cytoplasmic antibodies (ANCA), 258
- antinuclear antibodies (ANA)
- lupus erythematosus, 888
 - rheumatoid arthritis, 834
- antioncogenes, 820
- antioxidants
- and coronary heart disease, 315
 - and dyslipidaemia, 400–401
- antiplatelet therapy
- non-ST elevation myocardial infarction, 327–329
 - ST elevation myocardial infarction, 322, 324, 326
 - stroke, 153
- antiproteinase imbalance, 433
- antiprotozoal agents, 215*t*
- antipsychotic drugs
- adverse effects, 486–488
 - anxiety disorders, 461
 - depot formulations, 485, 485*t*
 - diarrhoea, 215*t*
 - individual response, 481
 - interactions, 475*t*, 485
 - long-acting formulations, 484–485
 - mania, 473
 - mode of action, 480–481

- antipsychotic drugs (*Continued*)
 neuroleptic equivalence, 484, 484*t*
 side effects, 481–482
 therapeutic drug monitoring, 485–486
- antiretroviral therapy
 adherence/non-adherence, 627
 choosing and monitoring, 626–627, 627*b*
 highly active *see* highly active antiretroviral therapy (HAART)
 in HIV infection, 625–637
 post-exposure prophylaxis, 627
 starting, 626
 studies, 626
 toxicity of, 637
 treatment interruptions, 627
- antispasmodics
 dysmenorrhoea, 717
 pain, 525*t*
- antithrombin III deficiency, 377
- antithrombotic drugs
 coronary heart disease, 315–317
 non-ST elevation myocardial infarction, 327
- antithymocyte globulin (ATG), 291, 795
- anti-thyroid drugs, 676
 adverse effects, 676
 counselling, 677, 677*b*
 regimens, 677
- anti-TNF agents
 adverse effects, 841
 place in therapy, 841
 psoriasis, 905
 rheumatoid arthritis, 840–841
 safety, 840–841
- antivirals
 diarrhoea, 215*t*
see also antiretroviral therapy
- anxiety disorders, 454–464
 aetiology, 456
 case studies, 462*b*
 in chronic heart failure, 337*t*
 clinical manifestations, 456
 and coronary heart disease risk, 313
 definitions, 454–455
 differential diagnosis, 457
 epidemiology, 454–455
 investigations, 457
 neurotransmitters, 456
 pathophysiology, 455–456
 ST elevation myocardial infarction, 326
 symptoms, 454–455, 454*f*
 treatment, 457–463
 antidepressants, 460–461
 benzodiazepines, 457–460, 458*t*, 460*b*
 pharmacotherapy, 457–463, 462*t*
 psychotherapy, 457
 types of, 454–455, 455*t*
- anxiolytics
 anxiety *see* anxiety disorders, treatment
 pain, 526
- aorta, coarctation of the, 297
- aplasia, 89*t*
- apnoea, neonates, 128
- apolipoprotein C-II deficiency, familial, 393
- apomorphine, Parkinson's disease, 514
- apo-proteins (apo), 390
- appendectomy, 186
- apraclonidine, glaucoma, 871, 872*t*
- Aptivus[®], 631*t*
- aqueous humour, 862
- arachidonic acid, menorrhagia, 719
- arachidonic acid pathway, 164, 164*f*
- arachnoid mater, 584–585
- arachnoid villi, 584–585
- area postrema, 535–536
- area under the concentration time curve (AUC), 35, 35*f*
- area-under-the-curve (AUC), 54–55
- aripiprazole, schizophrenia, 483*t*
- aromatase inhibitors, chemoprevention, 819
- arousal systems, 455–456, 456*f*
- arrhythmias, 354–375
 abnormal impulse formation, 356–358
 abnormal automaticity, 356–357, 357*f*
 triggered activity, 357–358, 357*f*
 abnormal impulse propagation, re-entry, 358, 358*f*
 cardiac action potential, 354–355, 355*f*
 case studies, 374*b*
 in chronic heart failure, 337*t*
 clinical problems, 358
 common therapeutic problems, 373*t*
 diagnosis, 358–359
 drug therapy, 366–373
 management, 358–359
 mechanisms, 356–358
 normal cardiac conduction, 355–356, 356*f*
 normal cardiac electrophysiology, 354–356
 patient care, 373–374
 refractoriness, 355
 during ST elevation myocardial infarction, 325
 Vaughan-Williams classification, 366–373
see also specific types
- arsenic salts, 203*t*
- arsenic trioxide (ATO), 792
- arterial blood gases, 83
- arterial leg ulcers, 919–920, 920*f*
 clinical signs, 919
 diagnosis, 919
 prevention of recurrence, 920
 treatment, 920
- arterial thromboembolism (ATE), 385–388
 aetiology, 385
 patient care, 387–388
 treatment and prevention, 385–386
 aspirin, 385–386
 clopidogrel, 386
 dipyridamole, 386
 glycoprotein IIb/IIIa inhibitors, 386
 prasugrel, 386
- arthritis, 155
see also osteoarthritis; rheumatoid arthritis
- arthropathies
 psoriatic, 902
 in ulcerative colitis, 190
- artificial sweeteners, 139
- ascites
 in liver disease, 243, 246–248
 management, 246–248, 246*b*, 247*t*
 diuretics, 246–247
 paracentesis, 247
 transjugular intrahepatic portosystemic shunting, 247, 247*f*
 refractory, 247
 spontaneous bacterial peritonitis, 247–248
- aseptic technique, 797
- Asian ginseng, 59
- AS METHOD, 5–6, 6*b*
- asparaginase, 790
- aspartame, 139
- aspartate transaminase (AST), 85
 in liver disease, 244
 liver function tests, 86
- aspergillosis, 658*t*, 660*t*, 667
- Aspergillus* sp., 659
- aspiration pneumonia, 555
- aspirin
 adverse effects, 65, 386
- arterial thromboembolism, 385–386
- chemoprevention, 820
- coronary heart disease, 11*t*, 12*t*, 315–316
 and dementia, 153
 drug-induced asthma, 412–413
 drug interactions, 836
 gout, 851, 853
 hepatotoxicity, 223, 226
 hypertension, 306
 interactions, 59
 in liver disease, 246
 non-ST elevation myocardial infarction, 327–328
 peptic ulcer bleeding, 165
 pharmacokinetics, 385–386
 ST elevation myocardial infarction, 322, 324
 stroke, 153, 362, 363
- Assign risk calculator, 397–398
- asteatotic eczema, 895–896
- asthma, 412–430
 acute severe, 414, 420–422, 421*f*
 aetiology, 412–413
 case studies, 428*b*
 in children, 133
 chronic, 415–422
 clinical manifestations, 413–414
 definition, 412
 drug interactions, 11*t*
 epidemiology, 412
 extrinsic, 413
 inhalation devices, 423–427, 424*t*
 breath-actuated metered dose inhalers, 426, 426*f*
 for children, 425*t*
 dry powder inhalers, 426, 426*f*
 metered dose aerosol inhalers, 424–425
 metered dose inhaler with a spacer extension, 425–426
 nebulisers, 426–427
 intrinsic, 413
 investigations, 414–415
 ladder of knowledge, 422, 423*b*
 pathophysiology, 413
 patient care, 422–429, 423*b*
 patient knowledge/education, 423
 refractory/difficult to treat, 414
 self-management programs, 427–429
 treatment, 415–422
 acute severe asthma, 420–422
 chronic asthma, 415–422
 preventer medication, 418–420
 reliever medication, 415–418
 triggers, 412–413, 413*t*
- astroviruses, 214
- atazanavir, 631*t*
- atenolol, 318*t*
 arrhythmias, 370
 clinical trials, 302
 hypertension, 309
 in chronic kidney disease, 284
 in pregnancy, 306
 stable angina, 317–318
 studies, 299–300
- atherosclerosis
 coronary heart disease, 313–314, 314*f*
 plaques, 313–314
- athlete's foot, 657
- atonic colon, 212–213
- atonic seizures, 491
- atopic eczema, 893–894, 906, 906*f*, 907, 907*f*
- atorvastatin
 adverse reactions, 73
 dyslipidaemia, 402
 metabolism, 55, 404

- atovaquone
 opportunistic infections in HIV, 639*t*
Pneumocystis jiroveci pneumonia, 638
- atracurium, 126
- atrial fibrillation, 334, 362–364
 case studies, 374
 classification, 362
 emergency management, 363
 long-term management, 363
 rhythm control, 363–364
 stroke risk, 362–363, 362*f*, 374
 treatment, 336
 ventricular rate control, 363
- atrial flutter, 359, 360*f*
- atrial natriuretic peptide (ANP), 296
- atrioventricular node, 356–357
- atrioventricular re-entry tachycardia (AVRT), 360, 361*f*
- Atripla[®], 628*t*
- atropine
 arrhythmias, 365–366
 diarrhoea, 217
 dysmenorrhoea, 717
 in the elderly, 152
- auranofin, 836, 837*t*, 839
- Australian National Blood Pressure Study Group, 302
- auto-antibodies, 244
- autoimmune haemolytic anaemia, 779–780, 780*b*
- autoimmune hepatitis (AIH), 241, 252
- automated peritoneal dialysis (APD), 292
- autonomy, 17, 17*b*
- autosomal dominant polycystic kidney disease, 277
- average costs, 117
- AV nodal re-entry tachycardia (AVNRT), 360, 361*f*
- 5-azacytidine, 792
- azapropazone, gout, 853
- azathioprine
 adverse effects, 198
 autoimmune hepatitis, 252
 drug interactions, 198, 899*t*
 eczema, 898, 904*t*
 graft-versus-host disease, 795
 inflammatory bowel disease, 198, 200–201, 203*t*
 interactions, 61
 interstitial nephritis, 258–259
 metabolism, 55*t*
 psoriasis, 904*t*
 renal transplantation, 289*t*, 291
 rheumatoid arthritis, 836, 837*t*
- azithromycin
 gastro-intestinal infections, 578, 579, 580
 Legionnaire's disease, 552
 mycobacteria, 644
 opportunistic infections in HIV, 639*t*
 tuberculosis, 616*t*
- azole ring, 663
- azotaemia, 662
- aztreonam, pneumonia, 554*t*
- B**
- Bacillus cereus*, 214
 gastro-intestinal infections, 574*t*, 576*t*
 investigations, 577
 treatment, 578
- back pain, 530, 533
- baclofen, 527
- bacterial infections
 in atopic eczema, 894
 in HIV infection, 643–644
 and psoriasis, 899
 wounds, 913–914, 914*f*
- bacterial meningitis, 593*t*
 aetiology, 585
 diagnosis, 586–587
 drug treatment, 587–593, 588*t*
 epidemiology, 585
 presentation, 586
- bacteriuria
 asymptomatic, 561
 of pregnancy, 569–570
 significant, 561
 treatment, 566
- Baker's cyst, 378
- balanitis, candida, 657
- balloon tamponade, oesophageal varices, 249–250
- balsalazide, inflammatory bowel disease, 196, 203*t*
- bandaging, eczema, 898
- barbiturates, 54
- bariatric surgery, 706
- baroreceptor reflex, 296
- Barrett's oesophagus, 173, 175
- basal cell carcinoma, 890, 890*f*
- basiliximab, renal transplantation, 291
- basophilia, 89*t*
- basophils, 90
- BCG vaccine, 608, 617
- BCR gene, 788, 793
- BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisolone), Hodgkin's lymphoma, 805, 807*t*
- BEAM (carmustine, etoposide, cytarabine, melphalan), non-Hodgkin's lymphoma, 811–812
- Beau's lines, 881–882
- Beck Depression Inventory, 468
- beclomethasone inhaler, 11*t*, 12*t*, 419, 419*t*
- behaviour
 medicines-taking, 5
 pharmaceutical consultation, 6, 6*b*
 benchmarking, prescribing influences, 29
- bendroflumethiazide
 chronic heart failure, 337, 339*t*
 clinical trials, 302
 hypertension, 300
 photosensitivity, 881
- benevolence, 18
- benefits, communicating, 23–24
- benign prostatic hyperplasia (BPH), 753–759
 case study, 767
 common therapeutic problems, 759*t*
 epidemiology, 753
 examination, 754–756
 investigations, 754–756
 pathophysiology, 753
 patient care, 758–759
 symptoms, 754
 treatment, 756–758, 759*t*
- benperidol, schizophrenia, 483*t*
- benserazide, Parkinson's disease, 511
- benzamides, schizophrenia, 483*t*
- benzbromarone, gout, 856
- benzodiazepines
 abuse, 460
 adverse effects, 450–451, 459–460, 460*b*
 anxiety disorders, 457–460
 choice of, 459
 role in treating, 459
 dependence, 459–460
 drug interactions, 451, 460
 effect on neonates, 124
 in the elderly, 152
 insomnia, 448–449, 448*t*
 mechanism of action, 449, 458–459
 pain, 526
- pharmacokinetics, 448–449, 457–458
 in pregnancy and lactation, 460
 profile of selected, 458*t*
 teratogenicity, 741*t*
 withdrawal, 460, 460*b*
- benzyl alcohol, 141
- benzylpenicillin
 meningitis, 589, 589*t*
 pneumonia, 551
- β -adrenoceptor agonists
 asthma, 415–417
 long-acting, 415–417
 short-acting, 415
- β -adrenoceptor antagonists *see* β -blockers
- β -adrenoceptors, 151
- β_2 -agonists, 57
 adverse reactions, 420*b*
 asthma, 11*t*, 418, 420, 422
 chronic obstructive pulmonary disease, 437
 drug interactions, 423*t*
- β -blockers
 adverse effects, 317, 318, 349, 367*t*, 370, 868–869, 870*t*
 anxiety disorders, 462
 arrhythmias, 325, 359, 361, 363, 365, 369–370
 cardioselective, 299
 chronic heart failure, 336, 340*t*, 341
 clinical trials, 302
 coronary heart disease, 11*t*
 diarrhoea, 215*t*
 disease interactions, 348*t*
 drug-induced asthma, 412–413
 drug interactions, 348*t*
 dyslipidaemia, 395
 effect on lipoprotein levels, 394*t*
 effect on neonates, 124
 glaucoma, 868–871, 869*t*
 hypertension, 155–156, 299–300, 302–304, 303*t*, 304*b*
 in chronic kidney disease, 284
 in diabetes, 305
 in the elderly, 304
 indications/contraindications, 307*t*
 in pregnancy, 306
 interactions, 57
 lipid solubility, 370
 non-ST elevation myocardial infarction, 329
 pharmacokinetics, 318*t*
 properties, 318*t*
 psoriasis, 899
 self-monitoring, 345*t*
 stable angina, 317–318, 318*t*
 ST elevation myocardial infarction, 326
 teratogenicity, 741*t*
 thyrotoxicosis, 676
- betahistine, antiemesis, 541
- β -lactams
 allergy, 604–605, 605*t*
 resistance, 566
 urinary tract infections, 566, 568
- betamethasone, 124, 126
- β thalassaemias, 782
- betaxolol, 318*t*
 adverse effects, 868
 glaucoma, 868, 869*t*, 870
- bevacizumab, solid tumours, 825
- bicalutamide, prostate cancer, 762
- bicarbonate, 83
 acidosis, 264
 extracellular fluid osmolality, 77
- Bifidobacteria*, 186
- biguanides
 adverse effects, 699
 diabetes mellitus, 699, 701*t*

- bilateral renal artery stenosis, 262, 262f
- bile acid binding agents
adverse effects, 406–407
drug interactions, 406t
dyslipidaemia, 403t, 405–407
- biliary excretion, 56
- biliary fistula, 105t
- bilirubin
conjugated, 85
in liver disease, 244
liver function tests, 84, 85
unconjugated, 85
- bimatoprost
adverse effects, 868
glaucoma, 864, 865, 867–868, 868t, 874
and timolol, 874
- bioavailability, 35
- biochemical tests, 76–84, 77t
arterial blood gases, 83
bicarbonate and acid-base, 83
calcium, 81–82
creatinine, 82–83
drug-induced liver disease, 228
glucose, 77t, 84
glycated haemoglobin, 84
liver disease, 244
magnesium, 82
phosphate, 82
potassium, 79–81
sodium and water balance, 76–79, 77f, 77t
urea, 77t, 83
uric acid, 84
see also laboratory data
- biofilms, 914
- biological agents
choice of, 842
contraindications, 201
inflammatory bowel disease, 193, 199–202, 200t, 203t
psoriasis, 905
rheumatoid arthritis, 839–840, 840f, 840t
- biopsy urease test, *Helicobacter pylori*, 167–168
- bipolar disorder
case studies, 476, 477
clinical features, 467, 467b
definition, 465
incidence, 465–466
management, 468
- bisacodyl, constipation, 157, 211, 212
- bismuth chelate
adverse reactions, 178
peptic ulcer disease, 178
- bismuth salts, inflammatory bowel disease, 203t
- bismuth subsalicylate, diarrhoea, 217
- bisoprolol, 318t
chronic heart failure, 340t
stable angina, 317–318
- bisphosphonates
absorption, 52
alternatives to HRT, 731
diarrhoea, 215t
hypercalcaemia, 81
hypocalcaemia, 82
osteoporosis, 154
pain, 525t
prostate cancer, 763
- bivalirudin
non-ST elevation myocardial infarction, 328–329
ST elevation myocardial infarction, 324
venous thromboembolism, 380
- black cohosh, 731
- bladder, menopausal changes, 726
- bleomycin, Hodgkin's lymphoma, 804, 805, 807t
- blood
cultures, gastro-intestinal infections, 577
glucose during ST elevation myocardial infarction, 325
pH, 83
- blood pressure
high *see* hypertension
home/ambulatory measurements, 297
low *see* hypotension
measurement, 295
normal values, 295
regulation, 296
- Blood Pressure Lowering Treatment Trialists Collaboration, 302
- blue bloater, 434
- boceprevir, hepatitis C, 252
- body mass index (BMI)
and dyslipidaemia, 396
parenteral nutrition, 97t
- body surface area, 138
- body weight
and dyslipidaemia, 399–400
and hormone replacement therapy, 727–728
- bone marrow
leukaemia, 788
sideroblastic anaemia, 775
suppression, chemotherapy, 813t, 814, 827
transplantation, 792
- bone(s)
disease in chronic kidney disease, 279–280, 279f
menopausal changes, 726–727, 732
metastatic pain, 529, 531t
tuberculosis, 614
in ulcerative colitis, 190
- Borage, 59
- Borago officinalis*, 59
- bortezomib, Hodgkin's lymphoma, 806
- botulinum toxin, 527
- botulism, 576
- bowel cancer, 818
- Braak hypothesis, 508
- bradycardia, 365–366
AV block, 365
first degree, 365
management, 365
second degree, 365
sinus, 365
third degree, 365
- bradykinesia, 508
- bradykinin
and blood pressure, 296
hypertension, 301
- bran, constipation, 212
- breast cancer
adjuvant chemotherapy, 824
case study, 830
and hormone replacement therapy, 734t, 735
- breastfeeding *see* lactation/breastfeeding
- breast milk
benefits of, 745
transfer of drugs into, 745–751
see also lactation/breastfeeding
- breath-actuated metered dose inhalers, 426, 426f
- breathlessness *see* dyspnoea
- bretylum
adverse effects, 367t
arrhythmias, 370
pharmacokinetics, 368t
- brimonidine
contraindications, 872
glaucoma, 871–872, 872t, 874
and timolol, 874
- brinzolamide
glaucoma, 873, 874
and timolol, 874
- British Hypertension Society (BHS), 297
- British National Formulary (BNF), 18
- Bromelain, 59
- bromocriptine
parkinsonism, 153
premenstrual syndrome, 715
- bronchiectasis, 433
- bronchiolitis, 432, 433, 550
- bronchitis
acute, 549–550
chronic, 431, 549
in chronic obstructive pulmonary disease, 434
clinical features, 549
definition, 549
diagnosis, 549
lung function tests, 435
treatment, 549–550
- bronchoconstriction, 412–413
- bronchodilators
asthma, 415–418, 418t
chronic obstructive pulmonary disease, 436–438, 439
comparison, 417t
dosage, 418t
high-dose, 437
inhaled, 415–417
long-acting, 437
oral, 417–418
short-acting β -adrenoceptor agonists, 415, 437
- bronchopneumonia, 551
- bronchopulmonary dysplasia (BPD), 126–127
- bronchospasm, 868–870
- buccal route of administration
children, 139
drug absorption in children, 136–137
neonates, 124
- Budd-Chiari syndrome (BCS), 227, 241
- budesonide
asthma, 417
autoimmune hepatitis, 252
inflammatory bowel disease, 195, 203t
- Buerger's Test, 919
- bulimia, 535
- bumetanide, chronic heart failure, 338, 339t
- bundle of His, 356, 366, 366t
- bupivacaine
local anaesthesia, 524
postherpetic neuralgia, 529
- buprenorphine, 523
- bupropion, smoking cessation, 436, 441–442
- Burkholderia cepacia* complex, 555, 556
- Burkitt's lymphoma, 807, 812
- burn pain, 531–533
- buserelin, prostate cancer, 762
- buspirone, anxiety disorders, 461
- butyrophenones, 483t, 538

C

- cabergoline, Parkinson's disease, 512
- caeruloplasmin, 244
- Caesarian section, antimicrobial prophylaxis, 603
- caffeine
neonates, 130
apnoea, 128
transfer into breast milk, 749
- calamine lotion, 246
- calcineurin inhibitors
eczema, 897
renal transplantation, 290
topical, 897

- calcipotriol, psoriasis, 902
 calcitonin
 and hypocalcaemia, 82
 osteoporosis, 155
 calcitriol, 279, 287
 hypoparathyroidism/hypocalcaemia, 680, 681*t*
 osteoporosis, 154
 calcium, 81–82
 in acute kidney injury, 265
 osteoporosis, 154
 and parathyroid hormone, 679–684
 premenstrual syndrome, 714, 715
 supplements, 81, 264
 see also hypercalcaemia; hypocalcaemia
 calcium acetate, hyperphosphataemia, 287
 calcium antagonists *see* calcium channel blockers
 calcium carbonate, hyperphosphataemia, 287
 calcium channel blockers
 arrhythmias, 363
 clinical trials, 302
 effect on lipoprotein levels, 394*t*
 hypertension, 156, 283, 301, 303*t*, 304, 304*b*
 in chronic kidney disease, 283
 in diabetes, 305
 in the elderly, 304
 indications/contraindications, 307*t*
 in pregnancy, 306
 metabolism, 55
 stable angina, 318–319
 calcium gluconate, hyperkalaemia, 81, 264
 calcium leucovorin, 825
 calcium phosphate precipitation, 106, 106*t*
 calf muscle pump, 917–918
 Calgary Cambridge framework, 21, 21*f*
 calicheamicin, acute myeloblastic leukaemia, 792
 campath-1H, chronic lymphocytic leukaemia, 793–794
Campylobacter, 214, 217, 573
 gastro-intestinal infections, 574*t*, 576*t*
 transmission, 573
 treatment, 578, 581*t*
 cancer
 cells, 820, 821*f*
 in children, 133
 in HIV, 623, 637–651
 and hormone replacement therapy, 733*t*, 734–735
 pain, 528–529
 adjuvant drugs and treatments, 528
 case study, 532
 opioid use, 528
 specific syndromes, 528–529
 parenteral nutrition in, 111
 venous thromboembolism, 377
 see also tumours; solid. specific cancers
 candesartan, chronic heart failure, 340*t*, 350
Candida sp.
 ear infections, 659
 fungal meningitis, 585
 candidiasis, 656–657, 660*t*
 balanitis, 657
 clinical presentation, 656
 ear infections, 659
 epidemiology, 656
 neonates, 127, 127*t*
 oesophageal
 presentation, 656
 treatment, 656–657
 oral
 presentation, 656
 treatment, 656–657
 oropharyngeal, 638–643
 skin, 656–657
 systemic, 658*t*
 treatment, 656–657, 663
 vaginal, 657
 presentation, 656
 treatment, 656–657
 cannabinoids
 antiemesis, 539
 pain, 527
 capecitabine, 825
 capreomycin, tuberculosis, 616*t*
 capsaicin, osteoarthritis, 845
 capsicum, 59
 captopril
 chronic heart failure, 340*t*
 clinical trials, 302
 Captopril Prevention Project (CAPPP), 302
 carbamazepine
 absorption, 42
 adverse effects, 66, 498, 500*t*
 distribution, 42
 drug interactions, 499*t*
 elimination, 42
 epilepsy, 498
 mania, 474
 metabolism, 53, 54, 55*t*
 pharmacokinetics, 42–43, 45*t*, 498, 498*t*
 plasma concentration–response relationship, 42
 postherpetic neuralgia, 529
 practical implications, 42–43
 rectal administration, 140
 trigeminal neuralgia, 529
 carbapenems
 cystic fibrosis, 556*t*
 gastro-intestinal infections, 579
 carbidopa, Parkinson's disease, 511
 carbimazole
 hyperthyroidism, 675–676, 677
 thyrotoxicosis, 676
 carbohydrates, diabetes mellitus, 694–695
 carbonic acid-bicarbonate buffer system, 83
 carbonic anhydrase inhibitors
 adverse effects, 873*b*, 873*t*
 glaucoma, 864, 873, 873*b*, 873*t*
 topical, 873
 carboplatin
 and hypomagnesaemia, 82
 nausea and vomiting, 540
 non-Hodgkin's lymphoma, 811–812
 cardiac action potential, 354–355, 355*f*
 cardiac arrhythmias *see* arrhythmias
 cardiac glycosides
 chronic heart failure, 342*t*
 self-monitoring, 345*t*
 cardiac markers, 77*t*, 87
 creatinine kinase, 87
 lactate dehydrogenase, 87
 troponins, 87
 cardiac output, 334
 cardiomyopathy, chemotherapy-induced, 813*t*
 cardiovascular disease, 312
 antiretroviral toxicity, 637
 and chronic kidney disease, 275
 COX-2 inhibitors risk, 835, 836
 in diabetes mellitus, 692
 hypertension risk for, 295, 298
 and lipid profile, 389–390
 cardiovascular system, menopausal changes, 727, 733–734
 carmustine, non-Hodgkin's lymphoma, 811–812
 carteolol, 318*t*
 adverse effects, 868
 glaucoma, 868, 869*t*, 870
 carvedilol, 318*t*, 340*t*
 case-control studies, 70–71
 case reports, 70
 caspofungin
 adverse effects, 797
 clinical use, 666
 fungal infections in compromised host, 663, 665–666
 infection in neutropenia, 797
 pharmacokinetics, 664*t*
 susceptible fungi, 666
 castration
 medical, 762–763
 surgical, 762, 763
 catechol-*O*-methyl transferase (COMT), 512
 catechol-*O*-methyl transferase (COMT) inhibitors, Parkinson's disease, 512–513
 Cates plot, 72, 73*f*
 catheter ablation, arrhythmias, 364
 catheter-associated urinary tract infections, 569
 catheters, antimicrobial, 569
 CCR5 inhibitors, 637
 CD20, 809
 CD4 count in HIV infection, 624–625
 cefaclor, 223*t*
 cefalexin
 bacteriuria of pregnancy, 570
 otitis media, 548
 urinary tract infections, 568*t*
 cefixime
 hepatotoxicity, 223*t*
 otitis media, 548
 cefotaxime
 infection in neutropenia, 797
 meningitis, 587–588, 589, 589*t*, 590, 591
 neonates
 infections, 127
 respiratory distress syndrome, 130
 spontaneous bacterial peritonitis, 247–248
 ceftazidime
 acute pyelonephritis, 568
 infection in neutropenia, 797
 meningitis, 587–588
 neonatal infections, 127
 pneumonia, 554*t*
 urinary tract infections, 569*t*
 ceftriaxone
 gastro-intestinal infections, 579
 meningitis, 588–589, 589*t*, 590, 591
 cefuroxime
 acute pyelonephritis, 568
 urinary tract infections, 569*t*
 celecoxib, 62
 celiprolol, 318*t*
 Celsentri[®], 636*t*
 central corneal thickness (CCT), 863
 centralised intravenous additive services (CIVAS), 141
 central nervous system (CNS)
 in leukaemia, 788, 791
 and the menopause, 736–737
 central venous pressure (CVP), 260
 cephalin, 92
 cephalosporins
 acute pyelonephritis, 568
 bronchitis/chronic obstructive pulmonary disease, 549–550
 cystic fibrosis, 556*t*
 epiglottitis, 548
 gastro-intestinal infections, 573–574, 579
 interstitial nephritis, 258–259
 meningitis, 587–588, 589–590
 neonates
 infections, 127
 respiratory distress syndrome, 130
 pneumonia, 554*t*
 sore throat, 547

- cephalosporins (*Continued*)
 spontaneous bacterial peritonitis, 247–248
 surgical site infection prophylaxis, 601
 urinary tract infections, 567
- cerebrospinal fluid (CSF), 584–585, 586, 587
- cerivastatin, dyslipidaemia, 402
- certolizumab pegol
 guidance on the use of, 841
 inflammatory bowel disease, 199, 200*t*, 202, 203*t*
 rheumatoid arthritis, 840
- cervical cancer, 818
- cervical intraepithelial neoplasia (CIN), 645
- cetirizine, pruritus in liver disease, 245, 245*t*
- cetuximab
 adverse reactions, 884
 solid tumours, 825
- CHADS₂, score, 362, 362*f*
- CHA2DS₂-VASc, 362–363
- chamomile, 59, 61
- channelopathies, 354, 364–365
- Chan Su, 59
- Charcot arthropathy, 694
- chelation, 52
- chemical exposure, leukaemia risk, 787
- chemoreceptor trigger zone (CTZ), 535–536
- chemotherapy, 823–825
 adjuvant, 824
 adverse effects, 813, 813*t*, 824–825
 chemotherapy-specific adjunctive treatments, 825
 neo-adjuvant, 824
 patient management, 826–830
 cumulative dosing, 826
 domiciliary treatment, 828
 dose modification or delay, 826
 drug interactions, 826
 inpatient/outpatient treatment, 827–828
 monitoring anti-cancer therapy, 828–830
 patient information and counselling, 826
 prescription verification, 826, 826*b*
 symptom control, 826–827
 prostate cancer, 763–764
 regimen, 823–825, 824*t*
 dose, 823–824
 scheduling, 823
 response to treatment, 828–830
 synchronous chemoradiation, 824
 toxicity, 828
- chemotherapy-induced nausea and vomiting, 540, 540*b*, 540*t*, 813, 813*t*
- chest pain, coronary heart disease, 315
- chest radiography
 chronic obstructive pulmonary disease, 435
 tuberculosis, 612
- child health clinics, 135
- children, 132–148
 adherence, 141–142
 adverse drug reactions, 65, 144
 bacteriuria in, 566
 biochemical ranges, 143*t*
 case studies, 146–147
 concordance, 141–142
 consent, 17
 constipation, 212
 counselling, 141–142
 definition, 132
 dehydration, 214–215, 216–217
 demography, 132–134
 alcohol use, 134
 asthma, 133
 cancer, 133
 congenital anomalies, 132–133
 drug use, 134
- eczema, 133
 hay fever, 133
 infections, 133–134
 mental health disorders, 134
 nutrition and exercise, 134
 smoking, 134
- drug absorption, 135–137
 drug distribution, 137
 drug excretion, 138
 drug metabolism, 137–138
 drug therapy in, 138–141
 buccal route, 139
 choice of preparation, 139–141
 dosage, 138–139, 138*t*
 dose regimen selection, 141, 142*t*
 intranasal route, 140
 nasogastric and gastroenterology administration, 140
 oral route, 139–140
 parenteral route, 140–141, 140*t*
 pulmonary route, 141
 rectal route, 140
- estimate glomerular filtration rate, 274
- fluid requirements, 140, 140*t*
- gastroenteritis, 214
- hepatotoxicity risk, 232
- insomnia, 451
- licensing of medicines, 145–146
- medication errors, 144–145
- medicines in schools, 142–143
- meningitis, 588–590, 588*t*
- mental health disorders, 134
- monitoring parameters, 143–144, 143*t*
- normal, 134–135
- parenteral nutrition, 112–115
 formulation and stability issues, 112–113
 heparin, 113
 nutritional requirements, 112, 112*t*
 route of administration, 113–115
- service frameworks, 146–148
- stages of development, 136*f*
- tuberculosis, 614
- urinary tract infection prophylaxis, 570–572
- urinary tract infections, 562, 563, 568
- Chinese ginseng, 59
- Chlamydia pneumoniae*, 313
- Chlamydia trachomatis*, 563, 717–718
- chloral hydrate, 140
- chlorambucil
 chronic lymphocytic leukaemia, 793
 Hodgkin's lymphoma, 805, 807*t*
- chloramphenicol
 adverse reactions, 65
 gastro-intestinal infections, 579
 meningitis, 588, 589, 589*t*, 590
 sideroblastic anaemia, 774–775
- chlordiazepoxide, 458*t*
- chloride, extracellular fluid osmolality, 77
- chlorphenamine
 pruritus
 in chronic kidney disease, 285
 in liver disease, 245, 245*t*
- chlorpromazine
 drug-induced parkinsonism, 509–510
 hepatotoxicity, 223, 223*t*
 schizophrenia, 483*t*
- chlortalidone
 clinical trials, 302
 hypertension, 155
- ChlVPP (chlorambucil, vinblastine, procarbazine, prednisolone), Hodgkin's lymphoma, 805, 807*t*
- cholecalciferol, 279
- cholera, 579–580
- cholestasis
 aetiology, 225–226
 clinical presentation, 228
 drugs associated with, 226*t*
 pathophysiology, 226–227
- cholesterol
 and coronary heart disease, 313–315
 high-density lipoprotein *see* high-density lipoprotein cholesterol (HDL-C)
 intermediate-density lipoprotein cholesterol *see* intermediate-density lipoprotein cholesterol (IDL-C)
 low-density lipoprotein *see* low-density lipoprotein cholesterol (LDL-C)
 total *see* total cholesterol (TC)
 very low-density lipoprotein *see* very low-density lipoprotein cholesterol (VLDL-C)
- cholesterol absorption inhibitors, dyslipidaemia, 407
- cholesterol ester transfer protein (CETP)
 inhibitors, dyslipidaemia, 407–410
- choline acetyltransferase, 151
- cholinergic system, age-related changes, 152
- cholinesterase inhibitors
 adverse effects, 152
 dementia, 152
 Parkinson's disease, 516
- chondrodysplasia punctata, 381
- CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone, rituximab), Hodgkin's lymphoma, 805
- chronic heart failure (CHF), 333–353
 aetiology, 334
 case studies, 350*b*
 classification, 333, 333*t*
 clinical manifestations, 335, 335*t*
 epidemiology, 333–334
 investigations, 335–336, 336*t*
 pathophysiology, 334–335
 patient care, 344–352
 patient education and self-monitoring, 344–345, 345*t*
 symptoms, 333, 334
 treatment, 336–344
 guidelines, 344
 monitoring effectiveness of, 345–346, 346*t*
 monitoring safety of, 346–352
 potential problems, 346–348, 349, 350–352
- chronic kidney disease (CKD), 272–294
 anaemia, 278–279
 bone disease, 279–280
 case studies, 292*b*
 causes of, 275–277
 classification, 273*t*
 clinical manifestations, 277–281, 277*f*
 common therapeutic problems in, 288*t*
 diagnosis, 281–282
 and dyslipidaemia, 395
 electrolyte disturbances, 280–281
 fluid overload, 278
 haematuria, 278
 hypertension, 278
 implementation of regular dialysis, 292–293
 incidence, 272
 investigations, 281–282
 monitoring, 281–282
 muscle function, 280
 neurological changes, 280
 nocturia, 278
 polyuria, 278
 prognosis, 282–283
 proteinuria, 278
 renal function measurement, 273–275

- chronic kidney disease (CKD) (*Continued*)
 renal transplantation, 288–292
 renin-angiotensin-aldosterone system, 272–273, 273*f*
 significance of, 275
 treatment, 283–288
 uraemia, 278
 urinary tract features, 277–278
 vs. acute kidney injury, 272
- chronic lymphocytic leukaemia (CLL), 786
 case study, 801
 clinical manifestations, 789
 epidemiology, 786
 pathophysiology, 788
 supportive care, 795–796
 treatment, 793–794
- chronic myelocytic leukaemia (CML), 786
 case study, 798
 clinical manifestations, 789
 epidemiology, 786
 pathophysiology, 788
 supportive care, 795–796
 treatment, 792–793
- chronic obstructive pulmonary disease (COPD), 431–445
 acute exacerbations, 439, 549–550
 aetiology, 432–433
 case studies, 443*b*, 558–559
 clinical features, 434–435, 549
 clinical manifestations, 434–435
 definition, 431
 diagnosis, 434, 549
 epidemiology, 431, 431*t*
 inflammation, 433
 investigations, 435, 436*t*
 oxidative stress, 433
 pathology, 431–432
 central airways, 431
 lung parenchyma, 432
 peripheral airways, 432
 pulmonary vasculature, 432
 pathophysiology, 433–434
 patient care, 440–445
 proteinase and antiproteinase imbalance, 433
 risk factors, 432*t*
 stable, 436–439
 systemic effects, 434
 treatment, 436–440, 549–550
 acute exacerbations of COPD, 439
 of hypoxia and cor pulmonale, 439–440
 stable COPD, 436–439
- Chronic Prostatitis Symptom Index (CPSI), 765
- chylomicron remnants, 390
- chylomicrons, 390
- ciclesonide, asthma, 419*t*
- ciclosporin
 adverse effects, 199, 290
 distribution, 44
 drug interactions, 290, 290*b*, 899*t*
 dyslipidaemia, 396
 eczema, 898, 904*t*
 effect on lipoprotein levels, 394*t*
 elimination, 44
 gout, 851
 graft-versus-host disease, 795
 and hypomagnesaemia, 82
 inflammatory bowel disease, 198–199, 203*t*
 metabolism, 54, 54*t*, 55
 pharmacokinetics, 44–49, 45*t*
 plasma concentration-response relationship, 44
 practical implications, 44
 psoriasis, 904*t*, 905
 renal transplantation, 289*t*, 290
 rheumatoid arthritis, 836, 837*t*
- cidofovir
 cytomegalovirus, 644
 opportunistic infections in HIV, 639*t*
- cigarette smoking
 affect on wound healing, 914
 and cancer risk, 818
 cessation, 436, 440–442
 in children, 134
 and chronic obstructive pulmonary disease, 432
 and coronary heart disease, 315, 330
 and drug metabolism, 54
 and dyslipidaemia, 396
 and inflammatory bowel disease, 186, 204
 and psoriasis, 899–900
 and rheumatoid arthritis, 832
 and surgical site infection, 599
- cilazapril, chronic heart failure, 340*t*
- ciliary dysfunction, chronic obstructive pulmonary disease, 433
- cimetidine
 distribution, 150
 drug interactions, 177
 peptic ulcer disease, 177
- cinnarizine, drug-induced parkinsonism, 509–510
- ciprofloxacin
 acute pyelonephritis, 568
 bacteriuria of pregnancy, 570
 bronchitis/chronic obstructive pulmonary disease, 550
 cystic fibrosis, 556
 diarrhoea, 217
 gastro-intestinal infections, 578–579
 hepatotoxicity, 223*t*
 meningitis, 589*t*, 591
 metabolism, 55
 pneumonia, 554*t*
 tuberculosis, 616*t*
 urinary tract infections, 568*t*, 569*t*
- cirrhosis, 238–239, 239*f*, 240
 alcoholic, 240–241
 drug-induced, 226*t*
- cisplatin
 and hypocalcaemia, 82
 and hypomagnesaemia, 82
 nausea and vomiting, 540
 non-Hodgkin's lymphoma, 811–812
- citalopram, depression, 471
- civil wrongs, 16
- clarithromycin
 bronchitis/chronic obstructive pulmonary disease, 549–550
 drug interactions, 176
 gastro-intestinal infections, 578
Helicobacter pylori eradication, 171, 172
 interactions, 59
 straws, 139
 tuberculosis, 616*t*
- clearance (CL), 34
 capacity limited, 36
 increasing, 36–37
- clindamycin
 gastro-intestinal infections, 573–574
 opportunistic infections in HIV, 639*t*
Pneumocystis jiroveci pneumonia, 638
 pneumonia, 554*t*
 toxoplasmosis, 643
- clinical governance, 19, 20*b*
- clinical negligence, 16
- clinical pharmacy, 2–13
 definition, 3*t*
 development of, 2–3
 functions and knowledge, 7–12
 patient details, 7–8
- pharmaceutical care *see* pharmaceutical care
 pharmaceutical consultation *see* pharmaceutical consultation
 quality assurance, 12–13
- clinical trials
 drug safety, 63
 pre-marketing, 63
- clobazam, epilepsy, 498–500
- clofarabine, acute myeloblastic leukaemia, 792
- clofazimine, tuberculosis, 616*t*
- clomethiazole
 distribution, 150
 metabolism, 150
- clomipramine
 anxiety disorders, 461
 depression, 470
- clonazepam
 adverse effects, 500*t*
 anxiety disorders, 459
 epilepsy, 500
 neonatal seizures, 128–129
 pain, 526
 pharmacokinetics, 498*t*
 profile, 458*t*
- clonidine
 alternatives to HRT, 731
 hypertension in chronic kidney disease, 285
 pain, 527
- clopidogrel
 arterial thromboembolism, 386
 coronary heart disease, 11*t*, 12*t*, 316
 metabolism, 55, 55*t*
 non-ST elevation myocardial infarction, 327–328, 329
 peptic ulcer disease, 169
 ST elevation myocardial infarction, 322, 324
 stroke, 153
- Clostridium botulinum*, 527, 574*t*
- Clostridium difficile*, 214, 216, 264–265, 575, 578
 gastro-intestinal infections, 574*t*, 576*t*
 investigation, 577
 surgical site infection, 601, 606
 treatment, 580, 581*t*
- Clostridium perfringens*, 214
 gastro-intestinal infections, 574*t*, 576*t*
 treatment, 578
- clotting abnormalities
 in liver disease, 246, 246*f*
 management, 246
- cloxacillin, 225–226
- clozapine
 mode of action, 481
 monitoring therapy, 72
 Parkinson's disease, 516
 and refractory illness, 482
 schizophrenia, 482, 483*t*
- cluster headaches, 531
- coagulation, 92*f*
 disorders, 231
 tests, 91
 in liver disease, 244
- coal tar preparations
 eczema, 898
 psoriasis, 903
- co-amoxiclav
 acute pyelonephritis, 568
 bacteriuria of pregnancy, 570
 bronchitis/chronic obstructive pulmonary disease, 549–550
 hepatotoxicity, 223, 234
 otitis media, 548
 pneumonia, 554*t*
 spontaneous bacterial peritonitis, 247–248
 urinary tract infections, 568*t*, 569*t*

- cobalamins, 93
 co-beneldopa, 511
 co-careldopa intestinal gel, 511
Coccidioides immitis, 585
 Cockcroft Gault formula, 37, 83, 144, 274, 274f
 codeine
 absorption, 52
 analgesia, 522, 523t
 diarrhoea, 217
 codeine diphenoxylate, inflammatory bowel disease, 202
 CODOX-M (cyclophosphamide, vincristine, doxorubicin, methotrexate), non-Hodgkin's lymphoma, 812
 cognitive behavioural therapy (CBT)
 anxiety disorders, 457
 depression, 472
 obsessive-compulsive disorder, 457
 post-traumatic stress disorder, 457
 cognitive biases influencing prescribing, 28, 28t
 cognitive function, in geriatrics, 151
 cognitive impairment, benzodiazepines, 459
 cohort studies, 70
 colchicine, gout, 852–854, 857
 cold agglutinin disease (CAD), 779–780
 cold autoimmune haemolytic anaemia, 779–780
 colds, 545
 colecalciferol, hypoparathyroidism/hypocalcaemia, 681t
 colesevelam
 drug interactions, 406t
 dyslipidaemia, 405, 406
 colestipol
 drug interactions, 406t
 dyslipidaemia, 405, 406
 patient counselling, 407
 pruritus in liver disease, 245
 colestyramine
 absorption, 52
 drug interactions, 406t
 dyslipidaemia, 405, 406
 inflammatory bowel disease, 202, 203t
 patient counselling, 407
 pruritus in liver disease, 245, 245t
 colitis, 188
 chronic, 188
 clinical features, 188–189
 diversion, 188
 pseudomembranous, 188, 202
 ulcerative *see* ulcerative colitis
 collagen, 912
 colloid dressings, leg ulcers, 156
 colloid replacement, ascites, 247
 colorectal cancer
 adjuvant chemotherapy, 824
 case study, 829
 and hormone replacement therapy, 734
 colostomy, electrolyte content of, 105t
 combined oral contraceptives (COCs)
 drug interactions, 176
 and dyslipidaemia, 396
 dysmenorrhoea, 717, 718t
 endometriosis, 722
 and hypertension, 306, 308
 interactions, 60
 menorrhagia, 719–720, 720t
 metabolism, 54t
 premenstrual syndrome, 715
 venous thromboembolism risk, 733
 Combivir®, 628t
 Commission on Human Medicines (CHM), 145
 community-acquired pneumonia, 550–552
 case study, 558
 causative organisms, 550–551, 551t
 clinical features, 551
 diagnosis, 551
 prevention, 552
 treatment, 553t
 empiric, 552
 targeted, 551–552
 competence, 19–20
 competency frameworks, 19–20, 20t
 complementary and alternative medicines
 antiemesis, 539
 interactions, 50
 complex partial seizures, 491–492
 complex regional pain syndrome, 530, 532
 compression bandaging, 919
 compression hosiery, 919
 computed tomography (CT)
 chronic kidney disease, 282
 liver disease, 244
 concordance, children, 141–142
 confidentiality, 17
 breach of, 16
 confusion in the elderly, 152, 152b
 congenital anomalies, 132–133, 277
 conjunctivitis, 191
 Conn's syndrome, 297
 consent, 17, 17b
 Gillick competence, 17
 constipation, 209–214
 aetiology, 209–210
 case studies, 219b
 causes of, 210, 211t
 chemotherapy-induced, 813t
 in chronic kidney disease, 285
 common therapeutic problems, 218t
 definition, 209
 diagnostic algorithm, 212f
 differential diagnosis, 210
 in the elderly, 151, 157, 209
 general management, 210–214
 drug treatment, 211–214
 non-drug treatment, 210–211
 incidence, 209
 opioid-induced, 524
 contact dermatitis, 894–895
 allergic, 894–895, 895t
 drug-induced, 885
 irritant, 895, 895f
 contingent valuation, 117–118
 continuous ambulatory peritoneal dialysis (CAPD), 292
 continuous arterio-venous haemofiltration (CAVH), 266
 continuous positive airway pressure (CPAP)
 neonates
 apnoea, 128
 bronchopulmonary dysplasia, 126
 respiratory distress syndrome, 125–126
 continuous venovenous haemofiltration (CVVH), 266
 contraception
 combined oral *see* combined oral contraceptives (COCs)
 HIV infection and, 646
 Control Hypertension and Hypotension Immediately Poststroke Study (CHHIPPS), 305–306
 controlled drugs, 16
 copper
 adult daily reference range, 102t
 deficiency, 101–102, 774–775
 excess *see* Wilson's disease
 co-proxamol, 522
 corneal microdeposits, amiodarone, 371
 coronary angiography, coronary heart disease, 315
 coronary artery disease (CAD) *see* coronary heart disease (CHD)
 coronary heart disease (CHD), 312–332
 acute coronary syndrome *see* acute coronary syndrome (ACS)
 aetiology, 313–314
 case studies, 331b
 and chronic heart failure, 334
 clinical syndromes, 315–320
 common therapeutic problems, 330t
 definition, 312
 drug interactions, 11t
 drugs for, 11t
 epidemiology, 312–313
 and hormone replacement therapy, 733, 733t
 and hypertension, 295
 modification of risk factors, 314–315, 314t
 patient care, 330
 prevalence, 313
 risk factors, 313, 313b, 391–392
 stable angina *see* angina, stable
 coronary steal, 319
 cor pulmonale, 434, 439–440
 corpus luteum, 711–712
 corticosteroids
 adverse reactions, 420b
 acneiform, 884
 in children, 144
 antiemesis, 539
 asthma, 418–419, 419t, 420b, 422
 autoimmune hepatitis, 252
 bacterial meningitis, 592–593
 bronchopulmonary dysplasia, 126–127
 cancer pain, 528
 chronic lymphocytic leukaemia, 793
 chronic obstructive pulmonary disease, 438, 439
 drug interactions, 423t
 dyslipidaemia, 396
 eczema, 896–897, 896t, 898
 effect on neonates, 124, 126
 gout, 852–853, 854
 hepatotoxicity management, 231
 inflammatory bowel disease, 193–195, 194b, 203t
 inhaled, 11t, 418–419, 419t, 420b
 metabolism, 54t
 mycobacteria, 644
 neonates, 126–127
 osteoarthritis, 845
 pain, 525t
 Pneumocystis jiroveci pneumonia, 638
 prostate cancer, 763
 renal transplantation, 289t, 290, 291
 teratogenicity, 741t
 topical
 adverse effects, 896–897
 allergies, 897
 base, 897
 combined with antibiotics, 897
 eczema, 896–897, 896t
 psoriasis, 902–903
 tuberculosis, 643
 cortisol, affective disorders, 466
Corynebacterium diphtheriae, 546
 cost-benefit analysis (CBA), 117–118
 cost-effectiveness analysis (CEA), 118
 cost-minimisation analysis (CMA), 118
 cost(s)
 of adverse drug reactions, 4
 average, 117
 categorisation of, 117
 fixed, 117
 incremental, 117

- marginal, 117
 opportunity, 117
 prescribing, 116
 variable, 117
 cost-utility analysis (CUA), 118–119
 co-trimoxazole
 opportunistic infections in HIV, 639*t*
 Pneumocystis jiroveci pneumonia, 638
 urinary tract infections, 567–568
 Cotswolds modification of Ann Arbor
 classification system, 804, 804*b*
 Counahan-Barratt equation, 144
 counselling
 anti-thyroid drugs, 677, 677*b*
 bile acid binding agents, 407
 chemotherapy, 826
 children, 141–142
 drug-induced liver disease, 233–234
 lymphomas, 812
 rheumatoid arthritis, 834–835, 843
 statins, 405
 tuberculosis, 618–619
 COX-1, 521
 inhibition, 165
 rheumatoid arthritis, 835
 COX-2, 521
 inhibitors
 chemoprevention, 820
 choice of agent, 836
 coronary heart disease, 316–317
 in liver disease, 246
 osteoarthritis, 845
 peptic ulcer disease, 165, 173
 rheumatoid arthritis, 835
 safety, 835
 rheumatoid arthritis, 835
 selective drugs, 521
 COX (cyclo-oxygenase)
 COX-1 *see* COX-1
 COX-2 *see* COX-2
 inhibition, 164
 rheumatoid arthritis, 835
 Coxsackie viruses, 585
 cranberry juice, 58, 570
 C-reactive protein (CRP), 91, 314
 creatine kinase (CK), 74, 87, 87*t*
 creatinine, 82–83
 acute kidney injury, 255, 259, 260, 265
 children, 144
 chronic kidney disease, 274
 creatinine clearance, 274, 274*f*
 estimation of, 37
 Crivivan[®], 631*t*
 Crohn's disease
 case studies, 205, 206
 clinical features, 188–189
 colitis, 188–189
 definition, 185
 diet and, 185, 186
 drug treatment
 aminosalicylates, 196
 antibiotics, 202
 biologic agents, 199, 200–201
 budesonide, 195
 colestyramine, 202
 thalidomide, 202
 epidemiology, 185
 fish oils, 202
 gastrointestinal and oral disease, 189
 genetic factors, 186
 infection, 186
 location and distribution, 187–188, 187*f*, 187*t*
 lymphomas in, 807
 nutritional therapy, 192
 perianal disease, 189
 small bowel, ileocaecal and terminal ileal
 disease, 188
 smoking, 186
 stricturing, 189, 189*f*
 surgical treatment, 204
 vs. ulcerative colitis, 189*t*
 Crohn's Disease Activity Index (CDAI), 192
 cromones, asthma, 419
 Crown report, 15
 cruciferous vegetables, 58
 cryopyrin, 851–852
 cryosurgical ablation of prostate (CSAP), 761
 cryptococcal meningitis, 593*t*
 in HIV patients, 592
 treatment, 591–592
 cryptococcosis, 658*t*, 660*t*, 663
Cryptococcus neoformans, 591
 fungal meningitis, 585
 HIV infection, 643
 cryptosporidiosis, 573, 643
Cryptosporidium, 214
 gastro-intestinal infections, 576*t*
 treatment, 580, 581*t*
 crystalloids, acute kidney injury, 263
 cultures
 blood, 577
 sputum, 551, 553
 stool, 216, 577
 urine, 565–566
 Cumberland report, 15
 CURE study, 327
 cyanocobalamin, 776, 778–779
 cyclic adenosine monophosphate (cAMP), 151
 cyclizine, antiemesis, 285
 cyclo-oxygenase *see* COX (cyclo-oxygenase)
 cyclophosphamide
 acute lymphoblastic leukaemia, 790
 chronic lymphocytic leukaemia, 793
 Hodgkin's lymphoma, 805, 807*t*
 metabolism, 825
 nausea and vomiting, 540
 non-Hodgkin's lymphoma, 809, 811, 812
 cycloserine, tuberculosis, 616*t*
 CYP450 enzymes
 and adverse drug reactions, 66
 benzodiazepines, 457–458
 classification, 53
 CYP1A2, 54*t*, 55
 CYP2C9, 54*t*, 55, 66
 CYP2C19, 54*t*, 55, 66, 176
 CYP2D6 (debrisoquine hydroxylase), 53, 54*t*, 66
 CYP2E1, 54*t*
 CYP3A, 53, 54–55, 176
 CYP3A4, 54*t*, 55, 56–57, 58
 CYP3A5, 66
 drug interactions, 53
 enzyme inhibition, 54–55
 identification, 55–56
 pharmacogenetics, 66
 in pregnancy, 742, 743*t*
 proton pump inhibitors metabolism, 176
 statin metabolism, 404
 cyproterone, prostate cancer, 762
 cystic fibrosis (CF), 138, 555–556
 case study, 559
 clinical features, 555
 infecting organisms, 555
 treatment, 555–556
 cystitis, 561, 563, 566
 cytarabine
 acute myeloblastic leukaemia, 791–792
 chronic myelocytic leukaemia, 792–793
 non-Hodgkin's lymphoma, 811–812
 cytochrome P450 enzymes *see* CYP450
 enzymes
 cytokine inhibitors, 215*t*
 cytomegalovirus (CMV)
 of the gastro-intestinal tract, 644
 in HIV infection, 644
 neonates, 127
 retinitis, 644
 cytosine arabinoside, acute myeloblastic
 leukaemia, 792
 cytotoxic agents
 acute tubular necrosis, 257*t*
 adverse effects, 824–825
 and diarrhoea, 215*t*
 leukaemia risk, 787
 therapeutic index, 138–139
 see also chemotherapy
 cytotoxin-associated gene A (CagA), 164
 cytotoxins, gastro-intestinal infections, 575

D

- dabigatran
 stroke, 154
 venous thromboembolism, 382–384
 dacarbazine, Hodgkin's lymphoma, 804, 807*t*
 daclizumab, renal transplantation, 291
 danaparoid, venous thromboembolism, 380
 danazol
 adverse effects, 722
 endometriosis, 722
 menorrhagia, 719–720, 720*t*
 premenstrual syndrome, 715
 dandruff, 658
 Danshen, 59
 dantrolene, pain, 527
 dantron, constipation, 212
 dapsone
 opportunistic infections in HIV, 639*t*
 Pneumocystis jiroveci pneumonia, 638
 daptomycin, meningitis, 589*t*, 590
 darbepoetin alfa, 286
 darifenacin, urinary incontinence, 157
 darunavir, HIV infection, 631*t*, 635
 darusentan, hypertension, 301
 dasatinib, chronic myelocytic leukaemia, 793
 DASH (Dietary Approaches to Stop
 Hypertension) diet, 298
 DaTSCAN, Parkinson's disease, 510
 daunorubicin, acute myeloblastic leukaemia,
 791–792
 D-dimers, 88*t*, 93
 debrisoquine hydroxylase (CYP2D6), 53, 66
 decision analysis, 119–120, 119*t*, 120*t*
 deep vein thrombosis (DVT), 376, 377–378
 diagnosis, 93
 in hormone replacement therapy, 729
 investigations, 378
 deferasirox
 iron overload, 775
 thalassaemias, 782
 deferiprone
 iron overload, 775
 thalassaemias, 782
 degarelix, prostate cancer, 763
 dehydration
 and diarrhoea, 214–216
 treatment/rehydration, 216–217, 216*t*
 delayed afterdepolarisations, 357–358, 357*f*
 demeclocycline, hypernatraemia, 79
 dementia, 152–153
 with Lewy bodies, 152
 in Parkinson's disease, 516
 see also Alzheimer's disease

- denosumab, 731
- depression
- adverse effects of benzodiazepines, 459
 - biochemical factors, 466
 - case studies, 476, 477
 - clinical features, 467
 - and coronary heart disease risk, 313
 - definition, 465
 - genetic, 466
 - incidence, 465–466
 - management, 468
 - menopause, 727, 735
 - in Parkinson's disease, 509
 - ST elevation myocardial infarction, 326
 - treatment, 469–473
 - drugs, 469–472
 - non-drug, 472–473
- dermatitis. *see also specific types*
- Dermatology Quality of Life Index (DQLI), 903
- dermatophytosis, 657–658
- clinical presentation, 657
 - diagnosis, 657
 - epidemiology, 657
 - treatment, 657–658
- dermis, 910
- desferrioxamine
- hepatotoxicity antidote, 231
 - iron overload, 775
 - thalassaemias, 782
- desmethyl-diazepam, 150
- desmopressin
- absorption in children, 137
 - intranasal administration, 140
- desvenlafaxine, 731
- detrusor instability, 156–157
- developmental model, schizophrenia, 480
- dexamethasone
- antiemesis, 539, 540, 542
 - bacterial meningitis, 592–593
 - cancer pain, 528
 - non-Hodgkin's lymphoma, 811–812
 - prostate cancer, 763
 - tuberculosis, 643
- dexamethasone suppression test, 466
- dextromoramide, 522
- dextropropoxyphene, 522
- DHAP (cisplatin, cytarabine, dexamethasone), non-Hodgkin's lymphoma, 811–812
- diabetes mellitus, 685–710
- aetiology, 686–687
 - affect on wound healing, 913, 913*t*
 - annual review, 706, 707*b*
 - antipsychotics, 486
 - β -blockers in, 317
 - case studies, 708*b*
 - causing chronic kidney disease, 276
 - classification, 685*b*
 - clinical manifestations, 688
 - common therapeutic problems, 707*b*
 - and coronary heart disease risk, 313
 - diabetic emergencies, 688–691
 - diagnosis, 688
 - dyslipidaemia, 394–395, 405
 - epidemiology, 686
 - foot problems, 693–694 (*see also* diabetic foot ulcers)
 - glycaemic management targets, 707
 - hypertension in, 305, 307
 - latent autoimmune diabetes in adults (LADA), 685–686
 - long-term complications, 691–694
 - macro- and microvascular disease combined, 693–694
 - macrovascular disease, 691*f*, 692
 - microvascular disease, 692–693, 692*f*
 - maturity-onset diabetes of the young (MODY), 685–686
 - monitoring glycaemic control
 - in the clinic, 707
 - at home, 707–709
 - myocardial infarction, 325
 - parenteral nutrition in, 111
 - pathophysiology, 687
 - of insulin resistance, 687
 - patient care, 706–709, 706*b*
 - surgical site infection, 599
 - treatment, 694–706
 - diet, 694–695
 - hypertension, 705
 - insulin therapy, 695–698
 - obesity, 706
 - structured education programs, 694
 - type 1, 695–698
 - type 2, 698–705
 - type 1, 394
 - aetiology, 686
 - definition, 685, 685*b*
 - incidence, 686
 - insulin therapy, 695–698
 - monitoring glycaemic control, 707–708
 - symptoms, 688
 - vs. type 2, 686*t*
 - type 2, 394–395
 - aetiology, 686–687
 - definition, 685, 685*b*
 - incidence, 686
 - insulin therapy, 705
 - management, 698–705
 - monitoring glycaemic control, 708–709
 - obesity management, 695
 - symptoms, 688
 - vs. type 1, 686*t*
- diabetic foot ulcers, 915–917
- aetiology, 915–916, 915*t*
 - case study, 923
 - clinical signs, 916, 916*f*
 - diagnosis, 916–917, 916*t*
 - epidemiology, 915
 - prevention of recurrence, 917
 - treatment, 917
- diabetic ketoacidosis, 690
- diagnosis, 690
 - treatment, 690
- diabetic nephropathy, 276
- diabetic peripheral polyneuropathy, 529, 531–532
- Diagnostic and Statistical Manual of Mental Disorders *see* DSM IV
- diamorphine
- absorption, 52
 - in children, 137
 - analgesia, 523*t*
 - cancer pain, 528
 - effect on neonates, 125
 - intranasal administration, 140
- diarrhoea, 209, 214–220
- aetiology, 214
 - case studies, 219*b*
 - common therapeutic problems, 218*t*
 - definition, 214
 - electrolyte content of, 105*t*
 - gastro-intestinal infections, 578
 - incidence, 214
 - investigations, 216
 - medicines causing, 215*t*
 - proton pump inhibitors adverse effects, 176
 - signs and symptoms, 214–216
 - traveller's, 214, 579
 - treatment, 216–220
- dehydration, 216–217, 216*t*
- drug treatment, 217–220
 - general measures, 216
- diastolic dysfunction, 334
- diazepam
- anxiety disorders, 459
 - distribution in the elderly, 150
 - epilepsy, 500
 - neonates, 124
 - seizures, 128–129
 - pain, 526
 - pharmacokinetics, 498*t*
 - profile, 458*t*
 - rectal administration, 140
- dibenzoxazepine tricyclics, schizophrenia, 483*t*
- diclofenac
- hepatotoxicity, 223*t*
 - inflammatory bowel disease, 186
- dicloxacillin, 225–226
- didanosine, HIV infection, 628*t*, 635
- diet
- affect on wound healing, 914
 - and cancer risk, 818
 - diabetes mellitus control, 694–695, 694*b*
 - and dyslipidaemia, 400–401
 - and endometriosis, 722
 - and gout, 851
 - and inflammatory bowel disease, 185–186
 - and iron deficiency anaemia, 771
 - modification in chronic kidney disease, 285, 286
 - and prostate cancer, 759, 764
 - vasomotor symptoms, menopause, 731–732
- dietary supplements, eczema, 898
- diethylene glycol poisoning, 67
- diethylstilboestrol (DES), prostate cancer, 763
- diffuse large B-cell lymphoma (DLBCL), 811, 812
- digitalis, 62
- digitoxin, chronic heart failure, 342*t*
- digoxin
- absorption, 38, 52
 - action and uses, 37, 342, 372
 - adverse reactions, 65, 342, 349, 372–373
 - arrhythmias, 359, 363, 372–373
 - bioavailability in children, 135
 - chronic heart failure, 336, 342, 342*t*, 344
 - disease interactions, 348*t*, 372*t*
 - distribution, 38
 - in the elderly, 150
 - drug interactions, 38, 348*t*, 372*t*
 - in the elderly, 150, 152
 - elimination, 38
 - and hypomagnesaemia, 82
 - pharmacokinetics, 37–38, 45*t*, 46, 368*t*, 372
 - plasma concentration-response relationship, 37
 - practical implications, 38
- dihydrocodeine, 522, 523*t*
- dihydropyridines
- adverse effects, 301, 349
 - hypertension, 301, 303*t*
 - in chronic kidney disease, 283
 - stable angina, 319
- dihydrotachysterol, hypoparathyroidism/hypocalcaemia, 681*t*
- dihydrotestosterone (DHT), 753
- prostate cancer, 759
 - urinary incontinence, 157
- di-iodotyrosine (DIT), 669
- dilator muscle theory, 862
- diloxanide, diarrhoea, 218
- diltiazem
- adverse effects, 73, 156, 349
 - arrhythmias, 325, 359

- coronary heart disease, 11*t*, 12*t*
hypertension, 156, 301
in chronic kidney disease, 283
interactions, 59
pharmacokinetics, 368*t*
stable angina, 319
- dimercapto succinic acid (DMSA) scan, 282
- dipeptidyl peptidase (DPP-4) inhibitors, 699
adverse effects, 704
diabetes mellitus, 701*t*, 704
drug interactions, 704
mode of action, 704
pharmacokinetics, 704
- Dipeptiven[®], 98
- diphenoxylate, diarrhoea, 217
- diphenylbutylpiperidines, schizophrenia, 483*t*
- dipipanone, analgesia, 522
- dipsticks, urinary tract infection, 564
- dipyridamole
arterial thromboembolism, 386
stroke, 153
- directly observed therapy (DOT), tuberculosis, 617–618
- disability in Parkinson's disease, 515
- discoid eczema, 895
- discounting, 119
- Disease Activity Score using 28 joint counts (DAS28), 833–834
- disease-modifying anti-rheumatic drugs (DMARDs)
choice of, 838
combination therapy, 836
key points, 838*b*
monotherapy, 836
onset of action, 836
rheumatoid arthritis, 836–839, 837*t*
- disinhibition, benzodiazepines, 459
- disopyramide
adverse effects, 367*t*
arrhythmias, 368–369
distribution, 53
pharmacokinetics, 368*t*
- distribution (of drugs)
in children, 137
drug interactions, 53
in the elderly, 150
in neonates, 124–125
in pregnancy, 742–743
in renal replacement therapy, 268
volume *see* volume of distribution (V_d)
- dithranol, psoriasis, 902, 903
- diuretics
adverse effects, 346–347
ascites, 246–247, 247*t*
chronic heart failure, 336, 337–338, 339*t*
disease interactions, 348*t*
drug interactions, 348*t*, 475*t*
and dyslipidaemia, 395
hypertension, 300–301, 303*t*, 307*t*
in chronic kidney disease, 284
in pregnancy, 306
loop *see* loop diuretics
neonatal heart failure, 127
patient education, 344
self-monitoring, 345*t*
thiazide *see* thiazide diuretics
- dobutamine, chronic heart failure, 342*t*, 343
- docetaxel, prostate cancer, 763–764
- docusate sodium, constipation, 157, 214
- dofetilide, adverse effects, 367*t*
- domperidone, antiemesis, 538, 541, 542
- donepezil
and dementia, 152, 153
hepatotoxicity, 223*t*
- Dong Quai, 59
- dopamine
in acute kidney injury, 263
affective disorders, 466
chronic heart failure, 342*t*, 343
premenstrual syndrome, 714
- dopamine agonists
Parkinson's disease, 512
side effects, 512
- dopamine receptors, 481
- dopaminergic agents, 215*t*
- dopexamine, chronic heart failure, 342*t*
- dorzolamide
glaucoma, 873, 874
and timolol, 874
- dosulepin, depression, 470
- DoTS system, 64, 65*t*
- doxapram
chronic obstructive pulmonary disease, 439
neonatal apnoea, 128
- doxazosin
benign prostatic hyperplasia, 757, 758
clinical trials, 302
hypertension, 301
- doxepin, depression, 470
- doxorubicin
Hodgkin's lymphoma, 804, 805, 807*t*
non-Hodgkin's lymphoma, 809, 811, 812
solid tumours, 826
- doxycycline
cholera, 579–580
interactions, 60
- D-penicillamine, rheumatoid arthritis, 836, 837*t*, 839
- dressings, wound, 922, 922*b*
- dronedaron, arrhythmias, 363
- drospirenone, 715
- drug abuse
benzodiazepines, 459–460
in children, 134
- drug-associated nausea and vomiting, 541
- drug-induced hypersensitivity syndrome (DIHS), 887–888, 887*f*
- drug-induced liver disease (DILD), 222–237
aetiology, 224–226
antidotes, 231
case studies, 235*b*
cholestatic, 224–225
clinical manifestations, 227–228
cytotoxic, 224–225
dose-related, 225*t*
enzyme elevation, 222–223, 223*t*
epidemiology, 222–223, 222*f*
idiosyncratic, 224–225, 225*t*, 229
incidence, 222
intrinsic, 224–225, 225*t*
investigations, 228
pathophysiology, 226–227
patient care, 232–236
patient counselling, 233–234
pruritus, 231
risk factors, 223–224
age, 223, 224*t*
concurrent diseases, 224, 224*t*
enzyme induction, 224, 224*t*
gender, 223, 224*t*
genetics, 224, 224*t*
polypharmacy, 224, 224*t*
pre-existing liver disease, 223, 224*t*
pregnancy, 224, 224*t*
risk minimisation, 234–236, 234*b*
treatment, 228–232
diagnosis, 228–229, 230*b*
long-term, 231
management, 231–232
- rechallenge, 231
supportive, 231
withdrawal, 229–231
- drug interactions, 50–61
case studies, 11*t*, 59, 60, 61
definition, 50
drug-disease, 8
drug-drug, 8–9
drug-food, 58
drug-herb, 58–59
drug-patient, 8
epidemiology, 51
high risk drugs, 51*b*
mechanisms, 51–59
pharmacodynamic interactions, 57–58
additive or synergistic interactions, 57, 57*t*
antagonistic interactions, 57
drug or neurotransmitter uptake interactions, 58
serotonin syndrome, 57–58
pharmacokinetic interactions, 51–57
absorption, 52
drug distribution, 53
drug metabolism, 53–56
elimination, 56–57
safety measures, 50
susceptible patients, 51
therapeutic benefits of, 50
see also specific drugs
- drug reaction with eosinophilia and systemic symptoms (DRESS), 887–888, 887*f*
- drug(s)
adherence *see* adherence/non-adherence
administration, 9, 9*t*, 10–12
advertising, 27
affect on wound healing, 914–915
communicating risks/benefits of, 23–24
controlled, 16
dosage, 9
and dyslipidaemia, 395–396
economic evaluation of, 120
establishing the need for, 7–8, 10
evaluating effectiveness, 10–12
and gout, 851
hepatotoxicity, 242
history, 8, 8*b*
and inflammatory bowel disease, 186
monitoring, 10, 12, 72
in the elderly, 158
in neonates, 129
patient advice/education, 10, 12
prescribing *see* prescribing (of drugs)
provision, 9–10
and psoriasis, 899
reconciliation, 4, 24
regimens, 9
safety, 63
selection, 8–9, 10
drug transport proteins, 52, 56–57
drug use process (DUP), 2, 3*t*, 5
dry powder inhalers (DPIs), 426, 426*f*
- DSM IV
affective disorders, 468
premenstrual dysphoric disorder, 713*b*
schizophrenia, 479
- dual energy, 99–100, 100*b*
- duloxetine
anxiety disorders, 461
depression, 472
pain, 526
- duodenal ulcer, 162, 163*f*, 164, 165, 174*f*
- Duodopa[®], 511
- Dupuytren's contracture, 242
- dura mater, 584–585

- dutasteride, benign prostatic hyperplasia, 758
 dyes in oral preparations, 139
 dysentery, 214, 217, 218, 575
 dyslipidaemia, 389–411
 aetiology, 392–396
 primary dyslipidaemia, 392–393
 secondary dyslipidaemia, 393–396
 case studies, 408*b*
 epidemiology, 389–390
 lipid-lowering therapy, 401–410
 bile acid binding agents, 405–407, 406*t*
 cholesterol absorption inhibitors, 407
 cholesterol ester transfer protein (CETP) inhibitors, 407–410
 fibrates, 405
 fish oils, 407
 nicotinic acid and derivatives, 407
 soluble fibre, 407
 statins, 402–405
 lipid transport, 390–392
 lipoprotein metabolism, 390–392
 risk assessment, 396–399
 primary prevention, 396–399
 secondary prevention, 399
 treatment, 399–401
 drugs, 401
 lifestyle, 399–401, 400*b*
 lipid profile, 399
- dysmenorrhoea, 716–718
 aetiology, 716–717
 epidemiology, 716
 pain management, 531
 primary, 716–717
 secondary, 717
 symptoms, 716–717
 treatment, 717–718, 718*t*
- dyspareunia, 732
 dyspepsia, 162–163, 165
 antacids, 178
 decision algorithm, 167*f*
 drugs causing, 166*b*
 gastro-oesophageal reflux disease, 173
 patient education, 178–179
 symptom subgroups, 166*b*
- dyspnoea
 in asthma, 414
 in chronic heart failure, 337*t*
 in the elderly, 156
- dystonia, 481
-
- E**
- ear infection, fungal, 659
 early afterdepolarisations, 357, 357*f*
 echocardiography, chronic heart failure, 335–336
 echoviruses, 585
 ecological model, schizophrenia, 480
 eczema, 893–898
 asteatotic, 895–896
 atopic, 893–894, 894*f*, 906, 906*f*, 907, 907*f*
 case studies, 906, 906*f*, 907, 907*f*
 in children, 133
 clinical features, 893, 894*f*
 discoid, 895
 drug-induced, 885
 gravitational, 919
 pathology, 893
 patient care, 898
 stasis, 895
 treatment, 896–898, 900*f*
 antihistamines, 897
 bandaging, 898
 calcineurin inhibitors, 897
 coal tar preparations, 898
 dietary supplements, 898
 drug interactions, 899*t*
 emollients, 896
 phototherapy, 898
 systemic therapies, 898, 904*t*
 topical corticosteroids, 896–897
 topical imidazoles, 897
 types, 893–896
- eczema herpeticum, 894, 907, 907*f*
 efaluzimab, psoriasis, 905
 efavirenz
 hepatotoxicity, 223*t*
 HIV infection, 628*t*, 630*t*
- eicosapentaenoic acid (EPA), dysmenorrhoea, 716
- elderly people *see* geriatrics
- electrocardiography
 normal, 355–356, 356*f*
 stable angina, 315
- electroconvulsive therapy (ECT), depression, 472–473
- electroencephalography (EEG), epilepsy, 492
- electrolytes, 77*t*
 acute kidney disease, 260
 acute kidney injury, 265
 cholera, 579–580
 chronic kidney disease, 280–281, 280*t*
 content of gastro-intestinal secretions, 105*t*
 gastro-intestinal infections, 578
 parenteral nutrition, 103
- elimination half-life, 35
- elimination (of drugs), 34–35
 in children, 138
 clearance, 34
 drug interactions, 56–57
 first-order, 34, 34*f*
 in neonates, 125
 total body, 34
- elimination rate constant (k_e), 34, 46
- emesis *see* nausea and vomiting
- EMLA, 136, 156
- emollient laxatives, 214
- emollients, eczema, 896, 896*f*
- emotional arousal system, 455
- emphysema, 432
 in chronic obstructive pulmonary disease, 434–435
 lung function tests, 435
- emtricitabine
 hepatitis B in HIV, 646
 HIV infection, 628*t*, 635
- Emtriva[®], 628*t*
- enalapril
 chronic heart failure, 340*t*
 clinical trials, 302
- encephalopathy
 hepatic, 248, 249*t*
 HIV, 645–646
 hypertensive, 296–297
- ENCORE, 5–6, 6*b*
- endocrine/autonomic arousal system, 455
- endocrine factors, affective disorders, 466
- endometrial ablation, menorrhagia, 721
- endometrial cancer, 718–719, 735
- endometriosis, 721–723
 aetiology, 721
 case study, 723
 epidemiology, 721
 symptoms, 721
 treatment, 721–723
- endorphins, 519–520
- endoscopic band ligation, oesophageal varices, 250
- endoscopy
 inflammatory bowel disease, 191
 peptic ulcer disease, 166, 168–169
- endothelins, dysmenorrhoea, 716
- endotracheal intubation, neonates, 125–126
- end-stage renal failure, 275
 causes of, 275
 clinical manifestations, 277
 renal transplantation, 288
- energy
 dual, 99–100, 100*b*
 parenteral nutrition, 99–101, 100*b*
- enfuvirtide, HIV infection, 636*t*, 637
- enoximone, chronic heart failure, 342*t*
- entacapone, Parkinson's disease, 513
- Entamoeba, 214, 576*t*
- entecavir, hepatitis B, 251
- enteric fever, 575–576
 investigations, 577
 treatment, 579–581, 581*t*
- enteric microflora, 186
- Enterobacter* sp., 591
 surgical site infection, 599–600
 urinary tract infections, 562
- enterohepatic shunt, 56
- enterotoxin, 214, 575
- enteroviruses, 585
- entry inhibitors, HIV infection, 636*t*, 637
- environmental factors
 affective disorders, 466
 inflammatory bowel disease, 185–186
 solid tumours, 818, 819*t*
- enzyme(s)
 induction, 54, 54*t*
 risk for drug-induced liver disease, 224
 inhibition, 54–55, 55*b*, 55*t*
 liver function tests, 85
- eosinophilia, drug-induced, 887–888, 887*f*
- eosinophils, 90
- epidermal growth factor receptor (EGFR), 825
- epidermis, 910
- Epidermophyton*, 657
- epidural analgesia, 524
- epidural local anaesthetics, 525
- epiglottitis, acute, 547–548
- epilepsy, 489–506
 aetiology, 490
 case studies, 504*b*
 chronic, 496
 clinical manifestations, 491–492
 common therapeutic problems in, 504*t*
 cryptogenic, 490
 diagnosis, 492
 epidemiology, 489–490
 evidence for clinical use of newer drugs, 503–506
 febrile convulsions, 493
 incidence, 490
 intractable, 496, 501
 mortality, 490
 pathophysiology, 490–491
 prevalence, 490
 prognosis, 490
 seizures *see* seizures
 severe myoclonic epilepsy of infancy, 503
 status epilepticus, 493
 treatment, 492–503, 492*b*
 general principles of, 493–496
 long-term, 493
 monitoring, 496–497
 during seizures, 493
- epinephrine *see* adrenaline
- episcleritis, 191
- Epivir[®], 628*t*
- eplerenone
 chronic heart failure, 339*t*, 341–342
 ST elevation myocardial infarction, 326

- epoetins, 286
 Epstein-Barr virus (EBV)
 and lymphomas, 807
 pharyngitis (sore throat), 546
 eptifibatide, arterial thromboembolism, 386
 ergocalciferol, 681*t*
 erlotinib, solid tumours, 825
 erythema multiforme, drug-induced, 885–886, 886*b*
 erythema nodosum, 190–191
 drug-induced, 885, 891
 erythrocyte glucose-6-phosphatase dehydrogenase (G6PD) deficiency *see* glucose-6-phosphatase dehydrogenase (G6PD) deficiency
 erythrocyte sedimentation rate (ESR), 88*t*, 91
 erythroderma, 883
 drug-induced, 888, 888*b*
 erythrodermic psoriasis, 902, 902*f*
 erythromycin
 adverse reactions, 65
 cholera, 579–580
 cystic fibrosis, 555–556
 diarrhoea, 217
 gastro-intestinal infections, 578
 hepatotoxicity, 223, 231
 Legionnaire's disease, 554
 metabolism, 53
 otitis media, 548
 pneumonia, 551
 erythropoiesis, 88
 normal, 770, 770*f*
 erythropoietin, 88, 770
 in sickle cell anaemia, 781
 erythropoietin analogues, 774
Escherichia coli, 127
 antibiotic resistance, 567
 diarrhoea, 214, 217–218
 gastro-intestinal infections, 574–575, 574*t*, 576*t*
 transmission, 573
 treatment, 578, 579
 urinary tract infections, 562
 verotoxin-producing, 133–134, 575, 576*t*
 escitalopram
 depression, 471, 472
 drug interactions, 176
 ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin), non-Hodgkin's lymphoma, 811–812
 eslicarbazepine acetate, epilepsy, 501
 esmolol
 arrhythmias, 370
 coronary heart disease, 318*t*
 esomeprazole
 drug interactions, 176
 formulations available, 175*t*
 intravenous, 175
 peptic ulcer disease, 173*t*, 175, 175*t*
 essential fatty acids, 714
 estradiol
 dose, 729
 hormone replacement therapy, 728–729
 menopause, 726, 732
 premenstrual syndrome, 713
 estrone, 726
 etanercept
 guidance on the use of, 841
 psoriasis, 905
 rheumatoid arthritis, 840
 ethambutol
 adverse effects, 616, 616*t*
 mycobacteria, 644
 tuberculosis, 612, 613, 613*t*, 614, 643
 ethanol *see* alcohol
 ethics, prescribing (of drugs), 17–18
 autonomy, 17, 17*b*
 beneficence, 18
 justice and veracity, 18
 non-maleficence, 17–18
 ethinylestradiol, 715
 ethionamide, tuberculosis, 616*t*
 ethnicity/race
 and adverse drug reactions, 66
 and chronic kidney disease, 272
 and coronary heart disease, 313
 and dyslipidaemia, 396
 and HIV infection, 648–651
 and hypertension, 296, 304–306, 307
 and inflammatory bowel disease, 186–187
 and prostate cancer, 759
 ethosuximide
 adverse effects, 500*t*
 drug interactions, 499*t*
 epilepsy, 501
 pharmacokinetics, 498*t*
 etidronate
 adverse effects, 154
 alternatives to HRT, 731
 osteoporosis, 154
 etoposide
 Hodgkin's lymphoma, 805
 non-Hodgkin's lymphoma, 811–812
 etoricoxib, gout, 853
 etravine, HIV infection, 630*t*, 635
 EUROPA study, 317
 evening primrose oil, 59
 exanthems, drug-induced, 883, 883*f*, 888*b*
 excitation-contraction coupling, 354
 excretion (of drugs)
 in pregnancy, 742–743
 in renal replacement therapy, 268
 see also elimination (of drugs)
 exenatide, 704–705
 exercise
 children, 134
 and coronary heart disease, 330
 and dyslipidaemia, 401
 exfoliative dermatitis, drug-induced, 888
 extended-spectrum β -lactamase (ESBL)-producing bacteria, 566
 extensively drug-resistant tuberculosis (XDR-TB), 608, 609
 extracellular fluid (ECF), 76
 osmolality, 77, 78
 potassium, 79
 volume, 78, 137, 137*t*
 extracorporeal membrane oxygenation (ECMO), 126
 extractable nuclear antigens (ENA), rheumatoid arthritis, 834
 extravasation, 827
 eye contact, 22
 eye drops administration, 875–876
 eye movement desensitisation and reprocessing (EMDR), 457
 eyes
 in chronic kidney disease, 278
 in ulcerative colitis, 191
 ezetimibe, dyslipidaemia, 403*t*, 407
-
- F**
 factor VIII, 91
 factor V Leiden
 thrombophilia, 715
 venous thromboembolism, 377
 faecal softeners, 214
 famciclovir, opportunistic infections in HIV, 639*t*
 familial apolipoprotein C-II deficiency, 393
 familial combined hyperlipidaemia, 393
 familial hypercholesterolaemia, 392–393, 399*b*
 familial lipoprotein lipase deficiency, 393
 familial type III hyperlipoproteinaemia, 393
 famotidine, peptic ulcer disease, 177
 fats, 695
 fatty acids, 100–101
 fatty liver disease, non-alcoholic, 241
 febrile convulsions, 493
 febrile neutropenia, 814
 febuxostat, gout, 856
 felbamate
 adverse effects, 501
 epilepsy, 501
 felodipine
 chronic heart failure, 343–344
 interactions, 58
 metabolism, 55
 fenofibrate, dyslipidaemia, 393–394, 405
 fenoldopam, acute kidney injury, 263
 fentanyl
 absorption in children, 136–137
 analgesia, 522, 523*t*
 intranasal administration, 140
 patches, 136
 ferritin, 88*t*
 anticoagulant therapy monitoring, 93
 in liver disease, 244
 ferrous sulphate, 772
 fetal cell transplantation, Parkinson's disease, 514–515
 feverfew, 59, 61
 fibrates
 adverse effects, 405
 drug interactions, 406*t*
 dyslipidaemia, 403*t*, 405
 fibre intake, 210–211
 in diabetes mellitus, 695
 fibrin, 91
 fibrinogen, 91, 314
 fibrinogen gamma 10034T, venous thromboembolism, 377
 fibrinolytic agents
 adverse effects, 324
 categories, 324
 contraindications, 324–325, 325*b*
 ST elevation myocardial infarction, 322, 323, 323*t*, 324–325
 venous thromboembolism, 384–385
 fibroids, 719
 Fibroscan, 244
 fibrosis
 liver, 227
 pulmonary, 371, 433, 813*t*
 finasteride
 benign prostatic hyperplasia, 757–758
 urinary incontinence, 157
 finger clubbing, 242
 fish, dyslipidaemia, 400
 fish oils
 dyslipidaemia, 400, 407
 inflammatory bowel disease, 202, 203*t*
 fixed costs, 117
 fixed drug eruptions, 884, 884*b*, 884*f*
 flecainide
 adverse effects, 367*t*
 arrhythmias, 359, 361, 365
 pharmacokinetics, 368*t*
 flexible cystoscopy, benign prostatic hyperplasia, 755
 flexural psoriasis, 901–902
 flu *see* influenza
 flucloxacillin
 cystic fibrosis, 555–556
 hepatotoxicity, 223, 224, 225–226
 neonates, respiratory distress syndrome, 130

- fluconazole
 absorption, 52
 candidiasis, 656–657
 clinical use, 663
 cryptococcus neoformans, 643
 fungal infections in compromised host, 663
 meningitis, 592
 opportunistic infections in HIV, 639*t*
 oropharyngeal candidiasis, 638–643
 pharmacokinetics, 664*t*
 resistance, 663
- flucytosine
 administrations, 663
 adverse effects, 663
 cryptococcus neoformans, 643
 fungal infections in compromised host, 662–663
 meningitis, 591–592
 mode of action, 662–663
 opportunistic infections in HIV, 639*t*
 pharmacokinetics, 663, 664*t*
- fludarabine
 acute myeloblastic leukaemia, 792
 chronic lymphocytic leukaemia, 793
- fluid balance in acute kidney disease, 260
- fluid intake, constipation, 210–211
- fluid overload, 263–264
 children, 140
 in chronic kidney disease, 278
- fluid replacement
 in acute kidney injury, 263
 cholera, 579–580
 gastro-intestinal infections, 578
 hyperosmolar hyperglycaemic state, 691
 oesophageal varices, 249
- fluid requirements, factors affecting, 98*t*
- fluid retention in chronic kidney disease, 286
- flumazenil, 459
- fluoroquinolones
 gastro-intestinal infections, 573–574, 578–579
 Legionnaire's disease, 552
 prostatitis, 766
 urinary tract infections, 566, 569
- 5-fluorouracil (5FU), 825
- fluoxetine
 depression, 469, 471
 interactions, 58, 60
- flupentixol, schizophrenia, 483*t*
- fluphenazine
 drug-induced parkinsonism, 509–510
 schizophrenia, 483*t*
- flutamide, prostate cancer, 762–763
- fluticasone, asthma, 419*t*
- fluvastatin
 dyslipidaemia, 402
 metabolism, 55, 404
- fluvoxamine, depression, 471
- focal atrial tachycardia, 359
- focal segmental necrotising glomerulonephritis (FSNGN), 258
- focal seizures, 491–492
- foetal development, 740
- foetal-placental transfer, 743
- folate deficiency anaemia
 aetiology, 776
 clinical manifestations, 777
 drugs implicated in, 777*b*
 epidemiology, 776
 investigations, 777
 pathophysiology, 776
 patient care, 779
 treatment, 778
- folic acid/folates, 88*t*
 anticoagulant therapy monitoring, 93–95
 deficiency in chronic kidney disease, 286
 pre-conceptual, 744
 in sickle cell anaemia, 781
 supplementation during pregnancy, 133
- folinic acid, 825
- toxoplasmosis, 643
- follicle-stimulating hormone (FSH), 726
- follicular lymphoma, 809
- folliculitis
 candida, 656
 Malassezia, 658, 659
- fondaparinux
 non-ST elevation myocardial infarction, 328–329
 ST elevation myocardial infarction, 324
 venous thromboembolism, 380
- food(s)
 adding medicines to, 139
 allergy, 894
 poisoning, 214, 573, 577, 578
 see also diet; nutrition
- foot problems in diabetes mellitus, 693–694
 see also diabetic foot ulcers
- forced expiratory volume (FEV)
 asthma, 414
 chronic obstructive pulmonary disease, 435
- forced vital capacity (FVC)
 asthma, 414
 chronic obstructive pulmonary disease, 435
- formoterol, asthma, 417, 418*t*
- formularies, 29
- formulation choice, 32
- fosamprenavir, HIV infection, 631*t*
- foscarnet
 cytomegalovirus, 644
 opportunistic infections in HIV, 639*t*
- fosfomycin, urinary tract infections, 567–568
- fosinopril, chronic heart failure, 340*t*, 341
- FP-CIT SPECT, Parkinson's disease, 510
- fractional excretion of sodium (FENa), 259
- fractures, osteoporotic, 726–727
- Framingham risk charts, 396–397
- Fraser guidance, 17
- free fatty acids, 248
- frontotemporal dementia, 152
- fumaric acid esters
 eczema, 904*t*
 psoriasis, 904*t*, 905
- fungaemia, 660*t*
- fungal infections, 654–668
 case studies, 667*b*
 classification, 655*t*
 in the compromised host, 659–668
 choice of treatment, 666–668
 clinical presentation, 660, 660*t*
 diagnosis, 660
 epidemiology, 659–668
 predisposing factors, 659–668
 treatment, 660
 deep-seated, 659, 660*t*
 in HIV, 638
 laboratory diagnosis, 654–655
 superficial, 656–659
- fungal meningitis, 660*t*
 aetiology, 585
 diagnosis, 586–587
 epidemiology, 585
 presentation, 586
- fungi, 654
 characteristics, 654*t*
 classification, 655*t*
 definition, 654
 reproduction, 654
- furazolidine, cholera, 579–580
- furosemide
 acute kidney injury, 263
 adverse reactions, 64
 ascites, 247, 247*t*
 chronic heart failure, 338, 339*t*, 351
 distribution in the elderly, 150
 elimination in children, 138
 gout, 853
 hypercalcaemia, 81
 and hypocalcaemia, 82
 and hypomagnesaemia, 82
 interstitial nephritis, 258–259
 neonates
 bronchopulmonary dysplasia, 127
 heart failure, 131
 fusarium keratitis, 659
 fusion inhibitors, 637
 Fuzeon[®], 636*t*
-
- G**
- GABA *see* γ -aminobutyric acid (GABA)
- gabapentin, 495*t*, 496
 adverse effects, 500*t*
 alternatives to HRT, 731
 epilepsy, 501
 pharmacokinetics, 44, 498*t*
 plasma concentration-response relationship, 44
 postherpetic neuralgia, 529
- galantamine, dementia, 152, 153
- gallstones, 191
- gametogenesis, 726
- γ -aminobutyric acid_A (GABA_A) receptors, 449, 449*f*, 458–459, 458*f*
- γ -aminobutyric acid (GABA)
 anxiety disorders, 456, 458–459, 458*f*
 hepatic encephalopathy, 248
- γ -glutamyl transpeptidase
 in liver disease, 244
 liver function tests, 86
- ganciclovir
 cytomegalovirus, 644
 opportunistic infections in HIV, 639*t*
- garlic, 59, 61
- gas exchange abnormalities, 434
- gastric acidity, 575
- gastric acid secretion, 164
- gastric juice, electrolyte content of, 105*t*
- gastric lavage, paracetamol overdose, 232
- gastric ulcers, 165, 170*f*
- gastric varices, 249–250
- gastrin, 164
- gastroenteritis, 214
 causes of, 576*t*
 clinical presentation, 575
 definition, 573
 investigations, 576
 transmission, 573
- gastro-intestinal erosions, uraemic, 264–265
- gastro-intestinal infections, 573–583
 aetiology, 573–574
 case studies, 582*b*
 causes, 574*t*
 clinical manifestations, 575–576
 epidemiology, 573–574
 investigations, 576–577, 577*f*
 pathophysiology, 574–575
 patient care, 581–583
 transmission, 573
 treatment, 578–581
 problems with, 581*t*
- gastro-intestinal motility
 effect of drugs on, 52, 210
 mechanisms of, 210
- gastro-intestinal secretions, electrolyte content of, 105*t*

- gastro-intestinal tract, 209–210, 210f
 cytomegalovirus, 644
 effect of NSAIDs on, 836
 haemorrhage/bleeding, 94
 in the elderly, 157
 pH, 52
 potassium loss from, 80
 symptoms in chronic kidney disease, 285
 ulceration (*see also* duodenal ulcer; gastric ulcers; peptic ulcer disease)
 in the elderly, 157
- gastro-oesophageal reflux disease (GORD), 162
 antacids, 178
 symptoms, 174b
 treatment, 173–175, 174f
- gastrostomy administration of drugs, 140
- gate control theory of pain, 519, 519f
- gatifloxacin, gastro-intestinal infections, 579
- gemcitabine
 Hodgkin's lymphoma, 806
 non-Hodgkin's lymphoma, 811–812
- gender
 adverse drug reactions, 65
 chronic kidney disease, 272
 constipation, 209
 coronary heart disease, 313
 dyslipidaemia, 396
 risk for drug-induced liver disease, 223
- generalised anxiety disorder (GAD), 454–455, 455t
 antidepressants, 460, 461
 pregabalin, 461
 recommended drug treatments, 462t
- generalised seizures, 491
- genetic liver disorders, 241–242
- genetic model, schizophrenia, 480
- genetics
 affective disorders, 466
 causing chronic kidney disease, 277
 gout, 850
 inflammatory bowel disease, 186–187
 leukaemia risk, 787
 Parkinson's disease, 507–508
 prostate cancer, 759
 rheumatoid arthritis, 832
 risk for drug-induced liver disease, 224
 solid tumours, 818–819
- genitals, psoriasis, 903
- gentamicin
 acute pyelonephritis, 568
 adverse effects, 39
 clinical use, 39
 distribution, 39
 dosage
 changing, 39
 initial, 39
 once daily, 39–40, 40f
 elimination, 39
 and hypomagnesaemia, 82
 meningitis, 589t, 593t
 neonates, 125
 respiratory distress syndrome, 130
 pharmacokinetics, 39–40, 45t
 renal clearance in children, 138t
 therapeutic range, 39
 urinary tract infections, 569t
- geriatrics, 149–160
 adverse drug reactions, 65, 459
 case studies, 159b
 common clinical disorders, 152–157
 arthritis, 155
 cardiac failure, 156
 constipation, 157, 209, 212
 dementia, 152–153
 gastro-intestinal ulceration and bleeding, 157
 hypertension, 155–156
 leg ulcers, 156
 myocardial infarction, 156
 osteoporosis, 154–155
 parkinsonism, 153
 stroke, 153–154
 urinary incontinence, 156–157
- dehydration, 216–217
- epilepsy in, 490
 and folate deficiency anaemia, 777
 hypertension, 304–305, 309
 insomnia, 451
- pharmacodynamics, 150–152
 age-related changes in specific receptors/
 target sites, 151–152
 reduced homeostatic reserve, 151
- pharmacokinetics, 149–150
- principles and goals of drug therapy, 157–158
- sleep patterns, 447
 urinary tract infections, 562, 563
- Giardia, 214, 218, 580
Giardia lamblia, 576t
- Gilbert syndrome, 242
- Gillick competence, 17
- ginger, antiemesis, 539, 541
- Ginkgo, 59
- ginseng, 59, 61
- Glamin®, 98, 99t
- Glasgow-Blatchford score, 166
- glaucoma, 861–879
 aetiology, 862
 case studies, 877b
 chronic open-angle
 clinical manifestations, 862–863
 epidemiology, 861, 862
 pathophysiology, 862
 patient care, 875–876
 treatment, 863–865, 866f
 clinical manifestations, 862–863
 common therapeutic problems, 877t
 epidemiology, 861–862
 chronic open-angle glaucoma, 862
 primary angle-closure glaucoma, 862
 secondary glaucomas, 862
 investigations, 863
 pathophysiology, 862
 patient adherence, 877–878
 patient care, 875–878
 chronic open-angle glaucoma, 875–876
 primary angle-closure glaucoma, 876–877
- primary angle-closure
 clinical manifestations, 863
 drugs contraindicated in, 876t
 epidemiology, 862
 pathophysiology, 862, 863f
 patient care, 876–877
 treatment, 865, 867f
- secondary, 862
 treatment, 863–865
 β-blockers, 868–871, 869t, 870t
 carbonic anhydrase inhibitors, 873, 873b, 873t
 chronic open-angle glaucomas, 863–865, 864t, 865t
 combination products, 873–874
 hyperosmotic agents, 875, 875t
 miotics, 872, 872b, 872t
 ocular prostanooids, 865–868, 868t, 869t
 primary angle-closure glaucoma, 865
 sympathomimetic agents, 871–872, 871t, 872t
- Gleason scale, 760, 760f
- glibenclamide, diabetes mellitus, 700
- gliptins *see* dipeptidyl peptidase (DPP-4)
 inhibitors
- glitazones *see* thiazolidinediones
- global introspection, 69
- Global Registry of Acute Coronary Events (GRACE), 321
- glomerular filtration rate (GFR), 82, 83, 268
 in children, 138
 in chronic kidney disease, 272
 in diabetes mellitus, 693
 estimate (eGFR), 37, 274, 274f
 graphical plots of, 282
 in pregnancy, 742
- glomerulonephritis, 258
 chronic, 276
 focal segmental necrotising, 258
 rapidly progressive, 258
- GLU9, 850
- glucagon, 690
- glucocorticoids
 effect on lipoprotein levels, 394t
 meningeal tuberculosis, 614
 rheumatoid arthritis, 839
- glucosamine, 74
- glucose, 77t
 in acute kidney injury, 265
 extracellular fluid osmolality, 77
 hyperkalaemia, 264
 hypoglycaemia, 690
 insulin release, 687
 oral rehydration solutions, 216–217
 parenteral nutrition, 100, 100t
 serum, 84
- glucose-6-phosphatase dehydrogenase (G6PD)
 deficiency, 782–785
 adverse drug reactions, 66
 aetiology, 782
 in breastfed infants, 749
 clinical manifestation, 783, 783b
 epidemiology, 782
 investigations, 783
 pathophysiology, 782
 patient care, 783–785
 treatment, 783
- glucose tolerance test, 688
- L-glutamine, 98
- glycaemic control, diabetes, 707–709
- glycated haemoglobin, 84
- glycerol, 139, 875
- glyceryl trinitrate (GTN)
 chronic heart failure, 340t, 343
 coronary heart disease, 11t, 12t
 stable angina, 319, 320t
 ST elevation myocardial infarction, 321
- glycogen storage disease, 241
- glycopeptides, surgical site infection prophylaxis, 604
- glycoprotein IIb/IIIa receptor antagonists
 arterial thromboembolism, 386
 non-ST elevation myocardial infarction, 327, 329, 329f
 ST elevation myocardial infarction, 324
- Glycyrrhizin glabra*, 59
- GnRH analogues *see* gonadotrophin-releasing hormone (GnRH) analogues
- goitre, toxic multinodular, 674, 676
- gold, rheumatoid arthritis, 836, 837t, 839
- golimumab, rheumatoid arthritis, 840
- gonadotrophin-releasing hormone (GnRH)
 analogues
 adverse effects, 722
 endometriosis, 722
 menorrhagia, 719–720, 720t, 721
 premenstrual syndrome, 716
- gonioscopy, glaucoma, 863
- Goodpasture's disease, 258
- goserelin, prostate cancer, 762

gout, 848–860
 case studies, 857*b*
 course of disease, 852, 852*f*
 definition, 848
 diagnosis, 851–852
 epidemiology, 848–849
 pathophysiology, 849–850, 850*b*, 850*t*
 patient care, 857–859
 presentation, 851–852
 preventing flare, 857
 primary, 850, 850*t*
 risk factors, 850–851
 secondary, 850, 850*t*
 tophi, 852, 852*f*
 treatment, 852–857, 852*b*
 acute gout, 852–854, 853*b*
 chronic gout, 854–857, 855*b*, 855*f*, 855*t*
 governance *see* clinical governance
 graduated compression, 919
 graft-versus-host disease (GVHD), 795
 grand mal seizures, 491
 granisetron, antiemesis, 540
 granulation tissue, 912
 granulocyte colony-stimulating factor (G-CSF)
 acute myeloblastic leukaemia, 792
 lymphomas, 815
 granulomatous hepatitis, 226*t*, 227
 grapefruit juice, 50, 55, 58
 Graves' disease, 674
 case study, 682
 extrathyroidal manifestations, 675
 ophthalmopathy, 678
 treatment, 676
 gravitational dermatitis, 895
 gravitational eczema, 919
 Griess test, 564
 griseofulvin, dermatophytosis, 658
 growth factors
 hepatitis C, 251–252
 leukaemia, 796–797
 lymphomas, 815–816
 growth hormone antagonists, 215*t*
 gut decontamination, 796
 guttate psoriasis, 901, 901*f*
 gynaecomastia, 243

H

HAART *see* highly active antiretroviral therapy (HAART)
 haem arginate, sideroblastic anaemia, 775
 haematological disorders, 787
 haematology data, 88–90, 88*t*
 D-dimers, 88*t*
 descriptive terms, 89*t*
 erythrocyte sedimentation rate (ESR), 88*t*
 ferritin, 88*t*
 haemoglobin, 88*t*, 90
 iron, 88*t*
 mean cell haemoglobin concentration (MCHC), 88*t*, 89–90
 mean cell haemoglobin (MCH), 88*t*, 89
 mean cell volume (MCV), 88*t*, 89
 packed cell volume (PCV), 88*t*, 89
 paediatric, 143*t*
 platelets (thrombocytes), 88*t*, 90
 red blood cell count, 88–89, 88*t*
 red cell folate, 88*t*
 reticulocytes, 88*t*, 89
 serum B₁₂, 88*t*
 total iron binding capacity (TIBC), 88*t*
 transferrin, 88*t*
 white blood cell count, 88*t*, 90, 90*f*
 haematuria in chronic kidney disease, 277–278
 haemochromatosis, 241, 242
 haemodiafiltration, 266
 haemodialysis, 265–266, 266*f*, 267*t*, 292
 haemofiltration, 266, 267*t*
 continuous arterio-venous, 266
 continuous venovenous, 266
 slow continuous ultrafiltration, 266
 haemoglobin, 88*t*, 90, 94
 concentration, 770–771
 glycosylated, 84
 low *see* anaemia
 haemoglobin S, 780, 781
 haemolytic anaemias, 769*t*, 779–785, 779*t*
 autoimmune, 779–780, 780*b*
 case study, 784
 clinical manifestations, 779
 treatment, 779
 haemolytic uraemic syndrome (HUS), 133–134, 575, 578
 Haemophilus influenzae
 bronchitis, 549
 chronic obstructive pulmonary disease, 438–439
 cystic fibrosis, 555
 otitis media, 548
 pneumonia, 552
 type b (Hib), 585, 588, 589
 chemoprophylaxis, 590–591, 590*b*, 591*b*
 epiglottitis, 547
 treatment, 590
 haemopoiesis, 787, 787*f*
 haemorrhage
 heparin-induced, 379
 torrential venous, 243
 warfarin-induced, 381, 384*t*
 haemorrhagic disease of the newborn, 128
 haemorrhagic stroke, aspirin-induced, 386
 haemosiderin, 918
 hair
 drug-induced changes, 882–883, 882*b*
 excessive, 882–883
 loss of, 882
 haloperidol
 mania, 473
 schizophrenia, 483*t*
 halothane hepatotoxicity, 223, 224, 234
 Hamilton Depression Rating Scale, 468
 Harris Benedict equation, 99
 Harvey-Bradshaw Index (HBI), 192
 hawthorn, 59
 hay fever, 133
 headache, 530–531
see also migraine
 head circumference, 135
 Health and Social Care Act (2001), 16
 healthcare-associated infections (HCAs), 596
see also surgical site infection
 health professionals, roles in adverse drug reactions, 71–74
 heart
 normal cardiac conduction, 355–356, 356*f*
 sinus rhythm, 354
 sounds, 335
see also entries beginning cardiac
 heart block, 365
 heart failure
 chronic *see* chronic heart failure (CHF)
 in the elderly, 156
 neonates, 127, 131
 parenteral nutrition in, 111
 with preserved ventricular ejection fraction (HFPEF), 334
 during ST elevation myocardial infarction, 325
 height, children, 135

Heinz bodies, 782
 Helicobacter pylori, 162*b*
 and coronary heart disease risk, 313
 detection, 166–168
 in the elderly, 157
 epidemiology, 163, 163*f*
 eradication, 166, 171–172
 pathogenesis, 163–164
 Henderson-Hasselbalch equation, 83, 83*f*
 heparin
 adverse effects, 379
 atrial fibrillation, 363
 hepatotoxicity, 223*t*
 low molecular weight *see* low molecular weight heparin (LMWH)
 non-ST elevation myocardial infarction, 327, 328–329
 parenteral nutrition in children, 113
 ST elevation myocardial infarction, 324
 stroke, 153
 unfractionated *see* unfractionated heparin
 venous thromboembolism, 379–380, 387
 heparinoids, venous thromboembolism, 380
 hepatic clearance, 150
 hepatic encephalopathy, 248, 249*t*
 hepatic microsomal enzyme inducers, 396
 hepatitis
 acute, 226*t*, 227
 antiretroviral toxicity, 637
 autoimmune, 241, 252
 chronic
 active, 226*t*, 227
 biochemical tests, 244
 granulomatous, 226*t*, 227
 hepatitis A virus (HAV), 239, 244
 hepatitis Be antigen (HBeAg), 240, 251
 hepatitis Bs antigen (HBsAg), 251
 hepatitis B virus (HBV), 239–240
 acute liver failure, 250
 in HIV, 646
 laboratory investigation, 244
 liver biopsy, 244
 management, 251
 vaccine in neonates, 130
 hepatitis C virus (HCV), 239, 240
 in HIV, 646
 laboratory investigation, 244
 liver biopsy, 244
 management, 251–252
 sustained virologic response, 251–252
 hepatitis D virus (HDV), 239, 240
 hepatitis E virus (HEV), 239, 240
 hepatocellular carcinoma, 240
 hepatocellular jaundice, 242–243
 hepatocytes, 238
 hepatomegaly, 242
 hepatorenal syndrome, 246–248, 257*t*
 hepatotoxicity *see* drug-induced liver disease (DILD)
 hepcidin, 93
 herbal medicines, 58–59
 hepatotoxicity, 230*b*
 interactions, 50
 hereditary haemochromatosis (HH), 241
 herpes zoster infection, 529
 high-density lipoprotein cholesterol (HDL-C), 389, 390
 and cardiovascular disease, 389
 lipid profile, 399
 menopause, 727
 metabolism, 390
 optimal, 389*t*
 reverse cholesterol transport pathway, 390–391

- high-grade prostatic intra-epithelial neoplasia (HGPIN), 759
- high-intensity focused ultrasound (HIFU), 761
- highly active antiretroviral therapy (HAART)
- AIDS dementia complex, 646
 - failure, 626
 - HIV infection, 625
 - impact on opportunistic infections, 645
- Hippocratic Oath, 17–18
- hirsutism, drug-induced, 882–883, 882*b*
- hirudins, venous thromboembolism, 380
- histamine H₁ antagonists *see* antihistamines
- histamine H₂ antagonists
- absorption, 52
 - adverse reactions, 177
 - drug interactions, 177–178
 - peptic ulcer disease, 169–170, 172, 173, 177–178
- Histoplasma capsulatum*, 585
- HIV infection, 621–653
- breastfeeding in, 745
 - case studies, 648*b*
 - CD4 count, 624–625
 - clinical manifestations, 622–624
 - drug treatment, 625–651
 - antiretroviral therapy, 625–637
 - opportunistic infections and malignancies, 637–651
 - epidemiology, 621
 - and ethnicity, 648–651
 - hepatitis B co-infection, 646
 - hepatitis C co-infection, 646
 - investigations and monitoring, 624–625
 - lifecycle, 623*f*
 - lymphomas in, 807
 - neurological manifestations, 645–646
 - pathogenesis, 621–622, 622*f*, 623*f*
 - pharmacogenetics, 66
 - primary, 624
 - resistance testing, 625
 - transmission to neonates, 127
 - tropism testing, 625
 - tuberculosis in, 609, 612, 615
 - viral load, 625
 - virus structure, 622*f*
 - in women, 646–648
- HIV-protease inhibitors, 54
- HLA-*B570, 66
- HLA-B*1502, 66
- HLA-*B5701, 66
- HMG-CoA, 402
- Hodgkin's lymphoma, 803–806
- aetiology, 803
 - case study, 816
 - investigations and staging, 804, 806*b*
 - laboratory findings, 804
 - management, 804–805
 - advanced disease, 805, 807*t*
 - early-stage (favourable) disease, 804
 - early-stage (unfavourable) disease, 805
 - new agents, 806
 - pathology, 803
 - salvage therapy for relapsed disease, 806, 807*t*
 - signs and symptoms, 804
 - types, 803
- homeostatic reserve, reduced in geriatrics, 151
- HOPE study, 317, 326
- hormonal analogues, 525*t*
- hormone replacement therapy (HRT), 727–731
- alternatives to, 731
 - case studies, 736, 737
 - clinical monitoring, 730–731
 - and coronary heart disease, 315
 - effects, 725
 - and hypertension, 306
- menopause, 727–731
- bone, 732
 - cancer, 734–735
 - cardiovascular system, 733
 - central nervous system, 736–737
 - psychological symptoms, 735
 - urogenital tract, 732
 - vasomotor symptoms, 731–732
- oestrogen *see* oestrogen therapy
- oestrogen and progestogen regimens, 729–730, 729*b*
- osteoporosis, 154–155
- prescribing, 727–728
 - progestogen therapy, 729–730
 - prostate cancer, 761–763
 - rалoxifene, 730
 - stopping, 731
 - tibolone, 730
- hormonogenesis, 726
- horse chestnut, 59, 61
- hospital-acquired (nosocomial) pneumonia, 552–555
- causative organisms, 552–553, 553*b*
 - clinical features, 553
 - diagnosis, 553
 - prevention, 554–555
 - treatment, 553–554, 554*t*
- hot flushes, 731–732, 736
- house dust mite, 412–413
- human epidermal growth factor receptor type 1 (HER1), 825
- human epidermal growth factor receptor type 2 (HER2), 825
- human growth hormone, 203*t*
- human *metapneumovirus* (hMPV), 545
- human T-lymphotrophic virus type 1 (HTLV-1), 807
- hyaline membrane disease *see* respiratory distress syndrome (RDS)
- hyaluronan, osteoarthritis, 845
- hydralazine
- chronic heart failure, 336, 340*t*, 343, 344
 - hypertension, 301
 - in chronic kidney disease, 285
 - in pregnancy, 306
- hydrazine, 224
- hydrochlorothiazide
- clinical trials, 302
 - and hypomagnesaemia, 82
- hydrocortisone
- asthma, 422
 - inflammatory bowel disease, 193, 195, 203*t*
 - prostate cancer, 763
- hydrocortisone sodium succinate, inflammatory bowel disease, 195
- hydrogen ions, 281
- hydrogen peroxide, 669
- hydromorphone
- analgesia, 522, 523*t*
 - cancer pain, 528
- hydroxocobalamin, 778–779
- hydroxycarbamide
- chronic myelocytic leukaemia, 792
 - psoriasis, 905
 - in sickle cell anaemia, 781
- hydroxychloroquine, rheumatoid arthritis, 836, 837*t*, 839
- 5-hydroxytryptamine (5HT) *see* serotonin
- hydroxyurea
- eczema, 904*t*
 - nail changes, 881–882
 - psoriasis, 904*t*, 905
- 25-hydroxy vitamin D (25-OHD), 82
- hydroxyzine
- anxiety disorders, 461
 - pruritus in liver disease, 245, 245*t*
- hyoscine butylbromide, dysmenorrhoea, 717
- hyoscine hydrobromide
- antiemesis, 538, 541
 - patches, 136
- hyperaldosteronism, 297
- Hyperamine®, 99*t*
- hyperammonaemia, 86
- hyperbilirubinaemia
- in neonates, 125
 - unconjugated, 85
- hypercalcaemia, 81
- causes of, 681
 - effect on digoxin pharmacokinetics, 38
 - treatment, 682–684, 682*t*
- hypercholesterolaemia, 313–314
- antiretroviral toxicity, 637
 - familial, 392–393, 399*b*
- hyperemesis gravidarum, 541
- hypergammaglobulinaemia, 88
- hyperglycaemic hyperosmolar non-ketotic coma, 94
- hyperkalaemia, 80–81, 81*b*, 261
- in acute kidney injury, 264
 - in chronic kidney disease, 281, 281*f*, 286
 - treatment, 264
- hyperkeratosis, 893, 900–901
- hyperlipidaemia, familial combined, 393
- hyperlipoproteinaemia, familial type III, 393
- hypermagnesaemia, 82
- hypernatraemia, 78–79, 79*b*, 280*t*
- hyperosmolar hyperglycaemic state (HHS), 691
- diagnosis, 691
 - treatment, 691
- hyperosmotic agents, glaucoma, 875, 875*t*
- hyperparathyroidism, 81, 280, 680–684
- aetiology, 680–681
 - case study, 683
 - in chronic kidney disease, 287–288
 - clinical manifestations, 681, 681*b*
 - epidemiology, 680
 - investigations, 681
 - treatment, 681–682
- hyperphosphataemia, 82, 264, 279–280, 287, 680
- hyperpigmentation
- drug-induced, 881
 - in liver disease, 242
- hyperresponsiveness, asthma, 412–413
- hypersensitivity reactions to drugs, 67, 67*t*
- see also* adverse drug reactions (ADRs)
- hypertension, 295–311
- blood pressure regulation, 296
 - case studies, 307*b*
 - causes of, 296*b*
 - causing chronic kidney disease, 276
 - and chronic heart failure, 334
 - in chronic kidney disease, 278
 - clinical presentation, 296–297
 - complications, 295*b*
 - in diabetes mellitus, 692, 705
 - in the elderly, 155–156
 - epidemiology, 296, 296*b*
 - essential, 296
 - genetic factors, 296
 - malignant (accelerated), 296–297, 299*t*
 - management, 297–298
 - assessment, 297–298
 - contributing factors, 297
 - determination of cardiovascular risk, 298
 - diagnosis, 297
 - evidence of end-organ damage, 297–298
 - home/ambulatory blood pressure measurements, 297
 - secondary causes, 297

- hypertension (*Continued*)
 menopause, 727
 ocular, 862, 864
 risk for cardiovascular disease, 295
 salt-sensitive, 278
 treatment, 155–156, 298–309
 ancillary drugs, 306–309
 antihypertensives *see* antihypertensives
 in chronic kidney disease, 283–285
 drugs, 283–285, 283, 298–299 *see also*
 antihypertensives)
 non-pharmacological approaches, 298
 special patient groups, 304–306
 target blood pressures, 298–299, 299*t*
 thresholds, 298, 299*t*
 white coat, 297
- Hypertension in the Very Elderly Trial
 (HYVET), 305
- Hypertension Optimal Treatment (HOT) study, 298
- hypertensive encephalopathy, 296–297
- hyperthyroidism, 674–678
 aetiology, 674–675, 674*t*
 amiodarone-induced, 371
 and chronic heart failure, 334
 clinical manifestations, 675
 effect on digoxin pharmacokinetics, 38
 epidemiology, 674
 investigations, 675
 nodular disease, 674, 676
 treatment, 675–678
 treatment of complications, 678
see also thyrotoxicosis
- hypertrichosis, drug-induced, 882–883, 882*b*
- hypertriglyceridaemia, 391–392, 637
- hyperuricaemia, 848–860
 definition, 848
 pathophysiology, 850
 prevalence, 850
 risk factors, 850
- hypnotic drugs
 adverse effects, 450–451
 over sedation and hangover effects, 450–451
 rebound insomnia, 450
 tolerance and dependence, 450
 choice of, 451–452
 drug interactions, 451
 duration and timing of administration, 452
 insomnia, 447–448
 rate of elimination, 451–452
- hypoalbuminaemia, 84, 85, 244
- hypocalcaemia, 82, 264, 279–280, 279*f*, 679–680
 aetiology, 679–680
 case study, 684
 clinical manifestations, 680, 680*b*
 investigations, 680, 680*b*
 treatment, 680
- hypochromia, 89*t*
- hypoglycaemia, 689–690
 causes of, 689, 689*t*
 nocturnal, 689–690
 symptoms of, 689, 689*b*
 treatment, 690
- hypogonadism, 243
- hypokalaemia, 80, 80*b*
 diuretic-induced, 347
 effect on digoxin pharmacokinetics, 38
 in vitamin B₁₂ deficiency anaemia, 779
- hypomagnesaemia, 38, 82
- hyponatraemia, 79, 79*b*, 280*t*
 diuretic-induced, 347
- hypoparathyroidism, 679–680
 aetiology, 679–680
 case study, 684
 clinical manifestations, 680, 680*b*
 investigations, 680, 680*b*
 treatment, 680
- hypoperfusion, acute tubular necrosis, 257*t*
- hypophosphataemia, 82
- hypopigmentation, drug-induced, 881
- hypotension, 257
 ACE inhibitor-induced, 339
 in the elderly, 151
- hypothalamic-pituitary-adrenal (HPA) axis,
 466
- hypothalamic-pituitary-thyroid (HPT) axis, 466
- hypothyroidism, 670–673
 aetiology, 671
 amiodarone-induced, 371
 case studies, 682, 683
 classification, 671*b*
 clinical manifestations, 671–672
 drug-induced, 671, 679
 and dyslipidaemia, 395
 effect on digoxin pharmacokinetics, 38
 epidemiology, 671
 investigations, 672
 patient care, 673
 prevention, 673
 signs and symptoms, 671*b*
 treatment, 672–673
- hypovolaemia, 256–257, 260
- hypoxaemia, 439–440
- hypoxia, 38
- hypoxic-ischaemic encephalopathy (HIE), 129
- hysterectomy, 721
-
- ibandronate, osteoporosis, 154
- ibuprofen
 leg ulcers, 156
 neonates, 126, 130
 patent ductus arteriosus, 130
- ICD 10
 affective disorders, 468, 468*b*
 bipolar disorder, 467, 467*b*
 schizophrenia, 479
- ICE (ifosfamide, carboplatin, etoposide),
 non-Hodgkin's lymphoma, 811–812
- ifosfamide
 metabolism, 825
 non-Hodgkin's lymphoma, 811–812
- ileostomy, 105*t*
- imatinib
 chronic myelocytic leukaemia, 792–793
 metabolism, 54
 solid tumours, 825
- imidazoles
 candidiasis, 656–657
 dermatophytosis, 657
 eczema, 897
 fungal ear infections, 659
 fungal infections in compromised host, 663
 pityriasis versicolor, 659
 topical, 897
- imipenem, meningitis, 589*t*
- imipramine
 adverse effects, 470
 anxiety disorders, 461
 depression, 470
 metabolism, 470
 toxicity, 470
- immune disorders
 hepatic, 241
 renal, 258
- immune reconstitution inflammatory syndrome
 (IRIS), 625
- immune system
 and gastro-intestinal infections, 575
 skin, 883
- immunisations
 childhood, 133, 135
 chronic obstructive pulmonary disease, 438–439
- immunocompromised patients
 infections in, 796–801, 796*t*
 meningitis treatment in, 591
 respiratory infection in, 556–559, 557*t*
 tuberculosis in, 615
- immunoglobulins, 88, 244
- immunological adverse drug reactions, 67, 67*t*
- immunosuppressants
 acute tubular necrosis, 257*t*
 asthma, 419
 and diarrhoea, 215*t*
 inflammatory bowel disease, 193, 198–199,
 200*b*, 203*t*
 liver transplantation, 250–251
 monitoring, 199
 renal transplantation, 289–292, 289*t*
- impulse control disorders (ICDs), 512
- inappropriate sinus tachycardia, 359
- incentives, prescribing, 29
- incontinence, urinary *see* urinary incontinence
- incremental cost, 117
- incretin mimetics
 adverse effects, 705
 diabetes mellitus, 701*t*, 704–705
 drug interactions, 705
 mode of action, 705
 pharmacokinetics, 705
- incretins, 704
- indapamide, hypertension, 155, 305
- independent prescribing, non-medical, 16
- indinavir, HIV infection, 631*t*
- indometacin
 adverse reactions, 67
 elimination, 56
 gout, 853
 neonates, 126, 130
 respiratory distress syndrome, 130
- indoramin, benign prostatic hyperplasia, 757
- infants
 definition, 132
 meningitis, 586, 587–588, 588*t*
 premature, drug transfer into breast milk, 748
 urinary tract infections, 561, 563
- infection(s)
 in acute kidney injury, 264
 affect on wound healing, 913–914, 914*f*
 in children, 133–134
 and coronary heart disease risk, 313
 diabetic foot, 917
 diarrhoea, 214
 in HIV, 622–623
 in inflammatory bowel disease, 186, 204
 in leukaemia
 in immunocompromised patients, 796–801, 796*t*
 prevention, 796–797
 treatment, 797–801
 neonates, 127, 127*t*
 viral *see* viruses/viral infections; *specific viruses*
- infective meningitis *see* meningitis, infective
- inflammatory bowel disease (IBD), 185–208
 aetiology, 185–187
 environmental, 185–186
 genetic, 186–187
 case studies, 205*b*
 clinical manifestation, 188–191
 disease location, 187–188
 epidemiology, 185
 future treatments, 202
 investigations, 191–192

- clinical assessment tools, 192
endoscopy, 191
laboratory findings, 191–192
radiology, 191
stool tests, 192
pathophysiology, 187–188
patient care, 204–207
surgical treatment, 204
treatment, 192–204
 drug treatment, 192–204, 193*t*, 194*b*, 194*f*, 195*f*, 203*t*
 nutritional therapy, 192
 see also Crohn's disease; ulcerative colitis
inflammatory renal disease, 258
infliximab
 case study, 205
 contraindications, 201
 guidance on the use of, 841
 inflammatory bowel disease, 199, 200–201, 200*t*, 203*t*
 psoriasis, 905
 rheumatoid arthritis, 840
influenza, 545–546, 551
informed patients, 27
infusion pumps, parenteral nutrition, 104
inhalation absorption (of drugs), 137, 141
inhalation devices, 423–427, 424*t*, 442, 442*t*
inotropes
 in acute kidney injury, 263
 chronic heart failure, 342*t*, 343
insomnia, 446–453
 aetiology, 447
 case studies, 452*b*
 clinical manifestations, 447
 definitions, 446
 differential diagnosis, 447
 epidemiology, 446
 investigations, 447
 pathophysiology, 446–447
 patient care, 451–452
 rebound, 450
 sleep systems, 446–447
 treatment, 447–450, 448*t*
 benzodiazepines, 448–449
 hypnotic drugs, 447–448
 melatonin, 450
 non-drug, 447
 zaleplon, 450
 zolpidem, 449–450
 zopiclone, 449
 types of, 451
insulin
 circulation, 687
 deficiency *see* diabetes mellitus
 hyperkalaemia, 264
 release, 687
 resistance, 687
 synthesis, 687
insulin therapy, 695–698
 administration routes, 137
 adverse effects, 698
 delivery, 697
 dose adjustment, 698
 preparations, 696–697, 696*t*
 fast-acting insulins, 696–697
 intermediate-acting insulins, 697
 long-acting insulins, 697
 regimens, 697–698
 mealtime plus basal, 697–698
 twice-daily, 698
 type 2 diabetes, 705
 species of origin, 695–696
 storage of insulin, 698
 in type 2 diabetes, 705
 integrase inhibitors, HIV infection, 637
 Intelence[®], 630*t*
 intensive care, 146
 interferon therapy
 chronic myelocytic leukaemia, 792–793
 hepatitis B, 251
 hepatitis C, 251–252
 interleukin-1 inhibitors, gout, 854
 intermediate-density lipoprotein cholesterol (IDL-C), 390
 International Classification of Diseases *see* ICD 10
 International Glaucoma Association, 875
 international normalised ratio (INR), 92
 in liver disease, 244
 target in venous thromboembolism, 382*t*
 International Prognostic Index, non-Hodgkin's lymphoma, 808–809, 809*t*
 International Prostatitis Collaborative Network (IPCN) classification of prostatitis, 765*t*
 international sensitivity index (ISI), 92
 interpersonal skills, 21
 interstitial brachytherapy, 761
 interstitial fluid, 76
 interstitial nephritis, 258–259
 intestinal motility, 575
 intracellular fluid (ICF), 76, 77
 intractable epilepsy, 496, 501
 intradialytic parenteral nutrition (IDPN), 110–111
 intramuscular route of administration
 drug absorption in children, 136
 neonates, 124, 129
 intranasal route of administration
 children, 140
 drug absorption in children, 137
 intraocular pressure (IOP)
 glaucoma, 861, 864*t*
 high, 861
 level of, 862
 measurement, 863
 normal, 861
 target, 861
 intraosseous route of administration, 136
 intravascular fluid overload, 263–264
 intravascular monitoring in acute kidney disease, 260
 intravenous urography (IVU), chronic kidney disease, 282
 Invirase[®], 631*t*
 iodine/iodide, 669
 hyperthyroidism, 678
 hypothyroidism, 671
 IONA study, 319
 ipratropium bromide
 adverse reactions, 420*b*
 asthma, 418*t*, 422
 irinotecan, metabolism, 54
 iron, 88*t*
 adult daily reference range, 102*t*
 anticoagulant therapy monitoring, 93
 binding, 93
 hepatotoxicity, 231
 overload, 775
 typical daily requirements, 771*t*
 iron deficiency anaemia, 93, 771–773
 aetiology, 771
 in chronic kidney disease, 286
 clinical manifestations, 771–772, 772*b*
 epidemiology, 771
 following bleeding peptic ulcer, 179
 in inflammatory bowel disease, 204
 investigations, 772
 major causes, 771*b*
 menorrhagia, 719
 pathophysiology, 771
 patient care, 773
 treatment, 772–773
 vs. anaemia of chronic disease, 773*t*
 irritant contact dermatitis, 895, 895*f*
 ischaemic heart disease *see* coronary heart disease (CHD)
 ischaemic leg ulcers, 156
 ischaemic nephropathy, 276
 Isentress[®], 631*t*
 islet cell antibodies (ICAs), 686
 isoniazid
 adverse effects, 615, 616*t*
 hepatotoxicity, 222–223, 223*t*, 224
 sideroblastic anaemia, 774–775
 tuberculosis, 612, 613, 613*t*, 614, 615, 617, 643
 isoprenaline
 arrhythmias, 365–366
 chronic heart failure, 342*t*
 isosorbide dinitrate
 chronic heart failure, 340*t*, 343
 stable angina, 319, 320*t*
 isosorbide mononitrate, 319
 chronic heart failure, 340*t*, 343
 stable angina, 320*t*
 isotretinoin, 394*t*
 ispaghula husk, constipation, 211, 212
 itching *see* pruritus
 itraconazole
 absorption, 52
 candidiasis, 656–657
 clinical use, 665
 dermatophytosis, 658
 fungal infections in compromised host, 665
 meningitis, 592
 oropharyngeal candidiasis, 638
 pharmacokinetics, 664*t*
 pityriasis versicolor, 659
 ivabradine
 arrhythmias, 359
 stable angina, 320

J
 jaundice
 common causes of, 243*f*
 hepatocellular, 242–243
 in liver disease, 242–243, 243*f*
 jejunostomy, 105*t*
 Joint British Societies (JBS2), 396, 397*f*, 398*f*
 joints
 tuberculosis, 614
 in ulcerative colitis, 190
 jugular venous pressure (JVP), 335
 junctional re-entry tachycardia, 360–361, 361*f*
 justice and veracity, 18

K
 Kaletra[®], 631*t*
 kanamycin, tuberculosis, 616*t*
 kaolin
 activated partial thromboplastin time, 92
 diarrhoea, 217
 kaolin-cephalin clotting time (KCCT), 379, 380
 Kaposi's sarcoma, 621, 645
 keratinocytes, 912
 Kernig's sign, 586
 ketamine, 526
 ketoconazole
 absorption, 52
 eczema, 897
 fungal infections in compromised host, 663
 prostate cancer, 763
 shampoo, 897
 ketones, 690

- kidney(s)
 acute injury/failure *see* acute kidney injury (AKI)
 auto-regulation, 263
 biopsy, 282
 blood flow changes, 56
 drug elimination, 56
 extrinsic renal tract obstruction, 277
 function
 assessment, 281
 assessment in children, 144
 measurement of, 273–275
 potassium loss from, 80
 renal perfusion optimisation, 263
 renal tubule *see* renal tubule
 stones, 276
 transplantation *see* renal transplantation.
see also entries beginning renal
- kininase, hypertension, 301
 Kivexa®, 628*t*
Klebsiella sp., 562
 Koebner phenomenon, 900, 901*f*
 Kupffer cells, 238
 kwashiorkor, 96
-
- L**
- labetalol, 318*t*
 clinical trials, 305–306
 hypertension in pregnancy, 306
 metabolism in the elderly, 150
- laboratory data, 76–95
 biochemical data, 76–84
 blood tests, 91
 cardiac markers, 77*t*, 87
 case studies, 94, 95
 haematology data, 88–90
 immunoglobulins, 88
 liver function tests, 77*t*, 84–86
 monitoring anticoagulant therapy, 91–95
 tumour markers, 87–88
- labyrinthitis, 541
- lacosamide, 495*t*
 adverse effects, 500*t*
 epilepsy, 501
 pharmacokinetics, 44
 plasma concentration-response relationship, 44
- lactate dehydrogenase, 87
- lactation/breastfeeding
 benzodiazepines in, 460
 drug effects on, 749–751
 drugs in, 745–751
 adverse reactions in infants, 745*t*
 calculating infant dose ingested via milk, 747
 case studies, 750, 751
 milk to plasma concentration ratio, 746–747
 reducing risk, to infant, 748
 risk assessment, to infant, 748
 special situations, 748–749
 transfer into breast milk, 745–751
 variability, 747–748
- lactic acid bacteria, 218
- lactic acidosis, 699
- Lactobacilli*, 186
- lactulose
 constipation, 213–214
 hepatic encephalopathy, 248, 249*t*
- lamivudine
 hepatitis B, 251
 in HIV, 646
 HIV infection, 628*t*
- lamotrigine, 495, 495*t*, 496
 adverse effects, 66, 500*t*, 501
 drug interactions, 499*t*
 epilepsy, 501
- mania, 474
 pharmacokinetics, 44, 498*t*
 plasma concentration-response relationship, 44
- lansoprazole
 adverse effects, 176
 coronary heart disease, 11*t*, 12*t*
 drug interactions, 176
 formulations available, 175*t*
 interactions, 61
 peptic ulcer disease, 173*t*, 175*t*
- lanthanum, hyperphosphataemia, 287
- laser therapy, benign prostatic hyperplasia, 758
- latanoprost
 adverse effects, 865–866
 glaucoma, 864, 865–866, 868*t*, 874
 and timolol, 874
- latent autoimmune diabetes in adults (LADA), 685–686
- law of Tort, 16
- laxatives
 bulk-forming agents, 212
 classification, 211
 constipation in chronic kidney disease, 285
 faecal softeners/emollient, 214
 hepatic encephalopathy, 248
 and hypomagnesaemia, 82
 osmotic, 213–214
 stimulant, 212–213
- lecithin, 152
- leflunomide, rheumatoid arthritis, 836, 837*t*, 839
- left ventricular systolic dysfunction (LVSD)
 causes of, 334
 ejection fraction, 334
 treatment, 337*t*
- Legionnaire's disease, 550–551, 552, 554
- leg ulcers, 917–920
 aetiology, 917
 arterial, 919–920, 920*f*
 clinical signs, 919
 diagnosis, 919
 prevention of recurrence, 920
 treatment, 920
 case study, 924
 in the elderly, 156
 epidemiology, 917
 mixed, 920
 venous, 917–919, 918*f*
 clinical signs, 918
 diagnosis, 918, 918*t*
 prevention of recurrence, 919
 treatment, 919
- lenalidomide, Hodgkin's lymphoma, 806
- lepirudin, venous thromboembolism, 380
- leucocyte esterase test, 564
- leucocytosis, 89*t*
- leuconychia, 881–882
- leucopenia, 89*t*
- leukaemia, 133, 786–802
 acute lymphoblastic *see* acute lymphoblastic leukaemia (ALL)
 acute myeloblastic *see* acute myeloblastic leukaemia (AML)
 acute promyelocytic, 788, 792, 801
 aetiology, 786–787
 case studies, 798*b*
 chronic lymphocytic *see* chronic lymphocytic leukaemia (CLL)
 chronic myelocytic *see* chronic myelocytic leukaemia (CML)
 clinical manifestations, 788–789
 common therapeutic problems in, 798*t*
 epidemiology, 786
 investigations, 789–790
 pathophysiology, 787–788
- patient care, 795–801
 treatment, 790–795
- leukapheresis, 202
- leukonychia, 242
- leukotriene receptor antagonists
 adverse reactions, 420*b*
 asthma, 419
- leukotrienes, menstrual cycle, 712
- leuprorelin, prostate cancer, 762
- levetiracetam
 adverse effects, 500*t*
 epilepsy, 501
 pharmacokinetics, 44
 plasma concentration-response relationship, 44
- levobunolol, glaucoma, 868, 869*t*, 870–871
- levodopa
 co-careldopa intestinal gel, 511
 controlled-release, 511
 immediate-release, 511
 long-term levodopa syndrome, 511
 parkinsonism, 153
 Parkinson's disease, 510, 511, 512, 516
 preparations, 511
- levofloxacin, bronchitis/chronic obstructive pulmonary disease, 550
- levomepromazine
 antiemesis, 538
 cancer pain, 528
 pain, 528
 schizophrenia, 483*t*
- levonorgestrel intrauterine contraceptive devices (LNG-IUS), menorrhagia, 720, 720*t*
- Lewy bodies, 507–508
- libido and the menopause, 735
- licensing of medicines for children, 145–146
 licensing process, 145
 recent legislation, 145–146
 unlicensed and off-label medicines, 145
- lichenoid eruptions, drug-induced, 885, 885*b*
- lidocaine
 adverse effects, 367*t*
 arrhythmias, 369
 distribution, 53
 in the elderly, 150
 inflammatory bowel disease, 203*t*
 local anaesthesia, 524
 neonatal seizures, 128–129
 pharmacokinetics, 368*t*
- linezolid
 interactions, 58
 meningitis, 589*t*, 590
 pneumonia, 554*t*
- lipid clearance monitoring, 101
- lipid destabilisation, parenteral nutrition, 106–107, 107*t*
- lipid emulsions, 100*t*, 101*f*
- lipid-lowering therapy, 401–410, 402*t*, 403*t*
 bile acid binding agents, 405–407, 406*t*
 cholesterol absorption inhibitors, 407
 cholesterol ester transfer protein (CETP) inhibitors, 407–410
 fibrates, 405
 fish oils, 407
 hypertension, 306–309
 nicotinic acid and derivatives, 407
 soluble fibre, 407
 statins, 402–405
 ST elevation myocardial infarction, 325–326
- lipid profile
 disorders adversely affecting, 394*b*
 dyslipidaemia, 399
 effect of HRT administration route on, 728*t*
 in liver disease, 244
 optimal, 389*t*

- lipid transport, 390–392
 lipodermatosclerosis (LDS), 918
 lipodystrophy, antiretroviral toxicity, 637
 lipophilicity, drug transfer into breast milk, 746
 lipoprotein(a), 393
 lipoprotein lipase, 390, 393
 lipoprotein(s)
 effects of drugs on, 394*t*
 high-density lipoprotein cholesterol *see* high-density lipoprotein cholesterol (HDL-C)
 intermediate-density lipoprotein *see* intermediate-density lipoprotein cholesterol (IDL-C)
 low-density lipoprotein cholesterol *see* low-density lipoprotein cholesterol (LDL-C)
 metabolism, 390–392, 391*f*
 very low-density lipoprotein cholesterol *see* very low-density lipoprotein cholesterol (VLDL-C)
- liquid paraffin, 214
 liquorice, 59
 liraglutide, 704–705
 lisinopril
 chronic heart failure, 340*t*, 351
 clinical trials, 302, 305–306
Listeria monocytogenes, 585, 588, 591, 593*t*
 lithium
 absorption, 474
 bioavailability, 474
 depression, 472
 discontinuation, 474
 distribution, 40
 dose-dependent effects, 40
 dose-independent effects, 40
 elimination, 40–41
 and hypercalcaemia, 81
 hypernatraemia, 79
 hyperthyroidism, 678, 679
 interactions, 475*t*
 mania, 473–474
 pharmacokinetics, 40–41, 45*t*, 47
 practical implications, 41
 and psoriasis, 899
 serum levels, 474
- liver
 adverse effects of drugs on *see* drug-induced liver disease (DILD)
 biopsy, 228, 244
 bloody supply, 238
 drug metabolism, 53
 fibrosis, 227, 240–241
 functions, 238, 238*f*
 necrosis, 225, 226, 226*t*, 227
 transplantation, 250–251
 see also entries beginning hepatic
 liver disease, 238–254
 acute, 238
 acute liver failure (ALF), 238
 case studies, 252*b*
 causes of, 239–242
 alcohol, 240–241
 drugs, 242
 immune disorders, 241
 metabolic and genetic disorders, 241–242
 non-alcohol-related fatty liver disease, 241
 vascular abnormalities, 241
 viral infections, 239–240
 chronic, 238–239
 disease specific therapies, 251–254 (*see also specific diseases*)
 drug-induced *see* drug-induced liver disease (DILD)
 investigations, 244
 parenteral nutrition in, 110
 patient care, 244–251
 acute liver failure, 250
 ascites, 246–248, 246*b*, 247*t*
 clotting abnormalities, 246, 246*f*
 hepatic encephalopathy, 248, 248*b*, 248*t*, 249*t*
 liver transplantation, 250–251
 oesophageal varices, 248–250, 249*f*
 pruritus, 244–246
 risk for drug-induced liver disease, 223
 signs of, 242, 242*t*
 symptoms of, 242
 tuberculosis in, 615
 liver enzymes elevation, drug-induced, 222–223, 223*t*
 liver function tests (LFTs), 77*t*, 84–86, 244
 albumin, 84–85
 alkaline phosphatase, 85–86
 ammonia, 86
 amylase, 86
 bilirubin, 85
 drug-induced liver disease, 228
 enzymes, 85
 γ -glutamyl transpeptidase, 86
 in hepatotoxicity, 233–234, 233*t*
 transaminases, 86
 Liverpool Care Pathway (LCP), 528
 loading dose, 32
 local anaesthetics, 524–525
 local guidelines, 29
 lofepramine, depression, 470
 lomustine, 823
 long-term levodopa syndrome, 511
 loop diuretics
 acute kidney injury, 263
 chronic heart failure, 338, 339*t*, 343, 344
 dyslipidaemia, 395
 gout, 851
 hypertension, 300, 304*b*
 in chronic kidney disease, 284
 hypokalaemia, 80
 loperamide, diarrhoea, 217
 lopinavir, HIV infection, 631*t*
 loratidine
 pruritus
 in chronic kidney disease, 285
 in liver disease, 245
 lorazepam
 anxiety disorders, 459
 profile, 458*t*
 losartan
 chronic heart failure, 340*t*
 gout, 853
 Losartan For Endpoint reduction in hypertension (LIFE) study, 299–300, 302
 lovastatin
 dyslipidaemia, 402
 metabolism, 404
 low birth weight (LBW), 124
 low-density lipoprotein cholesterol (LDL-C), 389, 390
 and cardiovascular disease, 389
 lipid profile, 399
 menopause, 727
 metabolism, 390
 optimal, 389*t*
 low molecular weight heparin (LMWH)
 adverse effects, 379
 non-ST elevation myocardial infarction, 327
 venous thromboembolism, 379, 380
 lumbar puncture, 586
 lung function tests, chronic obstructive pulmonary disease, 435
 lung(s)
 hyperinflation, 433
 mesothelioma, 529
 parenchyma, 432
 vasculature, 432
 see also entries beginning pulmonary
 lupus anticoagulant, venous thromboembolism, 377
 lupus erythematosus, drug-induced, 888–889, 888*b*
 luteinising hormone (LH), 761–762
 menopause, 726
 menstrual cycle, 711
 luteinising hormone-releasing hormone (LHRH), 761–762
 luteinising hormone-releasing hormone (LHRH) agonists, prostate cancer, 762, 763
 luteinising hormone-releasing hormone (LHRH) antagonists, prostate cancer, 763
 lymecycline, 60
 lymph nodes, tuberculosis of peripheral, 614
 lymphoblastic lymphomas/leukaemia, 812
 lymphocytes, 90
 lymphomas, 803–817
 Burkitt's, 807, 812
 case studies, 815*b*
 diffuse large B-cell, 811, 812
 follicular, 809
 in HIV infection, 645
 Hodgkin's *see* Hodgkin's lymphoma
 mantle cell, 815
 non-Hodgkin's *see* non-Hodgkin's lymphoma
 patient care, 812–816
 counselling and support, 812
 patient-specific treatment modifications, 812
 supportive care, 813–816
-
- ## M
- macroalbuminuria *see* proteinuria
 macrogols, constipation, 211, 213–214
 macrophages, wound healing, 912
 Madopar[®], 511
 magnesium, 82
 acute kidney injury, 265
 dysmenorrhoea, 718
 hypermagnesaemia, 82
 hypomagnesaemia, 82
 infusions, arrhythmias, 325
 magnesium salts, constipation, 213
 magnesium sulphate, asthma, 422
 magnetic resonance angiography (MRA), chronic kidney disease, 282
 magnetic resonance imaging (MRI)
 chronic kidney disease, 282
 deep vein thrombosis, 378
 epilepsy, 492
 liver disease, 244
 Maillard reaction, 107
 malabsorption, 52
Malassezia furfur, 658, 659, 660*t*, 895
 malignancy *see* cancer
 malignant hypertension, 296–297, 299*t*
 malnutrition, 96
 incidence, 96
 nutrition screening, 96
 Malnutrition Advisory Group of the British Association of Parental and Enteral Nutrition (BAPEN), 96
 mania
 clinical features, 467
 definition, 465
 treatment, 473–474
 mannitol
 acute kidney injury, 263
 glaucoma, 865, 875
 mantle cell lymphoma, 815
 Mantoux test, 611

- marasmus, 96
maraviroc, HIV infection, 636*t*, 637
marginal costs, 117
marketing authorisation (MA), 145
maturity-onset diabetes of the young (MODY), 685–686
mean cell haemoglobin concentration (MCHC), 88*t*, 89–90
mean cell haemoglobin (MCH), 88*t*, 89
mean cell volume (MCV), 88*t*, 89
mean corpuscular volume (MCV), 770–771
mechanical ventilation, neonates, 125–126
mechlorethamine, Hodgkin's lymphoma, 805
Medicago sativa, 59
Medical Dictionary for Regulatory Affairs (MedDRA), 70
medication-related problems (MRPs), 3–4, 4*b*
medication review, 25–26, 25*t*
medicines *see* drug(s)
Medicines and Health care Products Regulatory Authority (MHRA), 69–70, 71, 145
Medicines and Human Use (Prescribing; Miscellaneous Amendments) Order (2006), 16
Medicines for Children Research Network (MCRN), 146
medicines management, definition, 3*t*
medicines-taking behaviour, 5
medicines use review (MUR), 5
Mediterranean diet, 400
medroxyprogesterone acetate, 730
mefenamic acid
 dysmenorrhoea, 717
 premenstrual syndrome, 716
megaloblastic anaemias, 769*t*, 775–777
 aetiology, 776
 clinical manifestations, 777–779, 777*b*
 epidemiology, 776
 investigations, 777–778
 pathophysiology, 776–777
 patient care, 779
 treatment, 778–779
meglitinides
 adverse effects, 703
 diabetes mellitus, 699, 701*t*, 702–703
 dosage, 703
 drug interactions, 703
 mode of action, 702
 pharmacokinetics, 702–703
melatonin, insomnia, 448*t*, 450
melphalan, non-Hodgkin's lymphoma, 811–812
Melt® technology, 139
memantine, dementia, 153
menadiol sodium phosphate, coagulation disorders, 231
menarche, 711
meningeal tuberculosis, 614
meningitis, infective, 584–595
 aetiology, 585
 bacterial *see* bacterial meningitis
 case studies, 594*b*
 clinical manifestations, 586
 diagnosis, 586–587
 drug treatment, 587–593, 588*t*, 589*t*
 epidemiology, 585
 fungal *see* fungal meningitis
 in HIV infection, 643
 meningococcal *see* meningococcal meningitis;
 Neisseria meningitidis
 neonates, 127*t*
 pathophysiology, 586
 patient care, 593–595
 pneumococcal *see* pneumococcal meningitis;
 Streptococcus pneumoniae
 prevention of person-to-person transmission, 594–595
 shunt-associated, 591, 592*t*
 tuberculous *see* tuberculous meningitis
 viral *see* viral meningitis
 meningitis C vaccination, 135
meningococcal meningitis, 590–591, 590*b*, 591*b*
 see also Neisseria meningitidis
menopause, 725–738
 case studies, 736*b*
 definition, 725
 management, 727–731
 physiological changes, 725–727
 bone, 726–727
 cardiovascular system, 727
 miscellaneous, 727
 ovarian, 725–726
 urogenital system, 726
 psychological changes, 727
 treatment, 731–737
 vasomotor symptoms, 731–732
 see also hormone replacement therapy (HRT)
menorrhagia, 718–721
 aetiology, 718–719
 case studies, 722, 723
 causes of, 719*b*
 epidemiology, 718
 investigation, 718–719
 treatment, 719–721, 720*t*
menstrual cycle
 body temperature, 711–712, 712*f*
 disorders, 711–724
 hormonal events in, 711–712, 711*f*
menstruation, 711
Mental Capacity Act (2005), 17, 17*b*
mental health disorders, 134
menthol, pruritus in liver disease, 245*t*, 246
mepacrine, 881–882
mepacrine hydrochloride, 580
mercapto acetyl tri-glycerine (MAG3), 282
mercaptapurine
 adverse effects, 198
 drug interactions, 198
 inflammatory bowel disease, 198, 203*t*
6-mercaptopurine
 acute lymphoblastic leukaemia, 790, 791
 inflammatory bowel disease, 198
meropenem
 meningitis, 589*t*, 591
 pneumonia, 554*t*
 urinary tract infections, 569*t*
mesalazine
 formulations, 197, 198
 inflammatory bowel disease, 196–197, 196*f*, 198, 203*t*
mesothelioma of the lung, 529
metabolic acidosis, 83
metabolic alkalosis, 83
metabolic disorders
 antiretroviral toxicity, 637
 causing chronic kidney disease, 276
 metabolic liver diseases, 241–242
 metabolic syndrome, 687, 851
metabolism (of drugs)
 in children, 137–138
 drug interactions, 53–56
 predicting, 55–56
 in the elderly, 150
 in neonates, 125
 in pregnancy, 742, 743*t*
 in renal replacement therapy, 268
metastatic bone pain, 529
metered dose aerosol inhalers (MDIs), 424–425, 424*f*
 breath-actuated, 426, 426*f*
 with a spacer extension, 425–426, 425*f*, 426*f*
metformin
 adverse effects, 699
 diabetes mellitus, 699
methadone
 analgesia, 522, 523*t*
 cancer pain, 528
methionine, 231
methotrexate
 acute lymphoblastic leukaemia, 790, 791
 adverse reactions, 64, 198, 420*b*, 838
 drug interactions, 176, 899*t*
 eczema, 898, 904*t*
 graft-versus-host disease, 795
 inflammatory bowel disease, 198, 203*t*
 interactions, 198
 non-Hodgkin's lymphoma, 812
 pharmacokinetics, 838
 psoriasis, 904, 904*t*
 rheumatoid arthritis, 836, 837*t*, 838
 safety, 838, 839*b*
 toxicity, 56
methylcellulose, constipation, 212
methyldopa
 hypertension, 301
 in chronic kidney disease, 285
 in pregnancy, 306
methylprednisolone
 acute lymphoblastic leukaemia, 791
 graft-versus-host disease, 795
 inflammatory bowel disease, 193, 195
 non-Hodgkin's lymphoma, 811–812
 postherpetic neuralgia, 529
 renal transplantation, 291
 rheumatoid arthritis, 839
methylprednisolone acetate, gout, 854
meticillin-resistant *Staphylococcus aureus* (MRSA), 127, 599–600, 605
metipranolol, glaucoma, 869*t*
metoclopramide
 absorption, 52
 adverse reactions, 65
 antiemesis, 285, 538, 539, 541, 542
metolazone
 acute kidney injury, 263
 chronic heart failure, 338, 339*t*
 hypertension in chronic kidney disease, 284
metoprolol, 318*t*
 arrhythmias, 370
 chronic heart failure, 340*t*
 hypertension in chronic kidney disease, 284
 stable angina, 317–318
metronidazole
 amoebiasis, 580
 diarrhoea, 218
 gastro-intestinal infections, 580
 Helicobacter pylori eradication, 171, 172
 hepatic encephalopathy, 248, 249*t*
 infection in neutropenia, 797
 inflammatory bowel disease, 202, 203*t*
 necrotizing enterocolitis, 128
 neonates, 128
mexiletine
 adverse effects, 367*t*
 arrhythmias, 369
 pharmacokinetics, 368*t*
mianserin, depression, 472
micafungin, 664*t*
Michaelis-Menten model, 41
microalbuminuria, 693
microbial contamination, parenteral nutrition, 107
microcytic anaemias, 769*t*, 784
microflora, 575

- micronutrients, 101–103, 102b
microscopic polyangiitis, 258
microscopy, urinary tract infections, 564–565
Microsporium, 657
midazolam
 absorption in children, 136–137
 intranasal administration, 140
 neonates, 128–129
 seizures, 128–129
midstream urine sample (MSU), 563–564
migraine, 531, 541
miliary tuberculosis, 608–609, 614
milk to plasma concentration ratio, 746–747, 746f
milrinone, chronic heart failure, 342t
mineralocorticoids
 deficiency, 80
 excess, 80
minerals
 dysmenorrhoea, 718
 premenstrual syndrome, 714
mini tablets, 139
minocycline
 interactions, 60
 nail changes, 881–882
 pigmentation, 881f
minoxidil
 hair changes, 882–883
 hypertension, 301
 hypertension in chronic kidney disease, 285
miosis, 872
miotics
 adverse effects, 872b
 glaucoma, 865, 872, 872b, 872t
mirtazapine
 anxiety disorders, 461
 depression, 472
misoprostol, peptic ulcer disease, 173, 173t
mithramycin, hypocalcaemia, 82
mitochondrial toxicity of antiretrovirals, 637
mitomycin, 823
mitoxantrone
 acute lymphoblastic leukaemia, 790
 prostate cancer, 763–764
MMR vaccine, 63, 133, 186
moclobemide
 anxiety disorders, 461
 depression, 471
Modification of Diet in Renal Disease (MDRD)
 study equation, 37, 83, 274, 693
molecular weight, drug transfer into breast milk,
 746
mometasone, asthma, 419t
monoamine oxidase inhibitors (MAOIs)
 affective disorders, 466
 anxiety disorders, 461
 depression, 470–471
 effects, 471
 interactions, 50, 58, 470–471, 475t
 reversible, 470–471
 traditional, 470–471
monoamine oxidase type B, 513
monoamine oxidase type B inhibitors, Parkinson's
 disease, 513
monobactams, cystic fibrosis, 556t
monoclonal antibodies
 renal transplantation, 290, 291
 tuberculosis, 201
monocytes, 90
mono-iodotyrosine (MIT), 669
monosodium urate, 84, 849, 851
monounsaturated fats, 695
montelukast
 asthma, 419
 dysmenorrhoea, 717
MOPP (mechlorethamine, vincristine,
 procarbazine, prednisolone), Hodgkin's
 lymphoma, 805
Moraxella catarrhalis, 438–439, 549
morphine
 analgesia, 522, 523t
 cancer pain, 528
 diarrhoea, 217
 neonates, 126
motion sickness, 541
moulds, 654–655, 655t
moxifloxacin
 bronchitis/chronic obstructive pulmonary
 disease, 550
 meningitis, 590
 metabolism, 55
 pneumonia, 552
moxonidine, hypertension, 301
MPTP (1-methyl-4-phenyl-1,2,3,6-
 tetrahydropyridine), 507
MRSA *see* methicillin-resistant *Staphylococcus*
 aureus (MRSA)
mucolytics, chronic obstructive pulmonary
 disease, 438
mucormycosis, 660t
mucositis, chemotherapy-induced, 813t, 814
mucus hypersecretion, 433
multidrug-resistant tuberculosis (MDR-TB), 608,
 609
murine-human chimeric antibodies, 327
muromonab, renal transplantation, 289t
muscle relaxants, 525t, 526–527
muscles in chronic kidney disease, 280
MUST (Malnutrition Universal Screening Tool),
 96
mycobacteria, 643–644
Mycobacterium africanum, 608
Mycobacterium avium intracellulare (MAI), 644
Mycobacterium bovis, 608
Mycobacterium leprae, 608
Mycobacterium paratuberculosis, 186
Mycobacterium tuberculosis, 608, 612, 643, 644
mycophenolate
 autoimmune hepatitis, 252
 inflammatory bowel disease, 198, 199
mycophenolate mofetil (MMF)
 eczema, 898
 renal transplantation, 289t, 290, 291
Mycoplasma pneumoniae, 552
myocardial infarction
 acute, 320
 in diabetes mellitus, 692
 in the elderly, 156
 and hypertension, 295
 non-ST-elevation, 320, 321
 classification, 322f
 high-risk patients, 328t
 prognosis, 321
 treatment, 326–329
 risk, 313
 silent, 692
 ST-elevation
 classification, 322f
 complications, 325
 prevention of further infarction, 325–326
 prognosis, 321
 treatment, 321–326
myocardial ischaemia, 312
myoclonic seizures, 491
myocytes, 354
myofascial pain, 530
myopathy, statin-associated, 87, 404
myxoedema, 678
myxoedema coma, 671–672
N
N-acetyl-*p*-benzoquinoneimine (NABQI), 232,
 520–521
nadolol, 318t
nails
 candida infection, 656
 dermatophytosis, 657
 drug-induced changes, 881–882
 fungal infections, 667
 in liver disease, 242
 psoriasis, 901, 903
Na/K-ATPase pumps, 79, 80
nalidixic acid, diarrhoea, 217
nalmefene, pruritus in liver disease, 245
naloxone
 pruritus in liver disease, 245
 respiratory depression in neonates, 125
NALP3 inflammasome, 851–852
naltrexone, pruritus in liver disease, 245, 245t
naproxen
 in chronic heart failure, 351
 hepatotoxicity, 223t
naringenin, 58
naringin, 58
nasogastric route of administration, 140
natalizumab, inflammatory bowel disease, 200–201
nateglinide
 diabetes mellitus, 702
 dosage, 703
 pharmacokinetics, 702–703
National Cancer Institute Common Toxicity
 Criteria, 828, 828t
National Congenital Anomaly System (NCAS), 132
national guidelines, 29
National Institute for Health and Clinical
 Excellence guidelines *see* NICE
 guidelines
National Prescribing Centre competency
 framework, 19–20, 20t
National Service Frameworks (NSFs)
 influence on prescribing, 27
 paediatric, 146–148
natriuretic peptide hormone, 78
nausea and vomiting, 535–544
 case studies, 542b
 causes, 536, 536t
 central causes, 536, 536t
 chemotherapy-induced, 540, 540b, 540t, 813,
 813t, 826–827
 chronic kidney disease, 285
 common therapeutic problems, 537t
 drug-associated, 541
 epidemiology, 535
 labyrinthitis, 541
 migraine, 541
 motion sickness, 541
 opioid-induced, 523
 palliative care-associated, 542, 542b
 pathophysiology, 535–536, 537f
 patient management, 536
 peripheral causes, 536
 post-operative, 539
 pregnancy-associated, 540–541
neбиволол, 318t, 340t
nebulisers, 426–427
neck pain, 530
necrosis, liver, 225, 226, 226t, 227
necrotizing enterocolitis
 adverse drug effects, 139
 neonates, 127–128, 127t
nedocromil sodium
 adverse reactions, 420b
 asthma, 419

- nefopam, analgesia, 525
Neisseria gonorrhoeae, 563, 717–718
Neisseria meningitidis, 585, 588, 589
 nelfinavir, HIV infection, 631*t*
 neomycin
 absorption, 52
 hepatic encephalopathy, 249*t*
 neonates, 124–131
 adverse drug reactions, 65
 bacterial meningitis, 585
 case studies, 130, 131
 definition, 132
 drug absorption, 124
 drug distribution, 124–125
 drug elimination, 125
 drug metabolism, 125
 drug transfer into breast milk, 748
 major clinical disorders, 125–129
 apnoea, 128
 bronchopulmonary dysplasia, 126–127
 haemorrhagic disease of the newborn, 128
 infection, 127, 127*t*
 necrotizing enterocolitis, 127–128
 patent ductus arteriosus, 126
 respiratory distress syndrome, 125–126
 seizures, 128–129
 meningitis, 587–588, 588*t*, 593*t*
 premature, 124, 132
 principles and goals of therapy, 129–131
 avoiding harm, 129
 patient and parent care, 130–131
 rapid growth, 129
 therapeutic drug monitoring, 129
 time-scale of clinical changes, 129–130
 terminology, 125*t*
 theophylline metabolism, 38
 urinary tract infections, 561, 563
 nephropathy, diabetic, 693
 nephrotic syndrome, 395
 nephrotoxins, 262–263, 268–270
 neural tube defects, 133
 neuramidase inhibitors (NAIs), influenza, 546
 neurokinin-1 (NK₁) receptor antagonists,
 antiemesis, 538–539
 neuroleptic malignant syndrome (NMS), 486–488
 neuroleptics *see* antipsychotic drugs
 neurological changes in chronic kidney disease,
 280, 287
 neurological manifestations of HIV, 645–646
 neuroma, 530
 neurones, 490–491
 neuropathic pain, 529–530, 531*t*
 in cancer, 528
 case study, 531–532
 causes of, 529*t*
 specific syndromes, 529–530
 neuropathy, 530
 chemotherapy-induced, 813*t*
 diabetic peripheral, 529
 neuroprotective agents, stroke, 153
 neurotransmitters, 490–491
 affective disorders, 466
 anxiety, 456
 and pain, 519–520
 neutropenia, 89*t*
 febrile, 814
 fungal, 659
 lymphomas, 814
 prevention of infection in, 797
 treatment of infection in, 797
 neutrophilia, 89*t*
 neutrophils, 90, 912
 nevirapine
 hepatotoxicity, 223*t*
 HIV infection, 630*t*
 New York Heart Association (NYHA)
 classification, 333, 333*t*
 niacin, hepatotoxicity, 223*t*
 NICE guidelines
 hypertension management, 297
 influence on prescribing, 27
 prescribing strategies, 29
 nicorandil, stable angina, 319
 nicotinamide adenine dinucleotide phosphate
 (NADPH), 782
 nicotine
 inflammatory bowel disease, 203*t*
 transfer into breast milk, 749
 nicotine replacement therapy (NRT), 436, 440–441,
 441*t*
 nicotinic acid
 adverse effects, 407
 dyslipidaemia, 393–394, 403*t*, 407
 nifedipine, 150
 night sweats, 731–732
 nilotinib, chronic myelocytic leukaemia, 793
 nilutamide, prostate cancer, 762
 nitazoxanide
 cryptosporidiosis, 643
 gastro-intestinal infections, 580
 nitrates
 chronic heart failure, 336, 340*t*, 343, 344
 commonly used, 320*t*
 coronary heart disease, 11*t*, 12*t*
 drug interactions, 348*t*
 metabolism in the elderly, 150
 non-ST elevation myocardial infarction, 329
 patient education, 344–345
 preparations, 319
 self-monitoring, 345*t*
 stable angina, 319, 320*t*
 ST elevation myocardial infarction, 326
 tolerance, 319
 nitric oxide, 319
 and blood pressure, 296
 menorrhagia, 719
 neonates, 126
 nitric oxide-releasing NSAIDs, 165
 nitrite test, 564
 nitrofurantoin
 bacteriuria of pregnancy, 570
 hepatotoxicity, 223
 urinary tract infections, 566, 568, 568*t*
 nitrogen balance, 99
 nitroprusside, chronic heart failure, 340*t*
 nizatidine, peptic ulcer disease, 177
N-methyl-D-aspartate (NMDA) antagonists,
 dementia, 152
 nociceptors, 519
 nocturia, 277–278
 nocturnal hypoglycaemia, 689–690
 non-adherence *see* adherence/non-adherence
 non-alcoholic fatty liver disease (NAFLD), 241
 non-alcoholic steatohepatitis (NASH), 241
 non-Hodgkin's lymphoma, 806–812
 aetiology, 807
 case studies, 815
 diagnosis, 808
 histopathology and classification, 808
 laboratory findings, 808
 signs and symptoms, 808
 staging, 808–809
 treatment, 809–812, 810*f*, 811*t*
 aggressive non-Hodgkin's lymphoma, 811
 indolent non-Hodgkin's lymphoma, 809–811
 lymphoblastic lymphoma/leukaemia, 812
 relapsed aggressive non-Hodgkin's
 lymphoma, 811–812
 relapsed indolent non-Hodgkin's lymphoma,
 811
 very aggressive non-Hodgkin's lymphoma,
 812
 non-maleficence, 17–18
 non-medical prescribing, 15–16
 non-nucleoside reverse transcriptase inhibitors
 (NNRTIs), HIV infection, 626, 630*t*,
 635
 non-peptide synthetics, 327
 non-steroidal anti-inflammatory drugs (NSAIDs)
 acute tubular necrosis, 257*t*
 adverse reactions, 62, 836, 883–884
 analgesia, 521, 527
 chemoprevention, 820
 choice of agent, 836
 chronic heart failure, 350, 351
 clinical considerations, 521
 currently licensed (UK), 835*t*
 diarrhoea, 215*t*
 drug-induced asthma, 412–413
 drug interactions, 836
 dysmenorrhoea, 717, 718*t*
 elimination, 56
 gout, 852–853, 857
 guidance on use of, 521
 hepatotoxicity, 224, 228
 inflammatory bowel disease, 186
 interstitial nephritis, 258–259
 liver disease, 246
 menorrhagia, 720, 720*t*
 mode of action, 521
 nitric oxide-releasing, 165
 osteoarthritis, 845
 peptic ulceration, 162*b*
 epidemiology, 163
 pathogenesis, 164–165, 164*f*
 prophylaxis, 172–173
 risk factors, 164*b*
 treatment, 172
 pre-renal acute kidney injury, 256–257
 and psoriasis, 899
 rheumatoid arthritis, 835–836
 safety, 835–836
 teratogenicity, 740, 741*t*
 non-verbal communication, 21–22
 noradrenaline
 in acute kidney injury, 263
 affective disorders, 466
 chronic heart failure, 343
 drug interactions, 58
 water balance, 76
 norepinephrine *see* noradrenaline
 norethisterone, 730
 norfloxacin
 hepatotoxicity, 223*t*
 metabolism, 55
 spontaneous bacterial peritonitis, 247–248
 noroviruses, 214, 573
 nortriptyline
 depression, 470
 drug-induced parkinsonism, 509–510
 Norvir[®], 631*t*
 NO TEARS medication review, 26, 26*t*
 nuclear factor of activated T-cells (NFAT), 290
 nuclear medicine investigations, chronic kidney
 disease, 282
 nucleoside/nucleotide reverse transcriptase
 inhibitors (NRTIs), HIV infection, 626,
 627–635, 628*t*
 nucleus tractus solitarius (NTS), 535
 nummular dermatitis, 895
 nurses prescribing drugs, 16
 nutraceuticals, osteoarthritis, 845

- nutrition
 in acute kidney injury, 265
 affect on wound healing, 914, 914b
 children, 134
 screening, 96
 nutritional therapy, inflammatory bowel disease, 192
 nutrition support teams, 97
 nystatin
 candidiasis, 657
 fungal ear infections, 659
- O**
- obesity
 childhood, 134
 in diabetes mellitus, 695, 698, 706
 and dyslipidaemia, 395
 and hypertension, 298, 307, 308
 osteoarthritis risk, 843
 obsessive-compulsive disorder (OCD), 454–455, 455b, 455t, 457
 antidepressants, 460, 461
 benzodiazepines, 459
 case study, 462
 recommended drug treatments, 462t
 occupational therapy, rheumatoid arthritis, 834–835
 octreotide, oesophageal varices, 250, 250t
 ocular hypertension (OHT), 862, 864
 ocular prostanoids, 868t
 adverse effects, 869t
 glaucoma, 865–868
 oedema
 in chronic kidney disease, 286
 epidermal *see* eczema
 peripheral, 243, 246
 oesophageal candidiasis
 presentation, 656
 treatment, 656–657
 oesophageal ulceration, 162
 oesophageal varices, 248–250, 249f
 drug treatment, 250, 250t
 endoscopic management, 249–250
 prevention of rebleeding, 250
 transjugular intrahepatic portosystemic shunting, 250
 oesophagitis, 173–174, 175
 oestradiol, 394t
 oestrogen(s)
 blood pressure control, 727
 bone loss, 732
 diminishing, 726
 dyslipidaemia, 396
 effect on lipoprotein levels, 394t
 hair changes, 882
 menstrual cycle, 711
 osteoporosis, 154–155
 venous thromboembolism, 377
 oestrogen therapy
 administration, 728
 effect on lipid profile, 728t
 dose, 729
 implants, 729
 menopause, 728–729, 732
 natural oestrogens, 728
 oral, 728t
 with progestogen, 729–730, 729b
 prostate cancer, 763
 transdermal patches, 728–729
 vaginal creams, 729
 off-label medicines, 18, 19b
 for children, 145
 ofloxacin, tuberculosis, 616t
 olanzapine, schizophrenia, 483t, 484
- oliguria, 255, 259, 260–261
 olsalazine, inflammatory bowel disease, 196, 203t
 omalizumab, asthma, 419
 omega-3 fatty acids, 400
 dyslipidaemia, 407
 dysmenorrhoea, 716
 inflammatory bowel disease, 202, 203t
 omeprazole
 absorption, 52
 drug interactions, 176
 formulations available, 175t
 Helicobacter pylori eradication, 172
 interstitial nephritis, 258–259
 intravenous, 175
 peptic ulcer disease, 173t, 175, 175t
 oncogenes, 820
 ondansetron, antiemesis, 285, 540
 on-off phenomenon, 511
 ONTARGET study, 305
 onycholysis, 882
 onychomycosis, 656
 ophthalmic route of administration, 136
 ophthalmopathy, hyperthyroidism, 678
 opioid antagonists, pruritus in liver disease, 245
 opioid receptors, 519–520
 opioids
 absorption, 52
 addiction, 524
 adverse effects, 523–524, 883–884
 cancer pain, 528
 clinical considerations, 523
 constipation, 210
 dependence, 524
 effect on neonates, 124, 125
 epidural, 524
 relative potencies of, 523t
 smooth muscle spasm, 524
 special delivery techniques, 524
 strong, 522–523
 teratogenicity, 741t
 tolerance, 524
 weak, 521–522
 opportunistic infections
 in HIV, 622, 624, 624f, 637–651, 639t
 impact of HAART on, 645
 opportunity cost, 117
 optometrists, prescribing drugs, 16
 oral candidiasis
 presentation, 656
 treatment, 656–657
 oral contraceptives *see* combined oral contraceptives (COCs)
 oral hygiene
 in immunocompromised patients, 796
 mucositis, 814
 oral rehydration solutions, 216–217, 216t
 oral route of administration, 135, 139–140
 oral syringes, 139
 Organisation for Economic Co-operation and Development (OECD), 116
 orlistat
 absorption, 52
 obesity in diabetes, 706
 ormeloxifene, menorrhagia, 719–720
 oropharyngeal candidiasis, 638–643
 orthodox sleep, 446
 orthostatic circulatory responses, in geriatrics, 151
 oseltamivir, influenza, 546
 osmosin, 67
 osmotic laxatives, 213–214
 osteoarthritis, 843–846
 aetiology, 843–844
 clinical manifestations, 844
 epidemiology, 843
- investigations, 844–845
 pain management, 530
 pathogenesis, 844
 treatment, 845–846
 osteodystrophy, renal, 279–280, 279f, 287–288
 osteomalacia, 94
 osteomyelitis, neonatal, 127t
 osteoporosis, 154–155, 204
 definition, 726
 fractures, 726–727
 heparin-induced, 379–380
 menopause, 726, 732
 prevention, 154
 risk factors, 726–727
 treatment, 154–155
 otitis externa, 659
 otitis media, 548
 ovarian cancer, 734–735
 ovaries
 menopausal changes, 725–726
 premenstrual syndrome, 713
 overactive bladder syndrome, 157
 overflow incontinence, 156
 overweight children, 134
 ovulation, 711–712
 oxazepam, 458t
 oxcarbamazepine, 495, 496
 adverse effects, 66, 500t
 epilepsy, 501–502
 oxidative stress, chronic obstructive pulmonary disease, 433
 oxitacetam, dementia, 152
 oxprenolol
 anxiety disorders, 462
 coronary heart disease, 318t
 oxybutynin, urinary incontinence, 157
 oxycodone
 analgesia, 522
 cancer pain, 528
 oxygen therapy
 asthma, 422
 bronchiolitis, 550
 chronic obstructive pulmonary disease, 439–440, 442–445, 443t
 continuous long-term, 439–440, 442
 intermittent (short burst), 439
 neonates
 bronchopulmonary dysplasia, 126, 127
 respiratory distress syndrome, 125–126
 oxypurinol, gout, 855
 oxytetracycline, 60
- P**
- p53 protein, 820
 pacemaker activity, 356–357, 357f
 pacemaker potential, 354–355
 packaging and labelling of drugs, 158
 packed cell volume (PCV), 88t, 89
 PaCO₂ (partial pressure of carbon dioxide), 83
 paediatrics *see* children
 pain, 519–534
 acute, 519, 520
 adjuvant medication, 525–527, 525t
 aetiology, 519–520
 assessment, 520
 cancer *see* cancer, pain
 case studies, 531b
 definition, 519
 management, 520 (*see also* analgesia)
 neuroanatomy of pain transmission, 519
 neuropathic *see* neuropathic pain
 neurophysiology, 519–520
 neurotransmitters and, 519–520

- pain (*Continued*)
 persistent, 519, 520
 postoperative, 527
 ST elevation myocardial infarction, 321–322
 treatment of pain syndromes, 527–533
- Paling palette, 72
- paliperidone, schizophrenia, 483*t*
- palivizumab, bronchiolitis, 550
- palliative care
 associated nausea and vomiting, 542, 542*b*
 parenteral nutrition in, 111
- palmar erythema, 242
- palmoplantar psoriasis, 901, 908
- palonosetron, antiemesis, 540
- p*-aminosalicylate (PAS), tuberculosis, 612, 616*t*
- Panax ginseng*, 59
- pancreatic cancer, 528–529
- pancreatic fistula, 105*t*
- pancreatitis
 parenteral nutrition in, 111
 serum amylase, 86
- pancuronium, 126
- pancytopenia, 89*t*, 796
- panic attacks, 456
- panic disorder, 454–455, 455*b*, 455*t*
 antidepressants, 461
 benzodiazepines, 459
 recommended drug treatments, 462*t*
- panobinostat, Hodgkin's lymphoma, 806
- pantoprazole
 drug interactions, 176
 formulations available, 175*t*
 intravenous, 175
 peptic ulcer disease, 173*t*, 175, 175*f*
- PaO₂ (partial pressure of oxygen), 83
- paracentesis, ascites, 247
- paracetamol
 absorption, 52
 analgesia, 520–521, 527
 dose, 521
 metabolism, 54*t*, 137–138, 520–521, 521*f*
 neonates, 124
 osteoarthritis, 845
 overdose/toxicity, 232, 235
 acute liver failure, 250
 biochemical tests, 244
 hepatotoxicity, 222, 224, 225, 231, 232, 232*f*, 233, 235
- paradoxical effects of benzodiazepines, 459
- paradoxical sleep, 446–447
- paraldehyde
 neonates, 124
 seizures, 128–129
 rectal administration, 140
- parasites
 diarrhoea, 214, 216
 gastro-intestinal infections, 577
- parathyroid gland disorders, 669–684
- parathyroid hormone peptides, osteoporosis, 155
- parathyroid hormone (PTH), 81, 82, 279–280
 calcium and, 679–684
- parenteral administration of drugs
 children, 140–141
 dead space, 141
 displacement volume, 141
 excipients, 141
 fluid overload, 140
 intravenous access, 140
 lack of suitable paediatric formulations, 140–141
 rates of infusion, 141
 in urinary tract infections, 569*t*
- parenteral nutrition, 96–115
 administration, 103–105
 central route, 104
 cyclic infusions, 105
 infusion control, 104
 licensed ready-to-use products, 105
 peripherally inserted central catheters, 104
 peripheral route, 103–104, 103*b*
 routes of, 103–104
 standardised formulations, 104–105
- amino acids, 98–99, 99*t*
 body mass index, 97*t*
 in cancer and palliative care, 111
 in cardiac failure, 111
 case study, 113*b*, 114*t*
 children, 112–115
 formulation and stability issues, 112–113
 heparin, 113
 nutritional requirements, 112, 112*t*
 route of administration, 113–115
 complications, 109–110, 109*b*
 line occlusion, 110
 line sepsis, 109
 refeeding syndrome, 110, 110*t*
 in diabetes mellitus, 111
 electrolytes, 103
 energy, 99–101
 dual energy, 99–100, 100*b*
 glucose, 100, 100*t*
 lipid emulsions, 100–101, 100*t*, 101*f*
 indications for, 96–97
 initial assessment, 108
 intradialytic, 110–111
 in liver disease, 110
 long term, 111
 malnutrition *see* malnutrition
 micronutrients, 101–103
 factors affecting requirements of, 102*b*
 trace elements, 102, 102*t*
 vitamins, 102–103, 103*t*
 monitoring, 108–109
 nutrition screening, 96
 nutrition support teams, 97
 osmolality of formulations, 104
 in pancreatitis, 111
 pharmaceutical issues, 105–108
 chemical stability, 107
 drug stability, 108
 filtration, 108
 light protection, 108
 microbial contamination, 107
 physical stability, 106–107
 shelf-life and temperature control, 107–108
 regimen components, 97–103
 in renal failure, 110–111
 in respiratory disease, 111
 in sepsis and injury, 111
 in short bowel syndrome, 111
 water volume, 97–103
- paricalcitol, 287
- parkinsonism, 153
 differential diagnosis, 509, 509*t*
 drug-induced, 509–510
 epidemiology, 507
- parkinson-like side-effects, antipsychotic drugs, 481
- Parkinson's disease, 507–518
 aetiology, 507–508
 case studies, 516*b*
 clinical features, 508–509
 differential diagnosis, 509–510
 epidemiology, 507
 investigations, 510
 motor features, 508
 non-motor features, 509
 pathophysiology, 508
 patient care, 515–518
 treatment, 510–515
- Parkinson's Disease Society, 515
- paronychia, 656
- paroxetine, depression, 471
- paroxysmal nocturnal dyspnoea (PND), 156
- partial dopamine agonists, schizophrenia, 483*t*
- partial pressure of carbon dioxide (PaCO₂), 83
- partial pressure of oxygen (PaO₂), 83
- partial seizures, 491–492
- patent ductus arteriosus (PDA), 126, 130
- patient-controlled analgesia (PCA), 524
- patient education
 chemotherapy, 826
 chronic heart failure, 344–345, 345*t*
 diabetes mellitus, 694, 706, 706*b*
 peptic ulcer disease, 178–179
 rheumatoid arthritis, 834–835, 843
- patient information leaflets (PILs), 24, 27, 72
- peak and trough levels, 36
- peak expiratory flow (PEF), 414
- pegylated interferon alfa
 hepatitis C in HIV, 646
 opportunistic infections in HIV, 639*t*
- pegylated interferon alfa-2a
 hepatitis B, 251
 hepatitis C, 251–252
- pelvic inflammatory disease (PID), 717–718
- pemoline, hepatotoxicity, 234
- penicillamine, Wilson's disease, 252
- penicillin G, neonatal infections, 127
- penicillin(s)
 acute pyelonephritis, 568
 allergy, 604, 606
 elimination in children, 138
 hepatotoxicity, 225–226
 infection in neutropenia, 797
 interstitial nephritis, 258–259
 meningitis, 588
 neonates, respiratory distress syndrome, 130
 otitis media, 548
 resistance, 589–590
 sore throat, 547
 therapeutic index, 139
- penicillin V, sickle cell anaemia, 781
- Penicillium marneffei*, 659
- pentamidine
 and hypomagnesaemia, 82
 opportunistic infections in HIV, 639*t*
Pneumocystis jiroveci pneumonia, 638
- pentazocine, analgesia, 523
- peptic ulcer disease, 162–184
 bleeding, 165, 168–169
 case studies, 180*b*
 clinical manifestations, 165
 common therapeutic problems, 179*t*
 definition, 162
 duodenal ulcer, 162, 163*f*, 164, 165, 174*f*
 in the elderly, 157
 epidemiology, 163
 gastric ulcer, 165, 170*f*
Helicobacter pylori, 162*b*
 detection, 166–168
 epidemiology, 163, 163*f*
 eradication, 166, 171–172
 pathogenesis, 163–164
 investigations, 166–168
 endoscopy, 166
Helicobacter pylori detection, 166–168
 radiology, 166–168
- NSAID-associated, 162*b*
 epidemiology, 163
 pathogenesis, 164–165, 164*f*
 prophylaxis, 172–173, 173*t*
 risk factors, 164*b*
 treatment, 172

- pathogenesis, 163–165
 patient assessment, 165–166
 patient care, 178–183
 presentation, 162–163
 pyloric stenosis, 169
 treatment, 168–175
 complications, 168–169
 gastro-oesophageal reflux disease, 173–175, 174*b*, 174*f*
 Helicobacter pylori, 171–172
 Helicobacter pylori negative ulcers, 173
 NSAID-associated ulcers, 172
 NSAID-negative ulcers, 173
 stress ulcers, 169–170
 ulcer-healing drugs, 175–178, 175*t*, 176*t*
 uncomplicated disease, 170–172
 Zollinger-Ellison syndrome, 169
 percutaneous coronary intervention (PCI), 315, 323–324, 327
 performance status scales, 822, 822*b*
 pericardial tuberculosis, 614
 pericyazine, schizophrenia, 483*t*
 perimetry, glaucoma, 863
 perindopril
 chronic heart failure, 340*t*
 clinical trials, 302
 hypertension, 155, 305
 stable angina, 317
 peripheral arterial disease (PAD), 915*t*, 916, 916*f*
 peripheral blood stem cell transplantation, 794–795
 peripherally inserted central catheters (PICCs), 104
 peripheral nerve injury, 530
 peripheral neuropathy, 693, 915–916, 915*t*, 916*f*
 peripheral oedema, 243, 246
 peripheral vascular disease (PVD), 692
 peristalsis, 210
 peritoneal dialysis
 acute, 266–267, 267*f*, 267*t*
 in chronic kidney disease, 292
 complications of, 292
 peritonitis, 292
 pernicious anaemia
 case study, 784
 epidemiology, 776
 investigations, 778
 pathophysiology, 777
 peroxisome proliferator-activated receptor (PPAR)
 agonists, 314, 703
 perphenazine, schizophrenia, 483*t*
 persistent pulmonary hypertension, 126
 pethidine
 absorption, 52
 analgesia, 522, 523*t*
 effect on neonates, 125
 petit mal seizures, 491
 P-glycoprotein, 52, 56–57, 58
 inducers, 56–57, 57*t*
 inhibitors, 56–57, 57*t*
 pheochromocytoma, 297
 phantom limb pain, 530
 pharmaceutical care, 3–4
 benefits of, 4
 case study, 10*b*, 11*t*, 12*t*
 definition, 3, 3*t*
 delivery, 3
 medication-related problems, 3–4
 classification, 4*b*
 process, 5*t*
 pharmaceutical consultation, 4–6, 21–23, 21*f*
 behaviours, 6, 7*b*
 building relationships, 21–22
 closing the session, 23
 competency framework, 20*t*
 explanation and planning, 22–23
 gathering information, 22
 initiating the session, 22
 medicines-taking behaviour, 5
 mnemonics, 5–6, 6*b*
 physical examination, 22
 postconsultation questions, 7*b*
 process, 5–6, 5*t*, 6*t*
 providing structure, 22
 pharmaceutical industry, influence on prescribing, 28
 pharmacodynamics
 drug interactions, 57–58
 in the elderly, 150–152
 pharmacoeconomics, 116–122
 application, 122*b*
 choice of comparator, 117
 decision analysis, 119–120, 119*t*, 120*t*
 discounting, 119
 economic evaluations, 117–119
 cost-benefit analysis, 117–118
 cost-effectiveness analysis, 118
 cost-utility analysis, 118–119
 of medicines, 120
 incentives and disincentives, 122
 medication non-adherents, 121–122
 risk management of unwanted drug effects, 120–121
 terminology, 117
 pharmacogenetics, adverse drug reactions, 66
 pharmacokinetics, 32–49
 absorption *see* absorption (of drugs)
 basic concepts, 33–37
 case studies, 45*b*
 in children, 135–138
 clinical applications, 37–49
 distribution *see* distribution (of drugs)
 dosage
 adjustment, 36–37
 alterations, 32
 regimens, 35–36
 drug concentration data, 36
 drug interactions, 51–57
 in the elderly, 149–150
 elimination *see* elimination (of drugs)
 excretion *see* excretion (of drugs)
 formulation choice, 32
 general applications, 32
 loading dose, 32
 metabolism *see* metabolism (of drugs)
 peak and trough levels, 36
 in pregnancy, 742
 therapeutic drug monitoring, 33
 time to maximal response, 32, 32*f*
 volume of distribution, 33–34
 pharmacovigilance, 68–71
 case-control studies, 70–71
 cohort studies, 70
 published case reports, 70
 spontaneous reporting, 68–69, 69*t*
 Yellow Card Scheme, 69–70
 pharyngitis (sore throat), 546–547
 case studies, 558
 causative organisms, 546
 clinical features, 546–547
 diagnosis, 547
 treatment, 547
 phenelzine
 anxiety disorders, 461
 depression, 471
 phenobarbital
 adverse effects, 500*t*
 in children, 144
 bioavailability, 135
 distribution, 43
 drug interactions, 499*t*
 elimination, 43
 epilepsy, 502
 hypocalcaemia, 82
 neonates, 125
 monitoring in, 129
 seizures, 128–129
 pharmacokinetics, 43, 45*t*, 498*t*
 plasma concentration-response relationship, 43
 practical application, 43
 phenothiazines
 absorption, 52
 antiemesis, 538
 schizophrenia, 483*t*
 teratogenicity, 741*t*
 phenytoin
 adverse effects, 66, 67–68, 500*t*, 502
 distribution, 41, 53
 drug interactions, 499*t*
 elimination, 41
 epilepsy, 502
 hypernatraemia, 79
 hypocalcaemia, 82
 interactions, 60
 metabolism, 54, 55, 55*t*
 nasogastric administration, 140
 neonatal seizures, 128–129
 pharmacokinetics, 41–42, 45*t*, 48, 498*t*
 plasma concentration-response relationship, 41
 practical implications, 41–42
 pregnancy, 742
 Philadelphia chromosome translocation, 791, 792–793
 phlebitis, 103
 phobias, 454–455, 455*t*, 457
 phosphate, 82
 in acute kidney injury, 265
 hyperphosphataemia, 82
 hypophosphataemia, 82
 phosphate-binding agents, hyperphosphataemia, 287
 phosphate enemas
 constipation, 157, 213
 hypocalcaemia, 82
 phosphodiesterase inhibitors, chronic heart failure, 342*t*, 343
 photoallergic reactions, 881
 photosensitivity
 amiodarone-induced, 371
 antipsychotics, 486
 drug-induced, 881, 881*b*
 phototherapy
 eczema, 898
 psoriasis, 903
 phototoxic reactions, 881
 physical examination, 22
 physical status classification, 598*t*
 physiotherapy
 chronic obstructive pulmonary disease, 439
 rheumatoid arthritis, 834–835
 phytomenadione
 clotting abnormalities, 246
 coagulation disorders, 231
 see also vitamin K
 phytotherapy, benign prostatic hyperplasia, 758
 pia mater, 584–585
 pilocarpine
 adverse effects, 872, 872*b*
 commercially available forms, 872*t*
 glaucoma, 872, 872*b*, 872*t*
 Pilogel, 872
 pimecrolimus, eczema, 897
 pimozone, schizophrenia, 483*t*
 pindolol, 318*t*
 pink puffer, 434–435

- pioglitazone
 adverse effects, 703
 diabetes mellitus, 703
 dosage, 703
 drug interactions, 703–704
 pharmacokinetics, 703
- piperacillin
 infection in neutropenia, 797
 urinary tract infections, 569*t*
- piperazine, schizophrenia, 483*t*
- piperidines, schizophrenia, 483*t*
- pipotiazine, schizophrenia, 483*t*
- piracetam, dementia, 152
- pityriasis versicolor, 658–659
 clinical presentation, 658
 diagnosis, 659
 treatment, 659
- pivmecillinam, urinary tract infections, 567–568
- pK_a , 746
- placenta, 124
- plant sterols, 400
- plaque psoriasis, 901, 908, 909
- plasma concentration-response relationship *see specific drugs*
- plasma proteins, 53
- plasminogen activator inhibitors, menorrhagia, 720
- platelet-activating factor (PAF), asthma, 413
- platelets (thrombocytes), 88*t*, 90, 91, 770
- pluripotent stem cells, 770
- pneumococcal infections
 conjugate vaccines, 548
 pneumonia, 551
 resistance to penicillin, 551–552
 in sickle cell anaemia, 781
- pneumococcal meningitis, 585, 588, 589
 treatment, 589–590
see also Streptococcus pneumoniae
- Pneumocystis jiroveci* pneumonia (PCP), 638, 621
- pneumonia, 550–555
 aspiration, 555
 community-acquired *see* community-acquired pneumonia
 fungal infections, 660*t*
 hospital-acquired (nosocomial) *see* hospital-acquired (nosocomial) pneumonia
 pneumococcal lobar, 551
- poikilocytosis, 89*t*
- poisons, acute tubular necrosis, 257*t*
- pollen, 412–413
- polyangiitis, microscopic, 258
- polyclonal antibodies, renal transplantation, 291–292
- polycystic kidney disease, 297
- polyenes, candidiasis, 656–657
- polyethylene glycol-uricase (PEG uricase), gout, 857
- polymorphonucleocytes *see* neutrophils
- polymyxins, cystic fibrosis, 556*t*
- polypharmacy
 risk for drug-induced liver disease, 224
 schizophrenia, 482–484
- polysorbates, 141
- polyunsaturated fatty acids, 100–101
- polyuria, chronic kidney disease, 277–278
- porphyrias, 67
- portal hypertension, liver disease, 243
- portal tract, 238, 239*f*
- posaconazole
 clinical use, 665
 fungal infections in compromised host, 665
 meningitis, 592
 pharmacokinetics, 664*t*
- postamputation pain, 530
- post-conception advice, 744–745
- post-exposure prophylaxis, antiretroviral therapy, 627
- postherpetic neuralgia, 529
- post-operative nausea and vomiting, 539
- post-operative pain, 527
- post-transplant lymphoproliferative disorder (PTLD), 807
- post-traumatic stress disorder (PTSD), 454–455, 455*b*, 455*t*, 457
 antidepressants, 460, 461
 benzodiazepines, 459
 case study, 463
 recommended drug treatments, 462*t*
- postural control, in geriatrics, 151
- postural hypotension, antipsychotics, 486
- postural instability, Parkinson's disease, 508
- potassium, 79–81
 acute kidney injury, 265
 chronic kidney disease, 281
 hyperaldosteronism, 297
 hyperkalaemia, 264
 intracellular fluid osmolality, 77
 normal daily dietary intake, 80
 restriction in chronic kidney disease, 286
 secretion, 79
 total body, 79
 urinary tract infections, 566
see also hyperkalaemia; hypokalaemia
- potassium permanganate, nail changes, 881–882
- potassium salts, 345*t*
- potassium sparing diuretics
 and hyperkalaemia, 80
 hypertension in chronic kidney disease, 284
- practical skills, 21
- practolol, 62
- pramipexole
 adverse effects, 512
 Parkinson's disease, 512
- pramiracetam, dementia, 152
- prasugrel
 arterial thromboembolism, 386
 non-ST elevation myocardial infarction, 327–328
 ST elevation myocardial infarction, 324
- pravastatin
 dyslipidaemia, 402
 metabolism, 404
- prazosin
 benign prostatic hyperplasia, 757
 hypertension, 301
- precipitation, parenteral nutrition, 106
- pre-conception advice, 744
- prednisolone
 acute lymphoblastic leukaemia, 790
 autoimmune hepatitis, 252
 eczema, 898
 effect on neonates, 124
 gout, 854
 graft-versus-host disease, 795
 Hodgkin's lymphoma, 805, 807*t*
 inflammatory bowel disease, 193–194, 195, 203*t*
 meningeal tuberculosis, 614
 non-Hodgkin's lymphoma, 809, 811
 prostate cancer, 763–764
 renal transplantation, 291
 rheumatoid arthritis, 839
 tuberculosis, 643
- prednisone, autoimmune hepatitis, 252
- pre-eclampsia, 306
- pregabalin
 adverse effects, 502
 anxiety disorders, 461
 pharmacokinetics, 44
 plasma concentration-response relationship, 44
 postherpetic neuralgia, 529
- pregnancy
 bacteriuria in, 566, 569–570
- diabetic retinopathy in, 693
- drugs in, 739–745
 anti-thyroid drugs, 677
 benzodiazepines, 460
 case studies, 750
 dosing, 743–744
 foetal development periods, 740
 foetal-placental transfer, 743
 maternal pharmacokinetic changes, 742, 742*t*
 pharmacological effect, 741
 post-conception advice, 744–745
 pre-conception advice, 744
 principles of, 740–741
 selection, 744
 teratogenicity, 739–745, 739*b*
 teratology information services, 745
- embryonic stage, 740
- foetal stage, 740
- and folate deficiency anaemia, 777, 778
- HIV infection and, 646, 647
- hypertension in, 306, 309
 and inflammatory bowel disease, 204
 nausea and vomiting in, 540–541
- pre-embryonic stage, 740
- rheumatoid arthritis in, 842
- risk for drug-induced liver disease, 224
- tuberculosis in, 614
- pregnancy registries, 745
- premature infants, drug transfer into breast milk, 748
- premenstrual dysphoric disorder (PMDD), 712, 713*b*
- premenstrual syndrome (PMS), 712–716
 aetiology, 713–714
 diagnosis, 713*b*
 epidemiology, 712–713
 essential fatty acids, 714
 hormones, 713–714
 management, 714–716
 psychological factors, 714
 symptoms, 714
 vitamins and generals, 714
- prescribing (of drugs), 9–10, 14–31
 adherence *see* adherence/non-adherence
 communicating risks/benefits of treatment, 23–24
 consultation *see* pharmaceutical consultation
 costs of, 116
 factors influencing, 26–28
 cognitive factors, 28, 28*t*
 colleagues, 28
 health care policy, 27
 patients, 26–27
 pharmaceutical industry, 28
 inappropriate or irrational, 15
 legal framework, 15–20
 accountability, 16–17
 clinical governance, 19, 20*b*
 competence and competency frameworks, 19–20, 20*t*
 ethical framework, 17–18
 autonomy, 17, 17*b*
 beneficence, 18
 justice and veracity, 18
 non-maleficence, 17–18
 evolution of non-medical prescribing, 15–16
 non-medical independent prescribing, 16
 supplementary prescribing, 16, 16*b*
 off-label and unlicensed prescribing, 18, 19*b*
 prescribing between primary and secondary care, 18–19
 professional frameworks, 18
 medication review, 25–26, 25*t*

- process, 21–24
 rational and effective, 14–15, 15f
 definition, 14–15
 inappropriate or irrational, 15
 repeat, 25
 strategies to influence, 29–30
 managerial approaches, 29
 support and education, 30
- pressure ulcers, 920–921
 aetiology, 920–921
 case study, 924
 clinical signs, 921
 common sites of, 920
 definition, 920
 diagnosis, 921
 epidemiology, 920, 920t
 prevention, 921
 treatment, 921
- Prezista®, 631t
- prilocaine, 136
- primaquine, opportunistic infections in HIV, 639t
- primary antiphospholipid syndrome (PAPS), 377
- primary biliary cirrhosis (PBC), 241
 hyperpigmentation, 242
 management, 252
- primary sclerosing cholangitis (PSC), 241, 252
- Primene®, 98, 99t
- primidone
 epilepsy, 502
 pharmacokinetics, 43, 45t, 498t
- Prinzmetal's angina, 317–318, 319
- probenecid
 elimination, 56
 gout, 856
- probiotics
 diarrhoea, 218
 inflammatory bowel disease, 186, 203t
- procainamide
 adverse effects, 367t
 arrhythmias, 369
 pharmacokinetics, 368t
- procarbazine, Hodgkin's lymphoma, 805, 807t
- prochlorperazine
 antiemesis, 285, 538, 541
 drug-induced parkinsonism, 509–510
- proctitis
 treatment, 193, 199, 204
 ulcerative colitis, 190
- product licence (PL), 145
- PROFESS study, 305
- progesterone
 deficiency, 713
 menstrual cycle, 711–712
 premenstrual syndrome, 713
- progestins, 394t
- progestogens
 dyslipidaemia, 396
 endometriosis, 722
 menopause, 729–730
 menorrhagia, 719–720
 premenstrual syndrome, 715
- progressive multifocal leucoencephalopathy (PML), 646
- PROGRESS study, 305
- prolactin, premenstrual syndrome, 713–714
- promazine, schizophrenia, 483t
- promethazine, antiemesis, 541
- propafenone
 adverse effects, 367t
 arrhythmias, 363
 pharmacokinetics, 368t
- propantheline bromide, dysmenorrhoea, 717
- propiverine, urinary incontinence, 157
- propranolol, 318t
- absorption, 52
 anxiety disorders, 462
 arrhythmias, 370
 distribution, 53
 in the elderly, 150, 151
 metabolism, 150
 oesophageal varices, 250
- propylene glycol
 adverse reactions, 141
 in oral preparations, 139
- propylthiouracil (PTU)
 hyperthyroidism, 675–676, 677
 thyrotoxicosis, 676
- prostaglandin analogues, glaucoma, 865–868
- prostaglandins, 56
 dysmenorrhoea, 716
 kidney perfusion, 256–257
 menorrhagia, 719, 720
 menstrual cycle, 712
 premenstrual syndrome, 713–714
- prostaglandin synthesis inhibitors
 drug-induced asthma, 412–413
 premenstrual syndrome, 716
- prostanoids, ocular, 865–868, 868t, 869t
- prostate cancer, 759–764
 case studies, 766–767, 829
 chemoprevention, 764
 common problems associated with, 764t
 epidemiology, 759
 examination, 760
 investigation, 760–761
 pathophysiology, 759
 patient care, 764
 screening, 760
 staging, 761
 symptoms, 760
 treatment, 761–764
 castrate resistant prostate cancer, 763–764
 localised prostate cancer, 761
 locally advanced prostate cancer, 761–763
 metastatic prostate cancer, 763
- prostatectomy
 open, 758
 radical, 761
- prostate disease, 753–768
 case studies, 766b
 see also specific diseases
- prostate gland
 anatomy, 753, 754f
 biopsy, 760
 transurethral resection, 758
- prostate-specific antigen (PSA), 88
 age-specific levels, 760t
 prostate cancer, 760
- prostatitis, 764–767
 acute bacterial, 765
 asymptomatic inflammatory, 765
 chronic bacterial, 765, 766
 chronic prostatitis/chronic pelvic pain syndrome, 765, 766
 classification of, 765t
 definition, 764
 epidemiology, 764
 examination, 765
 investigations, 765
 pathophysiology, 765
 patient care, 766–767
 symptoms, 765
 treatment, 765–766
- prosthetic implants, 597
- protease inhibitors
 effect on lipoprotein levels, 394t
 HIV infection, 626, 631t, 635
- protective isolation, neutropenia, 797
- protein
 in diabetes mellitus, 695
 extracellular fluid osmolality, 77
- proteinase imbalance, 433
- protein binding, 137
 drug transfer into breast milk, 746
 in pregnancy, 742
- protein C
 activated, 715
 deficiency, 376–377
- protein S deficiency, 377
- proteinuria
 in chronic kidney disease, 277–278
 in diabetes mellitus, 693
- Proteus* sp, 562
- prothianamide, tuberculosis, 616t
- prothrombin 20210 mutation, 377
- prothrombin time (PT), 84, 91, 244
- proton pump inhibitors
 absorption, 52
 adverse reactions, 176
 available formulations of, 175, 175t
 clinical use, 177
 drug interactions, 176–177
 gastro-oesophageal reflux disease, 173–174
Helicobacter pylori eradication, 171
 interstitial nephritis, 258–259
 peptic ulcer disease, 169–170, 172–173, 175–177
 pharmacokinetics, 175, 176
- protozoa
 gastro-intestinal infections, 574t
 in HIV infection, 643
- pruritus
 in chronic kidney disease, 285
 drug-induced, 884
 drug-induced liver disease, 231
 in liver disease, 242, 244–246, 245t
 management, 244–246
 treatment, 231
- pseudohypoparathyroidism, 680
- pseudomembranous colitis, 188, 202, 216
- Pseudomonas aeruginosa*, 591
 cystic fibrosis, 555–556, 556t
 gentamicin, 39
 urinary tract infections, 562
- psoralens plus UVA light (PUVA), psoriasis, 903
- psoriasis, 898–909
 aetiology, 899–900
 case studies, 908, 909
 clinical features, 900–901, 900f
 clinical types, 901–902
 drug-induced, 885, 885b, 889–890
 pathology, 900–901
 patient care, 905–909
 precipitating factors, 899–900
 treatment, 902–905
 biologic therapy, 905
 drug interactions, 899t
 phototherapy, 903
 psoriasis at special fights, 903
 systemic therapy, 903–905, 904t
 topical retinoids, 903
 topical therapy, 902–903
- Psoriasis Area and Severity Index (PASI), 903
- psoriasis vulgaris, 901
- psoriatic arthropathy, 902
- psychological changes, menopause, 727, 735
- psychomotor impairment, benzodiazepines, 459
- psychosis, Parkinson's disease, 516
- psychotherapy, anxiety disorders, 457
- puberty, 711
- pulmonary arteriography, 378

pulmonary embolism (PE), 378
 acute submassive, 378
 diagnosis, 93
 investigations, 378
 maternal death, 376
 pulmonary fibrosis, 433
 amiodarone-induced, 371
 chemotherapy-induced, 813*t*
 pulmonary hypertension, 434
 pulmonary rehabilitation, chronic obstructive pulmonary disease, 440
 pure red cell aplasia (PRCA), 286
 purine analogues, chronic lymphocytic leukaemia, 793
 purines, 84
 Purkinje fibres, 356, 366, 366*t*
 pustular psoriasis, 901*f*, 902, 908
 PUVA (psoralens plus UVA light), psoriasis, 903
 pyelonephritis
 acute, 258, 561, 568–569
 chronic, 277, 561
 pyloric stenosis, 169
 pyoderma gangrenosum, 191
 pyrazinamide
 adverse effects, 615–616, 616*t*
 tuberculosis, 612, 613, 613*t*, 614, 643
 pyridoxine
 premenstrual syndrome, 715
 sideroblastic anaemia, 775
 Wilson's disease, 252
 pyrimethamine
 opportunistic infections in HIV, 639*t*
Pneumocystis jiroveci pneumonia, 638
 toxoplasmosis, 643
 pyroxidine phosphate, premenstrual syndrome, 714

Q

QRISK2, 398–399
 QT prolongation
 antipsychotics, 486
 drug interactions, 50
 quality-adjusted life-years (QALYs), 118–119
 quality of life, elderly, 157
 quetiapine
 Parkinson's disease, 516
 schizophrenia, 483*t*
 quinapril, chronic heart failure, 340*t*
 quinidine
 adverse effects, 367*t*
 arrhythmias, 368
 pharmacokinetics, 368*t*
 quinolone antibiotics
 absorption, 52
 acute pyelonephritis, 568
 cystic fibrosis, 556*t*
 interstitial nephritis, 258–259
 Legionnaire's disease, 552
 mycobacteria, 644
 urinary tract infections, 567, 568

R

rabeprazole
 drug interactions, 176
 formulations available, 175*t*
 peptic ulcer disease, 175*t*
 race *see* ethnicity/race
 radiation, leukaemia risk, 786–787
 radiocontrast media, acute tubular necrosis, 257*t*
 radio-frequency interstitial tumour ablation (RITA), 761
 radioiodine, 675–676, 677–678
 radiology
 drug-induced liver disease, 228

inflammatory bowel disease, 191
 peptic ulcer disease, 166.
see also specific modalities
 radiotherapy
 alongside chemotherapy, 824
 Hodgkin's lymphoma, 804, 806*f*
 prostate cancer, 761
 solid tumours, 823
 raloxifene
 alternative to HRT, 730, 732
 osteoporosis, 155
 raltegravir, HIV infection, 631*t*, 637
 ramipril
 chronic heart failure, 340*t*
 coronary heart disease, 11*t*, 12*t*
 hypertension, 305
 stable angina, 317
 ranitidine, peptic ulcer disease, 169–170, 173*t*, 177
 ranolazine, stable angina, 320
 rapid eye movement (REM) sleep, 446–447
 rapidly progressive glomerulonephritis (RPGN), 258
 rapport, 22
 rasagiline, Parkinson's disease, 513
 rasburicase
 gout, 856–857
 tumour lysis syndrome, 813–814
 rash, antiretroviral toxicity, 637
 Rawlins-Thompson classification, 63–64, 64*t*
 R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), non-Hodgkin's lymphoma, 809, 811
 R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone), non-Hodgkin's lymphoma, 809, 811
 reactive oxygen species (ROS), coronary heart disease, 314
 REAL (revised European-American lymphoma) classification, 808, 808*t*, 809*b*
 reasoning skills, 21
 rebound insomnia, 450
 reboxetine, depression, 472
 record keeping, 158
 recreational drug use, and breastfeeding, 749
 rectal route of administration
 children, 136, 140
 in inflammatory bowel disease, 193
 neonates, 124
 red blood cell count, 88–89, 88*t*
 red blood cells, 770
 red cell folate, 88*t*
 red clover, 59, 731
 re-entry, 358, 358*f*
 refeeding syndrome, 110, 110*t*
 refractoriness, 355
 regurgitation, 535
 rehydration, 216–217, 216*t*
 relationships, building, 21–22
 renal artery stenosis
 bilateral, 262, 262*f*
 in hypertension, 297
 renal clearance in the elderly, 150
 renal disease
 gout, 850
 hypertension in, 305
 tuberculosis in, 614
 renal osteodystrophy, 279–280, 279*f*, 287–288
 renal perfusion optimisation, 263
 renal replacement therapy, 265–270
 acute peritoneal dialysis, 266–267, 267*f*
 approximate clearances of, 267*t*
 characteristics of the ideal drug, 269*b*
 in chronic kidney disease, 292–293
 common adverse effects, 269*f*
 convection, 265
 diffusion, 265
 drug dosage in, 267, 267*t*
 factors affecting drug use, 267–270
 absorption, 267
 distribution, 268
 excretion, 268
 metabolism, 268
 nephrotoxicity, 268–270
 forms of, 265–267
 haemodiafiltration, 266
 haemodialysis, 265–266, 266*f*
 haemofiltration, 266
 primary diagnosis, 276*t*
 ultrafiltration, 265
 vs. transplantation, 288
 renal tract obstruction, 277
 renal transplantation, 288–292
 acute tubular necrosis, 257*t*
 donors, 288–289
 end stage renal failure, 288
 immunosuppressants, 289–292, 289*t*
 other precautions, 292
 vs. renal replacement therapy, 288
 renal tubule, active excretion, 56
 renin, 273
 renin-angiotensin-aldosterone antagonists, hypertension, 301
 renin-angiotensin-aldosterone system, 76
 ascites, 243
 in chronic kidney disease, 272–273
 and hypertension, 296
 kidney perfusion, 256–257
 repaglinide
 diabetes mellitus, 702
 dosage, 703
 pharmacokinetics, 702–703
 repeat prescriptions, 25
 reserpine, affective disorders, 466
 residual volume (RV), 435
 respiratory depression
 in neonates, 125
 opioid-induced, 523
 respiratory disease, parenteral nutrition in, 111
 respiratory distress syndrome (RDS)
 case study, 130
 in neonates, 125–126
 respiratory failure, acute, 435
 respiratory infections, 545–560
 case studies, 558*b*
 common therapeutic problems, 557*t*
 in the immunocompromised, 556–559, 557*t*
 lower respiratory tract, 549–556
 upper respiratory tract, 545–549
 respiratory syncytial virus (RSV), 134, 550
 retching, 535
 reteplase
 ST elevation myocardial infarction, 323*t*, 324
 venous thromboembolism, 385
 reticulocytes, 88*t*, 89
 retinitis, cytomegalovirus, 644
 retinoid drugs
 adverse effects, 885
 topical, psoriasis, 903
 retinopathy, diabetic, 693
 Retrovir[®], 628*t*
 reverse cholesterol transport pathway, 390–391
 reverse transcriptase, 621–622, 622*f*
 revised European-American lymphoma (REAL) classification, 808, 808*t*, 809*b*
 Reyataz[®], 631*t*
 Reye's syndrome, 144, 223
 rhabdomyolysis, 87, 87*t*, 257*t*
 rheumatoid arthritis, 832–843

- aetiology, 832–833
 case studies, 845, 846
 clinical manifestations, 833, 833*b*, 833*f*
 diagnosis, 833–834, 833*b*, 834*b*
 epidemiology, 832
 investigations, 834
 pain management, 530
 pathophysiology, 832–833
 patient care, 843
 therapeutic problems in management of, 844*t*
 treatment, 834–843
 abatacept, 842
 anakinra, 842
 anti-TNF agents, 840–841
 biological therapies, 839–840, 840*t*
 disease-modifying anti-rheumatic drugs, 836–839, 837*t*, 838*b*, 839*b*
 drugs, 835
 non-steroidal anti-inflammatory drugs, 835–836, 835*t*
 in pregnancy, 842
 rituximab, 841–842
 tocilizumab, 842
- rheumatoid factor (RF), 834
- ribavirin
 bronchiolitis, 550
 hepatitis C, 251–252, 646
 HIV, 639*t*, 646
 opportunistic infections, 639*t*
- ribonucleic acid (RNA), 89
- rifabutin
 mycobacteria, 644
 opportunistic infections in HIV, 639*t*
 tuberculosis, 616*t*
- rifampicin
 adverse effects, 615, 616*t*
 gastro-intestinal infections, 580
 hepatotoxicity, 223*t*, 226
 Legionnaire's disease, 552
 meningitis, 589*t*, 590, 591
 metabolism, 54
 pruritus in liver disease, 245
 tuberculosis, 612, 613, 613*t*, 614, 617, 643
- rifaximin
 gastro-intestinal infections, 579
 hepatic encephalopathy, 248, 249*t*
- RIFLE criteria, 255, 256*f*
- rilpivirine, HIV infection, 635
- ringworm, 657
- risedronate
 adverse effects, 154
 alternatives to HRT, 731
 osteoporosis, 154
- risk management of unwanted drug effects, 120–121
- risks, communicating, 23–24, 72–74, 73*f*
- risperidone, schizophrenia, 483*t*, 485
- ritonavir
 HIV infection, 626, 631*t*, 635
 metabolism, 55
- rituximab
 adverse effects, 841
 autoimmune haemolytic anaemia, 780
 chronic lymphocytic leukaemia, 793
 Hodgkin's lymphoma, 805, 806
 indications/contraindications, 841–842
 non-Hodgkin's lymphoma, 809, 811–812
 rheumatoid arthritis, 841–842
- rivaroxaban, venous thromboembolism, 384
- rivastigmine
 dementia, 152
 Parkinson's disease, 516
- Rockall risk scoring system, 166
- rofecoxib
 adverse reactions, 62
 safety, 835
- ropinirole
 adverse effects, 512
 Parkinson's disease, 512
- rosiglitazone, 703
- Rosser-Kind matrix, 118
- rosuvastatin
 dyslipidaemia, 402
 metabolism, 404
- rotaviruses, 214, 573
 vaccine, 218–220
- rubefacients, osteoarthritis, 845
- rufinamide, epilepsy, 502
- rumination, 535
-
- S**
- Saccharomyces*, 218
- St John's wort, 50
 depression, 473
 and drug metabolism, 54
 interactions, 59, 61, 475*t*
- salbutamol inhaler
 asthma, 415, 418, 418*t*, 422
 coronary heart disease, 11*t*, 12*t*
 hyperkalaemia, 264
- salicylates
 adverse reactions, 144
 elimination, 56
- salicylic acid, psoriasis, 903
- saliva, electrolyte content of, 105*t*
- salmeterol, asthma, 418*t*
- Salmonella*
 diarrhoea, 214, 217–218
 gastro-intestinal infections, 573, 574–575, 574*t*, 576*t*
 transmission, 573
 treatment, 578–579, 581*t*
- salt intake
 in diabetes mellitus, 695
 and dyslipidaemia, 401
- salt reduction
 ascites in liver disease, 246
 hypertension, 298
- saprophytic fungi, 659
- saquinavir, HIV infection, 631*t*
- Saving Lives programme, 554
- saxagliptin, 704
- scalp psoriasis, 901, 903, 908
- scarlet fever, 546–547
- scars, 910–911
- Scedospermium*, 659
- schizophrenia, 479–488
 acute psychotic illness, 479–480
 case studies, 487*b*
 causes of, 480
 chronic, 480
 classification, 479
 diagnosis, 479–480
 drug treatment, 480–488
 adverse effects, 486–488
 anticholinergic drugs, 485
 antipsychotics, 480–481, 483*t*, 484–485, 486–488
 augmentation strategies and polytherapy, 484
 clozapine and refractory illness, 482
 neuroleptic equivalence, 484
 non-acting formulations, 484–485
 polypharmacy, 482–484
 rationale, 481
 selection and dose, 481–482
 therapeutic drug monitoring, 485–486
 symptoms, 479–480
- Schofield equation, 99, 99*t*
- schools, medicines in, 142–143
 policies and guidance, 143
 responsibility for, medicines, 143
 special schools, 143
- Schwartz equation, 144
- scleritis, 191
- sclerosing cholangitis, 191
- Scottish Intercollegiate Guideline Network
see SIGN
- seborrhoeic dermatitis, 658, 659, 895
 case study, 907, 907*f*
- secondarily generalised seizures, 492
- sedation
 antipsychotics, 486
 opioid-induced, 523
- seizures
 febrile convulsions, 493
 generalised, 491, 494*t*
 absence attacks (petit mal), 491
 atonic seizures, 491
 myoclonic seizures, 491
 tonic clonic (grand mal) convulsions, 491
 incidence, 490
 neonates, 128–129
 partial/focal, 491–492, 494*t*
 complex partial seizures, 491–492
 secondarily generalised seizures, 492
 simple partial seizures, 491
 treatment during, 493
- selective decontamination of the digestive tract (SDD), 554–555
- selective oestrogen receptor modulators (SERMs), 730, 736
- selective serotonin reuptake inhibitors (SSRIs)
 antiemesis, 538, 540
 anxiety disorders, 461
 depression, 469, 471, 472
 hepatotoxicity, 223*t*
 interactions, 58, 475*t*
 pain, 526
 premenstrual syndrome, 716
 teratogenicity, 741*t*
- selegiline, Parkinson's disease, 513
- selenium, 102*t*
- selenium sulphide lotion, pityriasis versicolor, 659
- self-monitoring, chronic heart failure, 344–345, 345*t*
- senna, constipation, 157, 212
- sensory ataxia, 95
- sepsis
 acute tubular necrosis, 257*t*
 parenteral nutrition, 109, 111
- septicaemia, neonates, 127*t*
- serological markers, drug-induced liver disease, 228
- serotonin
 affective disorders, 466
 nausea and vomiting, 538
 premenstrual syndrome, 714
- serotonin-dopamine antagonists, schizophrenia, 483*t*
- serotonin-noradrenaline reuptake inhibitors (SNRIs), 472, 731
- serotonin syndrome (SS), 57–58, 60
- Serratia* sp., 562
- sertindole, schizophrenia, 483*t*
- sertraline
 depression, 471, 472
 effect on lipoprotein levels, 394*t*
- serum, 76
- sevelamer, hyperphosphataemia, 287
- severe acute respiratory syndrome (SARS), 555
- severe myoclonic epilepsy of infancy (SMEI), 503
- sexual characteristics, liver disease, 243

- sexual dysfunction
 antipsychotics, 486
 and the menopause, 735
- SGN-35, Hodgkin's lymphoma, 806
- Shankapushpi*, 59
- Shigella*, 214, 217
 gastro-intestinal infections, 574–575, 574*t*, 576*t*
 transmission, 573
 treatment, 579, 581*t*
- short bowel syndrome, 111
- shunt-associated meningitis, 591, 592*t*
- sickle cell anaemia, 780–781
 aetiology, 780
 clinical manifestations, 781
 epidemiology, 780
 inheritance patterns, 781*f*
 investigations, 781
 pathophysiology, 781
 patient care, 781
 treatment, 781
- sickle cells, 781
- sickle cell trait, 780, 781*f*
- sideroblastic anaemia, 774–775
 acquired, 774, 774*b*, 775
 aetiology, 774
 case study, 784
 clinical manifestations, 775
 drugs and toxins, 774–775
 epidemiology, 774
 hereditary, 774, 775
 investigations, 775
 iron overload, 775
 pathophysiology, 774–775
 patient care, 775
 treatment, 775
- SIGN, prescribing strategies, 29
- sildenafil
 metabolism, 55, 55*t*
 neonates, bronchopulmonary dysplasia, 127
- silent ischaemia, 315
- simple partial seizures, 491
- simvastatin
 adverse reactions, 73
 coronary heart disease, 11*t*, 12*t*
 dyslipidaemia, 402, 403*t*
 interactions, 59
 metabolism, 55, 404
 over-the-counter sale, 405
- Sinemet[®], 511
- sinusitis, 548–549
- sinus node, 356–357
- sinus rhythm, 354
- sirolimus
 adverse effects, 291
 renal transplantation, 289*t*, 291
- sitagliptin, 704
- skeletal muscle relaxants, 525*t*, 526–527
- skin
 in liver disease, 242
 menopausal changes, 727
 necrosis, drug-induced, 889
 neonates, 124
 pigmentary changes, 881, 881*f*, 882*t*
 structure, 910
 in ulcerative colitis, 190–191
 warfarin-induced reactions, 381
- skin cancer
 case study, 890, 890*f*
 drug-induced, 883
- skin disorders, drug-induced, 880–892
 case studies, 889*b*
 causing skin function changes, 881–883
 diagnosis, 880
 mild, 883–885
 patient care, 889–892
 severe, 885–889
- skip lesions, 187–188
- SLC2A9, 850
- SLC22A12* gene, 850
- sleep
 hygiene, 447, 447*b*
 problems and the menopause, 735
 systems, 446–447, 446*f*, 456*f*
- sleep apnoea syndrome, 435
- sleep attacks, 512
- slow continuous ultrafiltration (SCU), 266
- small round structured virus (SRSV), 214
- small-vessel vasculitis (SVV), 258
- smoking *see* cigarette smoking
- social phobia, 454–455, 455*t*
 antidepressants, 461
 case study, 463
 recommended drug treatments, 462*t*
- sodium
 in acute kidney injury, 265
 balance, 76–79
 in chronic kidney disease, 280, 280*t*
 depletion, 78
 distribution, 78
 excess, 78
 extracellular fluid
 osmolality, 77
 volume, 78
 oral rehydration solutions, 216–217
 restriction in chronic kidney disease, 286
see also hypernatraemia; hyponatraemia
- sodium aurothiomalate, rheumatoid arthritis, 836, 837*t*, 839
- sodium bicarbonate, acidosis, 264
- sodium channel blockade, 368*t*
- sodium citrate
 enemas, constipation, 213
 urinary tract infections, 566
- sodium cromoglicate
 adverse reactions, 420*b*
 asthma, 419
 inflammatory bowel disease, 203*t*
- sodium nitroprusside
 chronic heart failure, 343
 hypertension, 301
- sodium thiosulphate, pityriasis versicolor, 659
- sodium valproate
 adverse effects, 500*t*, 502–503
 in children, 144
 drug-induced parkinsonism, 509–510
 drug interactions, 499*t*
 epilepsy, 502–503
 hepatotoxicity, 223, 223*t*, 226, 233
 metabolism, 55*t*
 neonatal seizures, 128–129
 pharmacokinetics, 498*t*
- solifenacin, urinary incontinence, 157
- soluble fibre, dyslipidaemia, 407
- somatostatin, oesophageal varices, 250
- sorbitol, 139
- sore throat *see* pharyngitis (sore throat)
- sotalol
 adverse reactions, 65
 arrhythmias, 359, 361, 363, 370
 pharmacokinetics, 318*t*
- sphincter muscle theory, 862
- spider naevi, 242
- spina bifida, 133
- spiral computed tomography, pulmonary embolism, 378
- spirometry
 asthma, 414–415
 chronic obstructive pulmonary disease, 435
- spironolactone
 adverse reactions, 74, 243
 ascites, 246, 247, 247*t*
 chronic heart failure, 339*t*, 341–342
 drug interactions, 348*t*
 hyperkalaemia, 80
 hypertension, 285, 300–301
 neonatal bronchopulmonary dysplasia, 127
- splenomegaly, 242
- spontaneous bacterial peritonitis (SBP), 247–248
- spontaneous reporting, 68–69
 causality assessment, 69, 69*t*
 signal detection, 68–69
- sputum tests/cultures
 pneumonia, 551, 553
 tuberculosis, 611
- standard gamble method, 118
- stanol esters, 400
- staphylococcal infections
 coagulase-negative, 127
 pneumonia, 552
 urinary tract infections, 562
- Staphylococcus aureus*
 bacterial meningitis, 585
 chronic obstructive pulmonary disease, 438–439
 cystic fibrosis, 555
 diarrhoea, 214
 gastro-intestinal infections, 574*t*, 576*t*
 investigations, 577
 meticillin-resistant *see* meticillin-resistant *Staphylococcus aureus* (MRSA)
- neonates, 127
 surgical site infection, 599–600
 transmission, 573
 treatment, 578
- stasis eczema, 895
- statins
 adverse effects, 73, 87, 404, 885
 coronary heart disease, 11*t*, 317
 drug interactions, 404*t*
 dyslipidaemia, 402–405
 hepatotoxicity, 223*t*
 hypertension in chronic kidney disease, 285
 non-ST elevation myocardial infarction, 329
 over-the-counter sale, 405
 patient counselling, 405
 pleiotropic properties, 404–405
 stable angina, 317
 ST elevation myocardial infarction, 325
- status epilepticus, 493
- stavudine, HIV infection, 628*t*, 635
- steatohepatitis, 226–227, 241
- steatosis
 aetiology, 225
 clinical presentation, 227
 drugs associated with, 226*t*
 pathophysiology, 226–227
- stellate cells, 238
- stem cell transplantation, 794*f*
 acute myeloblastic leukaemia, 792
 basic principle, 794
 complications, 795
 leukaemia, 794–795
 Parkinson's disease, 514–515
 peripheral blood, 794–795
 place of, 795
 reduced intensity allografting, 795
 source of stem cells, 794
- STEPS, 14–15
- sterculia, constipation, 212
- steroids *see* corticosteroids
- steroid-sparing agents, asthma, 419
- Stevens-Johnson syndrome, 66

- clinical features, 886–887, 886f
 drug-induced, 886–887, 886f, 887b, 891
 stimulant laxatives, 212–213
 stimulation-produced analgesia, 527
 stiripentol, epilepsy, 503
 stool antigen tests, *Helicobacter pylori*, 166–167
 stool examination/tests
 diarrhoea, 216
 gastro-intestinal infections, 577
 inflammatory bowel disease, 192
 streptococcal infections
 group B β -haemolytic, 127
 sore throat, 546–547
Streptococcus pneumoniae, 585, 588, 589, 593t
 bronchitis, 549
 chronic obstructive pulmonary disease, 438–439
 otitis media, 548
Streptococcus pyogenes, 546
 streptokinase
 adverse effects, 324, 385
 leg ulcers, 156
 ST elevation myocardial infarction, 323t, 324
 venous thromboembolism, 384–385
 streptomycin
 adverse reactions, 65
 tuberculosis, 612, 613t, 614, 616t
 stress
 and anxiety, 456
 and inflammatory bowel disease, 186
 and peptic ulcers, 169–170
 and psoriasis, 900
 stress incontinence, 156–157
 stroke, 153–154
 and fibrinolytics, 324
 haemorrhagic *see* haemorrhagic stroke
 and hormone replacement therapy, 733t
 hypertension in, 295, 305–306, 309
 primary prevention, 154
 risk from atrial fibrillation, 362–363, 362f, 374
 secondary prevention, 153–154
 treatment, 153
 strontium ranelate
 alternatives to HRT, 731
 osteoporosis, 154
 Study of Cognition and Prognosis in the Elderly (SCOPE), 304
 subarachnoid haemorrhage, 93
 subarachnoid space, 584–585
 subcutaneous jet injection systems, 136
 substance P, 538–539
 substantia nigra, 508
 subthalamic nucleus, 514
 sucralfat
 adverse reactions, 178
 drug interactions, 178
 peptic ulcer disease, 169–170, 178
 sulfadiazine
 opportunistic infections in HIV, 639t
 toxoplasmosis, 643
 sulfapyridine, inflammatory bowel disease, 196
 sulfasalazine
 inflammatory bowel disease, 196, 203t
 rheumatoid arthritis, 836, 837t, 839
 sulphamonomethoxime, 67
 sulphapyridine, gout, 856
 sulphonamides
 bioavailability in children, 135
 hepatotoxicity, 223t
 sulphonylureas
 adverse effects, 700–701, 702t
 choice of, 700
 diabetes mellitus, 699, 700–701, 701t
 dosage, 701
 drug interactions, 701
 mode of action, 700
 pharmacokinetics, 700
 sulphuridone, schizizophrenia, 483t
 supplementary prescribing, 16, 16b
 supraventricular tachycardias, 359–364
 atrial fibrillation *see* atrial fibrillation
 atrial flutter, 359, 360f
 case study, 374
 focal atrial tachycardia, 359
 inappropriate sinus tachycardia, 359
 junctional re-entry tachycardia, 360–361, 361f
 surfactant deficiency, 125, 126
 surgery
 benign prostatic hyperplasia, 758
 duration of, 597
 hyperthyroidism, 678
 infection after *see* surgical site infection
 Parkinson's disease, 514–515, 514t
 solid tumours, 823
 venous thromboembolism, 377
 surgical site infection, 596–607
 case studies, 605b
 definition, 596, 597t
 epidemiology, 596
 pathogenesis, 599–600, 600f, 600t
 prevention/antibiotic prophylaxis, 600–606
 β -lactam allergy, 604–605, 605t
 cephalosporin-free, 603t
 choice of antimicrobial, 601–605
 common micro-organisms, 602t
 local, 605–606
 number needed to treat, 601t
 recommendations, 601t
 repeat doses, 604, 605t
 susceptibility of common pathogens, 602t
 timing and duration, 602–603, 603f
 topical, 605–606
 risk factors, 597–599, 598t, 599f, 599t
 surveillance, 596–597
 sustained virologic response (SVR), hepatitis C virus, 251–252
 Sustiva[®], 630t
 Swedish Trial in Old Patients with hypertension-2 (STOP-2), 304
 sweeteners, diabetes mellitus, 694–695
 Sweet's syndrome, 191
 sympathomimetics
 chronic heart failure, 342t
 glaucoma, 864, 871–872, 871t, 872t
 interactions, 58
 syndrome of inappropriate secretion of antidiuretic hormone (SIADH), 78, 79
 syndrome X, 687
 Synthamin[®], 98, 99t
 systemic lupus erythematosus (SLE), 258, 377
- ## T
- tacrolimus
 autoimmune hepatitis, 252
 drug interactions, 176
 effect on lipoprotein levels, 394t
 hypomagnesaemia, 82
 inflammatory bowel disease, 199
 metabolism, 54
 renal transplantation, 289t, 290
 topical, eczema, 897
 tafluprost, glaucoma, 865, 866, 868t
 tamoxifen
 chemoprevention, 819
 hair changes, 882
 and hypercalcaemia, 81
 tamsulosin, benign prostatic hyperplasia, 757
 tardive dyskinesia, 481, 482
 taxanes, Kaposi's sarcoma, 645
 tazobactam, urinary tract infections, 569t
 teicoplanin
 infection in neutropenia, 797
 surgical site infection prophylaxis, 604
 telaprevir, hepatitis C, 252
 telbivudine, hepatitis B, 251
 telmisartan
 clinical trials, 305
 hypertension, 305
 Telzir[®], 631t
 temazepam, 458t
 temocillin, pneumonia, 554t
 tenecteplase
 ST elevation myocardial infarction, 323t, 324
 venous thromboembolism, 385
 tenofovir
 hepatitis B, 251, 646
 HIV infection, 628t, 635
 TENS *see* transcutaneous electrical nerve stimulation (TENS)
 teratogenicity, 739–745
 drug dose, 740–741
 example drugs, 739b
 genotype and environmental interaction, 741
 principles, 740–741
 species, 741
 timing of exposure, 740
 teratology information services (TIS), 745
 terazosin
 benign prostatic hyperplasia, 757
 hypertension, 301
 terbinafine
 dermatophytosis, 657–658
 pityriasis versicolor, 659
 terbutaline, asthma, 415, 418, 418t
 teriparatide
 alternatives to HRT, 731
 osteoporosis, 155
 terlipressin, oesophageal varices, 250, 250t
 testosterone
 effect on lipoprotein levels, 394t
 hair changes, 882
 prostate cancer, 759, 761–762
 urinary incontinence, 157
 tetracyclines
 absorption, 52
 adverse reactions, 144
 bronchitis/chronic obstructive pulmonary disease, 549–550
 cholera, 579–580
 Helicobacter pylori eradication, 172
 hepatotoxicity, 225, 226
 interactions, 60
 and psoriasis, 899
 tetra-iodothyronine *see* thyroxine (T₄)
 thalassaemias, 782
 thalidomide, 62, 739–740
 graft-versus-host disease, 795
 inflammatory bowel disease, 202, 203t
 T-helper cells, 622
 theophylline
 adverse reactions, 420b
 asthma, 417, 418t
 chronic obstructive pulmonary disease, 437–438
 distribution, 38
 dosage in children, 137t
 drug interactions, 423t
 elimination, 38
 metabolism, 55
 pharmacokinetics, 38–39, 45t, 47, 419t
 plasma concentration-response relationship, 38
 practical implications, 39
 product formulation, 39

- therapeutic drug monitoring (TDM)
 antiepileptic drugs, 496–497
 practical pharmacokinetics, 33
- therapeutic index, 138–139
- therapeutic range, 37
- thermoregulation, in geriatrics, 151
- thermotherapy, benign prostatic hyperplasia, 758
- thiacetazone, tuberculosis, 616*t*
- thiazide diuretics
 in acute kidney injury, 263
 chronic heart failure, 337, 339*t*
 clinical trials, 302
 and dyslipidaemia, 395
 effect on lipoprotein levels, 394*t*
 and gout, 851
 and hypercalcaemia, 81
 hypertension, 155, 300, 304, 304*b*
 in diabetes, 305
 in the elderly, 304
 in renal disease, 284, 305
 and hypokalaemia, 80
 neonatal heart failure, 127
- thiazolidinediones
 adverse effects, 703
 diabetes mellitus, 701*t*, 703–704
 dosage, 703
 drug interactions, 703–704
 mode of action, 703
 pharmacokinetics, 703
- thiobenzodiazepines, schizophrenia, 483*t*
- thioguanines
 acute myeloblastic leukaemia, 791–792
 drug interactions, 198
 inflammatory bowel disease, 198
- thiols, 319
- thionamide
 adverse effects, 677*t*
 hyperthyroidism, 675–676
- thiopental, 150
- thiopurine methyl transferase (TPMT), 198, 898
- thioxanthines, schizophrenia, 483*t*
- thirst, 76
- throat, sore *see* pharyngitis (sore throat)
- thrombin, 91
- thrombocytes *see* platelets (thrombocytes)
- thrombocytopenia
 definition, 89*t*
 heparin-induced, 379
- thromboembolism
 arterial *see* arterial thromboembolism (ATE)
 in inflammatory bowel disease, 191
 venous *see* venous thromboembolism (VTE)
- thrombolytic agents
 myocardial infarction, 156
 stroke, 153
- thrombophilia, 715
- thromboplastin, 91
- thrombosis, 376–388
 arterial thromboembolism *see* arterial thromboembolism (ATE)
 case studies, 387*b*
 definition, 376
 venous thromboembolism *see* venous thromboembolism (VTE)
- thrush, 656
see also candidiasis
- thyroglobulin, 669
- thyroid ablative therapy, 677–678
- thyroid crisis, 678
- thyroid gland
 disorders, 669–684 (*see also specific disorders*)
 case studies, 682*b*
 drugs and the, 672*t*, 679
 function testing, 672, 675
- hormones, 669
 control, 669*f*
 metabolism, 670
 plasma protein binding, 670*t*
 secretion, 670
 synthesis, 670*f*
 physiology, 669–670
- thyroiditis, 674*t*, 675
- thyroid peroxidase (TPO), 669
- thyroid receptor antibodies (TRABs), 674
- thyroid stimulating hormone (TSH), 669
 hypothyroidism, 672
 thyroid function testing, 672
- thyrotoxicosis
 aetiology, 674–675, 674*t*
 amiodarone-induced, 371
 case study, 683
 clinical features, 675, 675*b*
 drugs and, 679
 epidemiology, 674
 investigations, 675
 treatment, 675–678, 676*t*
- thyrotrophin-releasing hormone (TRH), 669
- thyroxine (T₄), 669, 670
 hypothyroidism, 672
 replacement therapy, 672–673, 677
 thyroid function testing, 672
- tiagabine
 adverse effects, 500*t*
 epilepsy, 495*t*, 496, 503
 pharmacokinetics, 44
 plasma concentration-response relationship, 44
- tibolone, 730
- ticarcillin, cystic fibrosis, 556*t*
- time trade-off method, 118
- timolol, 318*t*
 adverse effects, 868–869
 and bimatoprost, 874
 and brimonidine, 874
 and brinzolamide, 874
 and dorzolamide, 874
 glaucoma, 866, 868, 869*t*, 871, 874
 and latanoprost, 874
 and travoprost, 874
- tinea, 657
- tinea cruris, 657
- tinea pedis, 657
- tinea unguium, 667
- tinidazole
 amoebiasis, 580
 gastro-intestinal infections, 580
- tiotropium, chronic obstructive pulmonary disease, 437
- tipranavir, HIV infection, 631*t*, 635
- tirofiban, arterial thromboembolism, 386
- tissue factor (TF), 91
- tissue plasminogen activator, stroke, 153
- tizanidine, pain, 527
- TNM classification
 prostate cancer, 761
 solid tumours, 822
- tobacco use *see* cigarette smoking
- tobramycin, hypomagnesaemia, 82
- tocilizumab
 anaemia of chronic disease, 774
 rheumatoid arthritis, 842
- tolcapone
 hepatotoxicity, 234
 Parkinson's disease, 513
- tolterodine, urinary incontinence, 157
- tonic clonic convulsions, 491
- tonography, glaucoma, 863
- tonometry, glaucoma, 863
- topical preparations
 absorption in children, 136
 in inflammatory bowel disease, 193
 pruritus in liver disease, 246.
see also specific drugs
- topiramate, 495*t*, 496
 adverse effects, 500*t*, 503
 drug interactions, 499*t*
 epilepsy, 503
 pharmacokinetics, 44
 plasma concentration-response relationship, 44
- torasemide, chronic heart failure, 338, 339*t*
- torrential venous haemorrhage, 243
- torsade de pointes, 50, 57, 370
 gender risk, 65
- total cholesterol (TC), 389
 and age, 390
 and cardiovascular disease, 389–390
 optimal, 389*t*
- total iron binding capacity (TIBC), 88*t*, 93
- tourniquets, 603
- toxic epidermal necrolysis (TEN), 66
 clinical features, 886–887
 drug-induced, 886–887, 887*b*
- toxic multinodular goitre, 674, 676
- toxins, gastro-intestinal infections, 575
- toxoplasmosis, HIV infection, 643
- trace elements, 102, 102*t*, 106
- tracheal route of administration, 124
- tramadol, analgesia, 523, 523*t*
- trandolapril, chronic heart failure, 340*t*
- tranexamic acid, menorrhagia, 720, 720*t*
- transaminases
 liver function tests, 84, 86
see also alanine transaminase (ALT); aspartate transaminase (AST)
- transcutaneous electrical nerve stimulation (TENS)
 analgesia, 527
 dysmenorrhoea, 718
 osteoarthritis, 845
 rheumatoid arthritis, 834–835
- trans fats, 400
- transferrin, 88*t*, 93
- transient insomnia, 451
- transjugular intrahepatic portosystemic shunting (TIPS)
 ascites, 247, 247*f*
 oesophageal varices, 250
- transmitter abnormality model, schizophrenia, 480
- transurethral resection of the prostate (TURP), 758
- tranylcypromine, depression, 471
- Traub and Johnson equation, 144
- traveller's diarrhoea, 214, 579
- travoprost
 glaucoma, 864, 865, 866, 868*t*, 874
 and timolol, 874
- trazodone, depression, 472
- Tredaptive[®], 407
- tremor, Parkinson's disease, 508
- triamcinolone, rheumatoid arthritis, 839
- triamcinolone acetonide, gout, 854
- triamterene, hyperkalaemia, 80
- triazoles, fungal infections in compromised host, 663
- Trichophyton*, 657
- tricyclic antidepressants
 absorption, 52
 affective disorders, 466
 anxiety disorders, 461
 depression, 469, 470
 distribution, 53
 interactions, 475*t*
 neuropathic pain, 530
 pain, 525–526
 Parkinson's disease, 514

- postherpetic neuralgia, 529
 teratogenicity, 741*t*
- trientine, Wilson's disease, 252
- trifluoperazine, schizophrenia, 483*t*
- Trifolium pratense*, 59
- trigeminal neuralgia, 529
- triglycerides, 389*t*, 391–392
- tri-iodothyronine (T₃), 669, 670
 hypothyroidism, 672
 replacement therapy, 672
 thyroid function testing, 672
- trimethoprim
 bacteriuria of pregnancy, 570
 cholera, 579–580
 diarrhoea, 217
 gastro-intestinal infections, 579
Pneumocystis jiroveci pneumonia, 638
 urinary tract infections, 566, 567, 568, 568*t*, 569
- trimipramine, depression, 470
- triptan drugs, migraine, 531
- triptorelin, prostate cancer, 762
- Trizivir[®], 628*t*
- troglitazone, 234, 703
- tropism testing, HIV infection, 625
- troponins, 87, 321
- Truelove and Witts criteria, 192, 192*t*
- Truvada[®], 628*t*
- tuberculin testing, 611–612
- tuberculosis, 201, 608–620
 aetiology, 608
 awareness of, 610–611
 bacterial characteristics, 612–613
 BCG vaccine, 608, 617
 bone and joint, 614
 case studies, 559, 618*b*
 chemoprophylaxis, 617
 clinical aspects, 608–609
 definition, 608
 diagnosis, 610–612
 in people with HIV, 612
 directly observed therapy, 617–618
 drug-resistant, 608, 609, 615
 epidemiology, 609–610, 610*t*
 in HIV infection, 609, 612, 643–644
 incubation period, 609
 investigations, 611–612
 latent, 609
 meningeal, 614
 miliary (disseminated), 608–609, 614
 patient care, 617–619
 pericardial, 614
 of peripheral lymph nodes, 614
 public health action, 612
 pulmonary (respiratory), 609, 613
 risk groups, 609
 symptoms, 610–611
 transmission, 609
 treatment, 612–616
 adverse reactions, 615–616, 616*t*
 dosage, 613*t*
 drugs, 612
 monitoring, 615
 regimens, 613–614
 in special circumstances, 614–615
 urinary tract, 562
- tuberculous meningitis, 591–592
 diagnosis, 586–587
 presentation, 586
- tubuloglomerular feedback (TGF), 263
- tumour lysis syndrome, 813–814, 813*t*
- tumour markers, 87–88, 821, 822*t*
- tumour necrosis factor alpha (TNF- α), 199
- tumour necrosis factor alpha (TNF- α) antagonists
see anti-TNF agents
- tumours, solid, 818–831
 aetiology, 818–819
 case studies, 828*b*
 cellular level, 820–821, 820*f*, 821*f*
 clinical assessment, 821–822
 diagnosis, 821
 drug-induced hepatic, 227, 228
 epidemiology, 818
 growth, 820, 821*f*
 performance status, 822, 822*b*
 presentation, 821
 prevention, 819–820
 prognostic factors, 822, 822*t*
 screening, 819
 spread, 820–821
 staging classification, 822
 staging investigations, 821
 targeted therapies, 825
 treatment, 822–823
 chemotherapy *see* chemotherapy
 goals, 822–823
 guidelines, 823
 methods, 823
 radiotherapy, 823
 surgery, 823
 tumour markers, 821, 822*t*
- tumour suppressor genes, 820
- turmeric, 59
- tyramine, 471
 interactions, 58

U

- ubiquitin-proteasome system, 507–508
- UK Prospective Diabetes Study Group, 299
- ulcerative colitis
 acute severe disease, 190
 case studies, 205, 206, 207
 clinical features, 189–191
 definition, 185
 drug treatment
 aminosalicylates, 196
 biologic agents, 199, 200, 201
 epidemiology, 185
 eyes, 191
 fish oils, 202
 genetic factors, 186
 hepatobiliary, 191
 and infection, 186
 joints and bones, 190
 location and distribution, 187*f*, 187*t*, 188
 moderately active disease, 190
 and primary sclerosing cholangitis, 241
 proctitis, 190
 remission, 192
 skin, 190–191
 and smoking, 186
 surgical treatment, 204
 toxic dilatation, 190
 vs. Crohn's disease, 189*t*
- ultrasonography
 chronic kidney disease, 282
 deep vein thrombosis, 378
 liver disease, 244
 prostate cancer, 760
 prostatic, 755, 760
- unfractionated heparin
 adverse effects, 379
 venous thromboembolism, 379, 380, 380*b*
- unipolar disorder, 465
- unlicensed medicines for children, 145
- unlicensed prescribing, 18, 19*b*
- uraemia, 259, 261
 in chronic kidney disease, 278
- dietary modification, 285
 and intravascular volume overload, 263–264
 uraemic gastro-intestinal erosions, 264–265
- URAT-1 transporter, 850
- urea, 77*t*, 83
 in acute kidney injury, 265
 in chronic kidney disease, 274–275
 extracellular fluid osmolality, 77
 liver function tests, 86
- urea breath tests, *Helicobacter pylori*, 166–167
- ureidopenicillins, cystic fibrosis, 556*t*
- urethra, menopausal changes, 726
- urethral syndrome, 561, 568, 725
- uric acid, 84, 849
- uricase, 849
- uricolytic agents, 856–857
- uricostatic agents, 855–856
- uricosuric agents, 856
- urinary incontinence, 156–157
- urinary pH changes, 56
- urinary tract
 abnormalities, 563
 in chronic kidney disease, 277–278
 diseases *see* urinary tract diseases
 infections *see* urinary tract infections (UTIs)
 tuberculosis, 562
- urinary tract diseases
 causing chronic kidney disease, 276–277
 chronic pyelonephritis, 277
 extrinsic renal tract obstruction, 277
 reflux disease, 276
 renal stone disease, 276
- urinary tract infections (UTIs), 561–572
 in adults, 562, 563
 aetiology, 562
 in babies and infants, 561, 563
 in benign prostatic hyperplasia, 754
 case studies, 570*b*
 in children, 562, 563
 clinical manifestations, 563
 common management problems, 567*t*
 in the elderly, 562, 563
 epidemiology, 561–562
 fungal, 659
 investigations, 563–566
 culture, 565–566
 dipsticks, 564
 microscopy, 564–565
 pathogenesis, 562–563
 prevention and prophylaxis, 570–572
 relapsing, 569
 risk factors, 562
 treatment, 566–570
 acute pyelonephritis, 568–569
 antimicrobial chemotherapy, 566
 bacteriuria of pregnancy, 569–570
 catheter-associated infections, 569
 in children, 568
 duration of, 568
 non-specific treatments, 566
 relapsing UTI, 569
 uncomplicated lower UTI, 567–568
 uncomplicated, 567–568
- urine
 culture, 565–566
 midstream sample, 563–564
 testing in chronic kidney disease, 281
- urobilinogen, 85
- urodynamic studies, benign prostatic hyperplasia, 755
- urogenital system
 menopausal changes, 726, 732
see also urinary tract
- urokinase, venous thromboembolism, 385

ursodeoxycholic acid (UDCA)
 primary biliary cirrhosis, 252
 primary sclerosing cholangitis, 252
 pruritus in liver disease, 245, 245*t*
 urticaria, drug-induced, 883–884, 883*f*, 884*b*,
 889
 ustekinumab, psoriasis, 905
 uveitis, 191

V

vac A, 164
 vaccination *see* immunisations
 vaccines, diarrhoea, 215*t*
 vaginal candidiasis, 657
 presentation, 656
 treatment, 656–657
 vaginal dryness, 732
 valaciclovir, opportunistic infections in HIV, 639*t*
 valganciclovir
 cytomegalovirus, 644
 opportunistic infections in HIV, 639*t*
 valproate
 distribution, 43
 effect on lipoprotein levels, 394*t*
 elimination, 43
 pharmacokinetics, 43–44, 45*t*
 plasma concentration-response relationship, 43
 practical implications, 43–44
 valproate semisodium, mania, 473
 valsartan
 chronic heart failure, 340*t*
 clinical trials, 302
 VALUE study, 302
 Vamin[®], 98, 99*t*
 Vaminolact[®], 98, 99*t*
 vancomycin
 gastro-intestinal infections, 580
 infection in neutropenia, 797
 meningitis, 589–590, 589*t*, 593, 593*t*
 neonates, 125
 monitoring in, 129
 respiratory distress syndrome, 130
 surgical site infection prophylaxis, 604
 varenicline
 adverse reactions, 74
 smoking cessation, 436, 442
 variable costs, 117
 variceal band ligation, 249–250
 variceal bleed, 243
 varicose eczema, 895
 varicose veins, 918
 vascular abnormalities, hepatic, 241
 drug-induced, 226*t*, 227
 vascular dementia (VaD), 152, 153
 vascular endothelial growth factor (VEGF), 825
 vasculitis
 drug-induced, 889, 889*b*
 small-vessel, 258
 vasodilators
 centrally acting, 303*t*, 307*t*
 chronic heart failure, 340*t*
 direct-acting, 303*t*, 307*t*
 hypertension, 303*t*, 307*t*
 in chronic kidney disease, 285
 ST elevation myocardial infarction, 324
 vasomotor symptoms, menopause, 731–732
 vasopressin *see* antidiuretic hormone (ADH)
 Vaughan-Williams classification, 366–373
 venlafaxine
 alternatives to HRT, 731
 anxiety disorders, 461
 depression, 472
 pain, 526
 venography, deep vein thrombosis, 378
 veno-occlusive disease, 228
 venous congestion, 335
 venous hypertension, 917–918
 venous leg ulcers, 917–919, 918*f*
 clinical signs, 918
 diagnosis, 918, 918*t*
 in the elderly, 156
 prevention of recurrence, 919
 treatment, 919
 venous thromboembolism (VTE), 376–385
 aetiology, 376–377
 case studies, 387
 clinical manifestations, 377–378
 diagnosis, 93
 epidemiology, 376
 hormone replacement therapy, 729, 733–734,
 733*t*, 734*b*
 investigations, 378
 oral contraceptives risk, 715
 patient care, 385
 recommended target international normalised
 ratios, 382*t*
 treatment, 378–385
 fibrinolytic drugs, 384–385
 fondaparinux, 380
 heparinoids, 380
 heparins, 379–380, 380*b*
 hirudins, 380
 oral anticoagulants, 381–384
 prophylaxis, 379
 ventilation-perfusion scanning, pulmonary
 embolism, 378
 ventricular fibrillation, 321, 364–365
 ventricular tachyarrhythmias, 364–365
 emergency management, 365
 ongoing management, 365
 ventricular tachycardia, 364
 complicating structural heart disease, 364
 normal heart, 364
 verapamil
 adverse effects, 156, 301, 349, 367*t*
 arrhythmias, 359, 361, 371
 hypertension, 156, 301
 in chronic kidney disease, 283
 pharmacokinetics, 150, 368*t*, 371
 stable angina, 319
 verbal rating scales, 520
 verotoxin-producing *Escherichia coli* (VTEC),
 133–134
 verotoxins, gastro-intestinal infections, 575
 very low birth weight (VLBW), 124
 very low-density lipoprotein cholesterol
 (VLDL-C), 390
 menopause, 727
 metabolism, 390
 Vibrio sp., 214
 gastro-intestinal infections, 574*t*, 576*t*
 treatment, 578
 Videx[®], 628*t*
 vigabatrin
 adverse effects, 500*t*, 503
 epilepsy, 495*t*, 496, 503
 pharmacokinetics, 44, 498*t*
 plasma concentration-response relationship, 44
 vildagliptin, 704
 vinblastine
 Hodgkin's lymphoma, 804, 805, 807*t*
 Kaposi's sarcoma, 645
 vincristine
 acute lymphoblastic leukaemia, 790, 791
 Hodgkin's lymphoma, 805
 non-Hodgkin's lymphoma, 809, 811, 812
 Viracept[®], 631*t*
 viral hepatitis, 239
 biochemical tests, 244
see also specific viruses
 viral load, HIV infection, 625
 viral meningitis
 aetiology, 585
 diagnosis, 586–587
 epidemiology, 585
 presentation, 586
 treatment, 592
 Viramune[®], 630*t*
 Viread[®], 628*t*
 viruses/viral infections
 in atopic eczema, 894
 diarrhoea, 214
 gastro-intestinal infections, 573, 574*t*, 576*t*,
 578
 in HIV infection, 644
 leukaemia risk, 787
 liver disease, 239–240
 and lymphomas, 807
 treatment, 578
 visceral muscle function, in geriatrics, 151
 visual aids
 adverse drug reactions, 72, 73*f*
 communicating benefits/risks of treatment,
 24
 visual analogue scales, 118, 520
 vital capacity (VC), 435
 vital signs, paediatric, 143*t*
 vitamin A, 107
 vitamin B₁₂
 anticoagulant therapy monitoring,
 93–95
 serum, 88*t*
 vitamin B₁₂ deficiency anaemia
 aetiology, 776
 case study, 785
 clinical manifestations, 777
 epidemiology, 776
 investigations, 777–778
 pathophysiology, 776–777
 patient care, 779
 treatment, 778–779
 vitamin C
 with iron, 775
 stability, 107
 vitamin D, 81
 deficiency, 82, 94, 279
 in chronic kidney disease, 287–288
 hypoparathyroidism/hypocalcaemia, 680,
 681*t*
 osteoporosis, 154
 and parenteral nutrition, 102–103
 premenstrual syndrome, 714
 vitamin D analogues, psoriasis, 902
 vitamin E, 107
 vitamin K, 246
 vitamin K-dependent bleeding *see* haemorrhagic
 disease of the newborn
 vitamin K epoxide reductase (VKOR), 66
 vitamin(s)
 adult reference range, 103*t*
 dysmenorrhoea, 718
 fat-soluble, 102
 parenteral nutrition, 102–103
 and premenstrual syndrome, 714
 stability, 107
 water-soluble, 102.
see also specific vitamins
 volume of distribution (*V_d*), 33–34, 33*f*
 vomiting *see* nausea and vomiting
 vomiting centre, 535, 536
 vomiting reflex, 536

von Willebrand factor, 91
 voriconazole
 absorption, 52
 administration, 665
 adverse effects, 665
 candidiasis, 657
 clinical use, 665
 fungal infections in compromised host, 665
 infection in neutropenia, 797
 meningitis, 592
 pharmacokinetics, 664*t*, 665
 vulnerability model, schizophrenia, 480

W

waist measurement, dyslipidaemia, 399–400
 warfarin
 absorption, 52
 action, 381
 adverse effects, 66, 74, 381
 atrial fibrillation, 363
 distribution, 53
 in the elderly, 150
 drug interactions, 177, 383*t*
 effects, 381
 in the elderly, 152
 interactions, 58, 59, 61, 74
 management of bleeding, 384*t*
 metabolism, 66, 381
 stroke, 154
 stroke prevention in atrial fibrillation, 362, 363
 suggested induction schedule, 384*t*
 venous thromboembolism, 381–382, 384*t*, 387
 warm autoimmune haemolytic anaemia (WAIHA), 779–780
 water
 balance, 76–79, 77*f*, 77*t*
 depletion, 77–78, 94
 excess, 78
 and extracellular fluid osmolality, 78
 parenteral nutrition, 97–98
 total body water, 137, 137*t*

Wegener's granulomatosis, 258
 weight, children, 134–135
 weight gain
 antipsychotics, 486
 menopause, 727
 weight loss
 ascites in liver disease, 246
 in diabetes mellitus, 698
 in liver disease, 242
 white blood cell count, 88*t*, 90, 90*f*
 basophils, 90
 eosinophils, 90
 lymphocytes, 90
 monocytes, 90
 neutrophils, 90
 white blood cells, 770
 white coat hypertension, 297
 WHO *see* World Health Organization (WHO)
 widespread cutaneous necrosis, 889
 willingness to accept, 117–118
 willingness to pay, 117–118
 Wilson's disease, 241, 252–254
 Wolff-Chaikoff effect, 679
 Wolff-Parkinson-White pattern, 360, 361*f*
 women
 adverse drug reactions, 65
 HIV infection, 646–648
 see also gender
 Working formulation, non-Hodgkin's lymphoma, 808
 World Health Organization (WHO)
 adverse drug reactions definition, 63
 causality categories for adverse drug reactions, 69, 69*t*
 make medicines child size programme, 146
 wounds, 910–925
 assessment, 915, 915*f*
 case studies, 923*b*
 healing, 910–915, 911*f*
 factors affecting, 913–915, 913*t*
 moist, 912
 phases of, 911, 912, 912*f*
 by primary intention, 911, 911*f*
 by secondary intention, 911, 911*f*

management principles, 921–925, 922*b*
 skin structure, 910, 910*t*
see also surgical site infection
 WWHAM, 5–6, 6*b*

X

xanthine oxidase, 61, 84, 849, 855
 xanthochromia, 93

Y

yeasts, 654–655, 655*t*
 Yellow Card Scheme, 69–70, 71
 Yerks Dodson curve, 454*f*
Yersinia, 214

Z

zafirlukast, asthma, 419
 zaleplon, insomnia, 448*t*, 450
 zanamivir, influenza, 546
 Zerit[®], 628*t*
 Zevalin[®], non-Hodgkin's lymphoma, 811
 Ziagen[®], 628*t*
 zidovudine, HIV infection, 628*t*, 635
 zinc
 acute kidney injury, 265
 adult daily reference range, 102*t*
 deficiency, 101–102
 diarrhoea, 218
 Wilson's disease, 252
 ziprasidone, schizophrenia, 483*t*
 Zollinger-Ellison syndrome, 163, 169
 zolpidem, insomnia, 448*t*, 449–450
 zonisamide, 495*t*
 adverse effects, 500*t*, 503
 drug interactions, 499*t*
 epilepsy, 503
 pharmacokinetics, 498*t*
 zopiclone, insomnia, 448*t*, 449
 zotepine, schizophrenia, 483*t*
 zuclopenthixol, schizophrenia, 483*t*
 zygomycosis, 658*t*, 660*t*